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Spinal cord injury (SCI) patients rarely recover full functionality with current 
clinical treatments. There are two approaches for developing treatments for SCI: 
1) rehabilitation strategies and 2) regenerative medicine strategies. Individually, 
each strategy has not been able to facilitate full functional recovery after severe 
SCI. Rehabilitation strategies have shown better functional recovery compared 
to regenerative medicine approaches, especially when motor training was 
combined with electrical stimulation (ES) for patients with incomplete SCIs. 
However, patients with more severe injuries may not recover full functionality 
from only rehabilitation approaches. As discussed in the SCI literature, there is a 
need to combine the fields of rehabilitation and regenerative medicine to 
maximize functional recovery, but there are not many methods to synergistically 
combine the fields. Conductive biomaterials may be the missing link that enables 
synergistic combination of regenerative medicine with the rehabilitation approach 
of ES. Unfortunately, there are a paucity of in vivo studies using conductive 
biomaterials for SCI. One problem is that most conductive biomaterials are 
preformed scaffolds that are risky and challenging to implant in an SCI, which 
does not have defined borders. However, an injectable biomaterial may be easier 
to deliver into the most common contusion SCI than a preformed scaffold and 
thus, may be more translational. Given that the bioprinting field focuses on 
several of the same parameters used in developing injectable biomaterials, that 




an existing fast-crosslinking pentenoate-functionalized hyaluronic acid (PHA) 
hydrogel precursor was first developed into a bioink and the rheology of the bioink 
was characterized to predict printability. The PHA bioink was then developed to 
be adhesive for rat neural stem cells (rNSCs) through the incorporation of a newly 
developed pentenoate-functionalized gelatin (PGel) based on the same 
chemistry employed for PHA. The rheology of the adhesive formulations of the 
PHA/PGel bioink were characterized to determine the printable formulations. 
Finally, a conductive and injectable/bioprintable hydrogel was developed by 
incorporating gold nanorods (GNRs) into PHA/PGel, and was subsequently 
applied to a thoracic level (T8) lateral hemi-section rat spinal cord injury (SCI) 
model. While no significant differences in functional recovery or axon 
regeneration were found across any of the tested material groups, the feasibility 
of the injectable/paste-like GNR hydrogel precursors and the long-term safety of 
the crosslinked hydrogels were demonstrated. No previous studies have applied 
a GNR-based conductive hydrogel to SCI, therefore, the significance of the 
current dissertation was the development of a conductive biomaterial that was a 
bioprintable/translational platform for contusion SCIs. The GNR hydrogel may be 
further refined with the addition of other regenerative medicine approaches to 
promote axon regeneration and synergistically combined with rehabilitative 






Chapter 1 : Introduction 
The long-term goal of this dissertation is the development of a conductive 
and injectable biomaterial for bioprinting and application to treat spinal cord injury 
(SCI). SCI causes permanent damage to the spinal cord and full functional 
recovery is uncommon with current clinical treatments. While motor training alone 
does not typically promote full functional recovery, combinations of rehabilitation 
strategies (e.g., motor training with electrical stimulation (ES)) have been the 
most effective treatment in promoting over ground independent stepping in 
humans thus far. Rehabilitation strategies aim to promote neural plasticity in any 
remaining, undamaged axonal pathways and/or activate intrinsic spinal cord 
neural circuits, known as central pattern generators (CPGs), that produce 
rhythmic activation of muscles, such as for walking, and are intact and exist below 
the injury. However, the most severely injured SCI patients have not benefited as 
much from motor training with ES compared to patients with incomplete injuries, 
possibly due to patients with severe injuries having little to no remaining spared 
pathways. For more severely injured patients, locomotion may be possible from 
task-specific ES combined with motor training to activate CPGs related to 
locomotion. While rats and cats have long been able to recover locomotion after 
complete transections via ES-enabled CPG activation, translation to humans has 
been slower, but there have been recent successes of over-ground independent 
stepping in a few patients. Determination of the requisite ES parameters to 




remains a challenge and for full functional recovery beyond locomotion, the 
axonal pathways may need to be regenerated and retrained. Several 
regenerative medicine approaches aim to regenerate the axonal pathways; 
however, regenerative medicine approaches alone so far have not yet been 
successful in promoting full functional recovery either.  
The SCI literature has indicated the need to combine rehabilitation 
strategies with regenerative medicine strategies to maximize the functional 
outcomes, which embodies the principles of regenerative rehabilitation. In 
regenerative rehabilitation for SCI, regenerative medicine approaches are 
needed to regenerate the spinal cord tissue and rehabilitation approaches are 
needed to enhance neural plasticity to form new neural pathways. Currently, 
there are few methods that synergistically combine regenerative medicine 
approaches with rehabilitation approaches; however, conductive biomaterials 
may be the linchpin that synergistically combines the two fields. Currently, there 
are a paucity of in vivo studies with conductive biomaterials. One challenge with 
conductive biomaterials is that many scaffolds are preformed and unable to 
conform to the irregular borders of typical contusion SCIs, and implantation risks 
further damage. However, an injectable material able to conform to the injury may 
have better translation for SCIs. The bioprinting field focuses on several of the 
same parameters that apply to the development of injectable biomaterials and 
therefore, may offer insight in designing injectable materials. Fortunately, the 




biomedical applications. There is a need for additional injectable conductive 
biomaterials for SCI and bioinks have relevant rheology that enable easier 
translation.  
In the current dissertation, a conductive and bioprintable hydrogel was 
developed, refined for neural tissue engineering, and applied to a rat SCI model 
in the following three aims. The first aim was to develop and characterize the 
rheology of a bioprintable pentenoate-functionalized hyaluronic acid (PHA) 
hydrogel precursor. The second aim was to promote neural stem cell adhesion 
and viability by developing a pentenoate-functionalized gelatin (PGel) hydrogel 
and fabricating a printable PHA/PGel hydrogel. The final third aim was to 
establish a conductive and injectable PHA/PGel hydrogel through the 
incorporation of gold nanorods (GNRs), and to apply and evaluate the feasibility 
and long-term safety of the GNR hydrogel in a rat SCI model. The following 
chapters are the chronological organization of the content of the current 
dissertation: 
Chapter 2 is a review of SCI, including the current regenerative medicine 
approaches in clinical trials and the rehabilitation approaches for SCI, with 
discussion of the translational limitations of each approach. I further discussed 
the potential for conductive biomaterials to synergistically link the two fields and 
leverage the principles of regenerative rehabilitation to maximize functional 
recovery after SCI. Finally, the main categories of conductive composites (e.g., 




materials) were reviewed and the translational potential of each approach was 
discussed. I concluded that several of the current conductive biomaterials were 
preformed scaffolds, which may be difficult to translate to contusion SCIs; 
however, injectable composites with blended conductive fillers may be more 
translational for SCI and able to synergistically combine regenerative medicine 
and rehabilitation approaches (e.g., ES). 
Chapter 3 addresses Aim 1, which developed an existing biomaterial, 
PHA, as a bioink. The rheology and bioprinted shape fidelity of different molecular 
weights and concentrations of PHA precursors were evaluated. We aimed to 
universalize the bioprinting field by selecting and promoting three standard 
rheological tests (i.e., viscosity, yield stress, and storage modulus recovery) to 
characterize the rheology of bioinks and correlate it to the printability.  
Chapter 4 addresses Aim 2, which developed the PHA bioink to support 
rat neural stem cell (rNSC) adhesion and viability for nerve tissue engineering. 
The same functionalization chemistry was used to develop a PGel hydrogel. 
Varying formulations of PGel hydrogels were evaluated with rNSCs to evaluate 
adhesion, but the PGel hydrogels degraded quickly. Therefore, the adhesive 
PGel formulations were incorporated into PHA to make PHA/PGel hydrogels 
adhesive for rNSCs with long-term stability in culture. Finally, the rheology and 
printability of the adhesive formulations of PHA/PGel hydrogel precursors were 
evaluated to select a PHA/PGel hydrogel formulation that supported rNSCs and 




Chapter 5 addresses Aim 3, which developed the PHA/PGel bioink that 
was adhesive for rNSCs into a conductive bioink through the incorporation of 
GNRs. High aspect ratio GNRs were synthesized and various concentrations of 
GNRs were tested in PHA/PGel hydrogels to develop conductive GNR hydrogels. 
The cytotoxicity and printability of the GNR hydrogels were evaluated with rNSCs 
in vitro and to select a formulation for further evaluation in vivo. The feasibility of 
injecting the selected GNR hydrogel and the long-term safety of the hydrogel was 
evaluated in vivo in a thoracic level (T8) lateral hemi-section SCI model in rats. 
Chapter 6 is the conclusion to the dissertation, where the major findings 
of all three aims, limitations of the studies, and recommendations for future 




Chapter 2 : Regenerative Rehabilitation with Conductive 
Biomaterials for Spinal Cord Injury1 
 
Abstract 
 The individual approaches of regenerative medicine efforts alone and 
rehabilitation efforts alone are insufficient to fully restore function after severe 
spinal cord injury (SCI). Regenerative rehabilitation may harness the power of 
these two disparate fields by combining them to maximize recovery. For SCI, 
regenerative medicine approaches may be leveraged to promote regeneration of 
the spinal cord tissue, and rehabilitation approaches may be able to promote 
reorganization of the regenerated neural pathways and intact spinal circuits. 
Conductive biomaterials could be a linchpin than empowers the synergy between 
regenerative medicine and rehabilitation approaches, as electrical stimulation 
applied to the spinal cord could facilitate neural reorganization. In this review, we 
discussed current regenerative medicine approaches in clinical trials and the 
rehabilitation, or neuromodulation, approaches for SCI, along with their 
respective translational limitations. Furthermore, we reviewed the translational 
potential of conductive composites (e.g., conductive polymers, carbon-based 
materials, metallic nanoparticle-based materials) as they pertain to SCI. We 
            
1In preparation for submission to Acta Biomaterialia as: Kiyotake EA, Martin MD, Detamore 




concluded that pre-formed scaffolds may be difficult to translate to contusion 
SCIs; however, injectable composites that contain blended conductive 
components and that can form a scaffold within the injury may be more 
translational. Injectable, conductive biomaterials thereby may enable 
regenerative medicine to become a translational tool to enhance the outcomes 
associated with the latest rehabilitation treatments. There are currently no in vivo 
SCI studies that evaluated conductive materials combined with rehabilitation 
approaches. The use of conductive biomaterials creates a synergistic opportunity 
to merge the fields of regenerative medicine and rehabilitation and redefine what 
regenerative rehabilitation means for the spinal cord. 
Introduction 
There are two separate approaches discussed individually in recent 
reviews of the most translational approaches for promoting functional recovery 
after spinal cord injury (SCI) (see Table 2.1 for a list of acronyms): regenerative 
medicine and rehabilitation (see Fig. 2.1). Regenerative medicine approaches(1) 
are methods using cells, drugs, biologics, and/or materials; for example, for the 
purposes of replenishment of lost cell populations, promotion of axon sprouting, 
growth, or synapse formation, intrinsic enhancement of cell survival, and/or 
neutralization of the extrinsic axon-inhibiting environment. By manipulating the 
intrinsic and/or extrinsic environment, regenerative medicine approaches for SCI 
typically aim to promote regeneration of the axons and restore the spinal cord to 




SCI have been described with other terminologies in other reviews, such as 
microscopic approaches/cellular-molecular interventions,(2) biological 
approaches,(3) or Hutson and Giovanni(4) used specific subdivisions of neuronal 
intrinsic signaling, neuronal extrinsic environment, and neural stem cell grafts.  
In contrast to regenerative medicine, rehabilitation methods for SCI 
include motor training and external stimuli such as electrical stimulation (ES) to 
drive the reorganization of remaining axons in the spared tissue or intact spinal 
circuits. Additionally, the definition of rehabilitation approaches for SCI can be 
expanded to include neurochemical stimulation (e.g., serotonergic and 
dopaminergic receptor agonists), as these stimulation methods have been 
applied to SCI to achieve outcomes similar to using other rehabilitation methods. 
Rehabilitation approaches have been referred to in other reviews as 
neuromodulation,(4) technological approaches,(3) and macroscopic/systems-
circuitry level approaches.(2)  
For SCI, regenerative medicine approaches and rehabilitation approaches 
individually have not yet resulted in full functional recovery. Combinations of 
rehabilitation approaches, specifically motor training paired with ES, have shown 
the greatest recovery of walking after SCI in small clinical studies compared to 
individual regenerative medicine therapies and individual rehabilitation 
approaches. Even so, patients with more severe injuries and little to no spared 
tissue may need regenerative medicine approaches to regenerate the damaged 




synergistic combination of regenerative medicine approaches and rehabilitation 
approaches is known as regenerative rehabilitation.(5-7) 
The underlying principle of regenerative rehabilitation is to apply 
rehabilitation protocols with regenerative medicine to optimize functional 
recovery through tissue regeneration. For SCI, given the better functional 
outcomes of the rehabilitation protocols, there is a need to develop regenerative 
medicine therapies that are not only combined with rehabilitation approaches, but 
further augment the effects and maximize functional recovery. Regenerative 
rehabilitation principles have been applied in areas such as skeletal muscle, 
cardiac tissue, brain plasticity, and bone.(1) Even though the specific terminology 
of “regenerative rehabilitation” has only been used in few SCI studies,(8) several 
clinical, in vivo, and in vitro SCI studies have already utilized the principles (e.g., 
cells + motor training,(9) conductive biomaterials + ES,(10-16) scaffold + cells + 
ES(17)). The limited reviews of “regenerative rehabilitation” with mention of SCI 
have broadly focused on neural pathologies(18) or specifically focused on neural 
stem cells and physical rehabilitation.(19) While not specifically using the 
“regenerative rehabilitation” terminology, concepts akin to regenerative 
rehabilitation principles for SCI have been discussed within several excellent 
reviews.(2-4, 20) Each review discussed the need to combine approaches in the 
future, but there remains a need for a review about the synergistic development 




approaches, and moreover about how to improve the clinical translatability of 
combined approaches.  
To further build upon and universalize the principles of regenerative 
rehabilitation for SCI, we cover current regenerative medicine approaches and 
rehabilitation approaches for SCI and further discuss the emerging field of 
conductive biomaterials, which falls at the intersection of regenerative medicine 
and rehabilitation for SCI (see Fig. 2.1). Conductive biomaterials could provide a 
medium for ES to be delivered directly to cells to enhance neural plasticity and 
thereby promote a regenerative biological response. Several reviews have 
discussed the application of conductive biomaterials for biomedical 
applications(21) and tissue engineering,(22, 23) but the most recent review of 
conductive biomaterials for nerve tissue engineering was in 2011.(24) These 
reviews of conductive biomaterials have been broad in scope and only mentioned 
SCI as one example application. Therefore, an updated review of conductive 
biomaterials for SCI is needed. In this review, we additionally cover the 
conductive biomaterials that have been developed to date and their advantages 
and disadvantages for translation to application in SCI.  
Spinal Cord Injury 
Clinical significance 
Traumatic spinal cord injury (SCI) causes permanent damage to the spinal 
cord and there are currently no clinical treatments that promote full recovery of 




research, new clinical treatments are not surfacing as rapidly. In the United 
States, SCI currently affects approximately 294,000 people with approximately 
17,800 new cases of SCI each year.(25) The majority of civilian SCIs result from 
motor accidents, falls, and gunshot wounds. SCIs in the military were found to be 
typically from blast injuries as opposed to penetrating injuries, and compared to 
civilian injuries, military SCIs were more severe and typically involved multiple 
spinal levels.(26) SCI usually entails a traumatic impact to the spine that shifts or 
crushes one or more vertebrae, causing compression of the spinal cord and 
disruption of motor and/or sensory axon tracts. Depending on the level (i.e., 
cervical, thoracic, lumbar) and on the extent of damage across the cord (i.e., 
complete, incomplete), varying amounts of paralysis may occur below the level 
of the injury.  
Patients are typically assessed for neurological recovery using the 
American Spinal Injury Association (ASIA) Impairment Scale (AIS), which is an 
internationally standardized system,(27) and which provides scores for motor and 
sensory loss. Completeness of SCIs according to ASIA protocols range from 
grade A to E, where grade A is complete motor and sensory loss below the level 
of injury, grade B is complete motor loss with incomplete sensory loss, grade C 
and D are incomplete motor and sensory loss (where grade C patients have less 
than half of key muscle functions and grade D patients have at least half of key 




Current treatments can include early decompression surgery, to alleviate 
pressure of a malaligned or broken spinal column and prevent further damages 
the spinal cord, and/or rehabilitation, which attempts to leverage the intrinsic 
plasticity of the nervous system to re-train remaining uninjured pathways. Other 
current treatments include mean arterial pressure (MAP) therapy, steroids, and 
moderate hypothermia. MAP therapy aims to avoid systemic hypotension and to 
improve spinal cord perfusion.(28) Delivery of the steroid methylprednisolone 
sodium succinate (MPSS) was historically used for neuroprotection, but the 
clinical use of MPSS has rapidly decreased following three large randomized 
trials from the National Acute Spinal Cord Injury Studies that showed no 
difference in neurological recovery.(29) Moderate hypothermia (33C) introduced 
by intravascular cooling strategies aims to protect against ischemia and neural 
cell death.(30) While MAP therapy, steroids, and hypothermia treatments may 
result in some neurological recovery, they aim to help prevent the damaging 
cascade of events (i.e., secondary injury) after the initial injury and typically do 
not result in full functional recovery.  
Even though spontaneous recoveries of motor, sensory, and/or autonomic 
functions within the first year after the injury can occur, the recovery usually 
plateaus 12 to 18 months post-injury and patients do not typically recover 
additional functions. The extent of spontaneous recovery is typically limited and 
was found to be dependent on the severity, where improvement of at least 1 




19% of AIS A, 74% of AIS B, 87% of AIS C, and 47% of AIS D patients.(31) 
Additionally, and not surprisingly, full recovery was reportedly more common in 
less severely injured patients than more severely injured patients (i.e., 47% of 
AIS D patients fully recovered but only 9% of AIS C patients, 0.3% AIS B, and 
0% of AIS A patients recovered). The National Spinal Cord Injury Statistics 
Center 2019 Annual Statistical Report of SCI patients from 1972 to 2019, showed 
that at the time of initial injury the largest group of patients was the most severe, 
where 43% were AIS A, 29% were AIS D, 12% were AIS C, 11% were AIS B, 
<1% were recovered and AIS E, and <5% were unknown.(32)  
 In the last few decades, overall neurological recovery has not significantly 
improved,(31) and an effective treatment is still needed, particular for the most 
severe AIS A patients. 
Pathophysiology creates challenges in determining when to deliver 
treatments 
Developing treatments for SCI is challenging as the pathophysiology of 
SCI is complex with physical, cellular, and molecular variations over time 
depending on the severity (i.e., complete, incomplete) and type of injury (e.g., 
contusion, penetrating).(33-36) In addition to the type of treatment, the timing of 
treatment delivery and how it gets delivered are important considerations. SCI 
consists of a primary and secondary injury, where the primary injury is the initial 
mechanical insult that causes direct damage to neural and glial cells and may 




known as the secondary injury, where there is hemorrhage, apoptosis, swelling, 
inflammation, excitotoxicity, ionic imbalance, and an overall unstable 
environment. The secondary injury is typically described as the acute (i.e., hours 
to a few days post-injury), subacute (i.e., weeks to months post-injury), and 
chronic injury (i.e., more than 1-year post-injury). To treat the acute injury in the 
short timeframe immediately after injury (i.e., within the first 1 to 2 days), 
injectable drugs or biologics are easier to deliver than complex treatments such 
as autologous cell therapies because it is not possible to do 1 to 2 weeks of cell 
expansion in 1 to 2 days. Implantation of biomaterial therapies in the early stages 
risk compromising spontaneous recovery, especially if spinal cord tissue must be 
removed to make a scaffold fit. Additionally, the exact size and shape of an injury 
is difficult to discern, and therefore challenging for a surgeon to trim a scaffold to 
fit into the injury. Injectable therapies still have risk, but they are less invasive and 
may not be as risky as biomaterial implantation. 
Subsequently, in the following days to weeks, the subacute stage 
encompasses additional cell death, ischemia, hypoxia, inflammation, free radical 
production, and edema. Within the first day after injury, spinal cord ependymal 
cells from the lining of the central canal, which are normally dormant, rapidly 
proliferate.(37) Within 3 days, these ependymal cells migrate from the central 
canal to the injury, and differentiate into astrocytes that surround the injury core 
of stromal cells.(37) The injury becomes inhibitory toward axon regeneration due 




associated inhibitors (MAIs). CSPGs and MAIs activate Nogo receptors (NgRs), 
several of which inhibit neurite growth. CSPGs are astrocyte-secreted 
proteoglycans (e.g., aggrecan, neurocan, phosphacan, versican) that activate 
NgRs and subsequent signaling pathways known to inhibit axon growth, and 
prevent protein tyrosine phosphatase sigma (PTPΩ; a transmembrane protein) 
from activating axon-growth-promoting signaling pathways,(38) among other 
mechanisms covered by other excellent reviews.(39) MAIs are transmembrane 
proteins normally present in myelin that are thought to be released from disrupted 
myelin after injury.(40) In the later subacute stage, astrocytes secrete fibrous-like 
scar tissue that develops into a stable glial scar in the chronic stage, which 
creates a physical barrier that prevents axon regeneration. The inhibitory 
environment and glial scar never resolve, creating a permanent physical and 
chemical barrier to axon regeneration, resulting in permanent functional deficits.  
As nerve regeneration is typically a slow process over months to years, 
injectable drugs, biologics, and more complex treatments delivered in the 
subacute and chronic stages, would most likely need a sustained delivery 
platform or multiple dosages to maintain a therapeutic effect for an extended 
period. Treatments delivered in the subacute stage may face similar challenges 
to acute treatments where it is more difficult to differentiate the efficacy of the 
treatment versus normal spontaneous recovery. In clinical trials, larger numbers 
of patients will be required to demonstrate the efficacy of acute and subacute 




improvement is lower. Delivery of treatments, including implantation of 
biomaterials, in the chronic stage after spontaneous recovery plateaus, may be 
less risky than the subacute or acute stages because spontaneous recovery will 
not be compromised.  
In summary, in the early stages after SCI, cell therapies may not be 
feasible to deliver and they risk compromising spontaneous recovery. Injectable 
drugs and biologics might be easier to deliver shortly after injury and in the acute 
stage to reduce the secondary injury compared to cell or biomaterial therapies; 
however, discriminating between spontaneous recovery and the effect of the 
treatment will be difficult and will require large sample sizes. During the later 
subacute and chronic stages, sustained release of drugs from biomaterials might 
be more translatable than repeated dosages of drugs or biologics by themselves. 
Cell and biomaterial therapies may be less likely to compromise spontaneous 
recovery in the chronic stage. Furthermore, injectable biomaterials are less 
invasive and less risky than preformed scaffold implantation, and therefore, more 
translational for SCI. 
Current therapeutic approaches: Regenerative medicine 
The principles of regenerative rehabilitation are based on combining 
rehabilitation approaches and regenerative medicine treatments to maximize the 
functional outcomes; therefore, regenerative medicine approaches must be 
developed with clinical translation and synergism with rehabilitation approaches 




biologics, and biomaterials in clinical trials and further discuss the current clinical 
limitations of each approach. Different regenerative medicine approaches share 
the same overarching goal, which is typically to repair the damaged tissues. 
However, there are two distinct mechanisms separating regenerative medicine 
approaches. Specifically, cellular therapies are typically used to replace the lost 
neural cell population and/or create a regenerative environment, whereas 
biomaterials are typically intended to aid or facilitate regeneration via the existing 
cell population. 
Cell-based therapies 
Cell-based therapies for spinal cord repair have been reviewed extensively 
and encompass the use of neural stem cells (NSCs),(41, 42)  pluripotent stem 
cells (i.e., embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs)) 
(43), mesenchymal stem cells (MSCs),(34, 44, 45) olfactory ensheathing cells 
(OECs),(46) and/or Schwann cells (SCs).(47) There are 17 cell-based U.S. 
clinical trials for SCI, not including cells with biomaterials, that are recruiting, not 
yet recruiting, active not recruiting, or enrolling by invitation on ClinicalTrials.gov 
as of July 2020 (see Table 2.2). The majority of current cell-based therapies for 
SCI utilize MSCs or other bone-marrow derived stem cells. Fewer SCI studies 
involve NSCs or OECs, and there no current trials using iPSCs or SCs. Neural 
progenitor cell types (e.g., NSCs and iPSCs) that can differentiate into neurons 
have been investigated for SCI treatments for the purpose of directly replenishing 




SCs) are hypothesized to support functional recovery through a variety of 
mechanisms such as regulating inflammation, secreting growth factors to support 
cell survival, and remyelinating axons.(48) While many cell therapies with varying 
types of neural and non-neural cells have shown functional improvement after 
transplantation in animal SCI models, the efficacy in humans has yet to be 
proven. Many small clinical studies have not resulted in sufficient functional 
improvement or have had limitations in the experimental design (e.g., lack of 
appropriate controls and showing increased efficacy compared to normal 
spontaneous recovery).(34)  
There are several translational disadvantages that will need to be 
overcome for cell-based therapies to succeed: 1) limited cell sources, 2) costly 
and time-consuming in vitro culture, and 3) low cell survival after implantation. 
Adult NSCs are only found in the brain and spinal cord,(37) which are difficult and 
perhaps impractical to harvest for autologous use, but could be harvested from 
allogeneic donor tissue. ESCs and fetal-derived NSCs have ethical hurdles, but 
these hurdles may perhaps be mitigated by relying on immortalized cell lines such 
as the NSCs derived from fetal spinal cords used in clinical trials by Neuralstem 
Inc. (ClinicalTrials.gov Identifier: NCT01772810). Additionally, NSCs 
differentiated from iPSCs that were derived from autologous somatic cells are 
easily accessible and a more practical source than autologous brain or spinal 
cord derived NSCs. Other non-neural autologous cell sources are more surgically 




routine procedures, autologous MSCs can be obtained from bone marrow or 
adipose tissue, and either autologous (if available) or allogeneic Wharton’s jelly 
mesenchymal cells can be obtained from umbilical cords. OECs can be 
harvested from the olfactory bulb or the olfactory mucosa, and SCs can be 
harvested from the sural nerve. The downside of harvesting autologous tissues 
is that patients must undergo and recover from a second surgery (with autologous 
umbilical cord cells being an exception). Allogeneic cells from donor tissues can 
be a feasible source, but patients may need to take immunosuppressive drugs 
and donor cells may be limited. 
Regardless of cell source, a limitation of most cell therapies is the need for 
in vitro cell expansion because of the low number of cells obtained from biopsies 
or grafts. Given that the survival rate of transplanted cells is low, a therapeutic 
effect is only achieved with large numbers of cells. Note for example that current 
clinical trials implant up to 100 million cells (ClinicalTrials.gov, see supplemental 
Table 2.2). Harvested cells typically require 4-5 weeks of in vitro expansion in 
addition to the time needed for isolation and differentiation (e.g., of progenitor 
cells). Furthermore, isolated cells, such as progenitor cells or from tissues that 
include multiple types of cells (i.e., olfactory bulb/mucosa), need standardized 
testing to verify the purity of final implanted cells to prevent unwanted side effects 
or tumorigenicity.(41) Cell expansion is time consuming, expensive, and requires 
current good manufacturing practice (GMP) for regulatory approval. There are 




cell density to avoid clotting, when to deliver cells for the maximum therapeutic 
effect, and the route of administration, which are discussed in more detail by Tang 
et al.(41) 
In summary, before cell therapies can become a widespread realistic 
treatment option, there are current translational limitations that need to be 
addressed such as the limited efficacies shown so far and low cell survival after 
implantation. Other inherent challenges of cell therapies that will be more difficult 
to address are the time-consuming in vitro cell culture and the need for GMP 
facilities. Despite the latter challenges that will likely remain, the future of cell-
based therapies is thought to require combinations with other strategies to reduce 
some of the former limitations,(34, 48, 49) such as using biomaterials and/or 
biologics to improve cell viability. Promising combinations of cells with other 
regenerative medicine approaches are further discussed in later sections. 
Drugs & Biologics 
Given the translational issues of cell-based treatments, several small 
molecule drugs and biologics are in clinical trials that promote some degree of 
functional recovery after SCI by 1) neutralizing/degrading the extrinsic inhibitory 
components that prevent axon growth, and/or 2) intrinsically preventing apoptosis 
to promote neuron survival. For a few excellent reviews, we refer readers to 
Vecino and Kwok(39) and Badhiwala et al.(50) There are several antibodies and 
proteins in clinical trials (ClinicalTrials.gov, see Table 2.3) that bind to the 




neurite outgrowth inhibitor (Nogo-A), MAIs, Repulsive Guidance Molecule A 
(RGMa)) are designed to prevent receptor binding to either deactivate 
downstream axon-inhibitory signaling pathways and/or enable axon-growth 
signaling pathways. Aside from targeting extrinsic factors, there are small 
molecule drugs and biologics in clinical trials for intrinsically preventing apoptosis 
and supporting cell survival (ClinicalTrials.gov, see Table 2.3). Some small 
molecule drugs (e.g., cation channel blockers) aim to reduce excitotoxicity and 
the ionic imbalance causing apoptosis, and some biologics (e.g., growth factors) 
aim to upregulate cell survival pathways, reduce inflammation, or promote 
angiogenesis. 
Several drugs and biologics have had success in improving functional 
recovery in animal models that target extrinsic inhibitory components, intrinsic 
cell survival pathways, and inflammation.  An enzyme (i.e., chondroitinase ABC 
(ChABC)) and a peptide (i.e., intracellular sigma peptide (ISP)) have been 
particularly successful in promoting some functional recovery by degrading or 
preventing the binding of chondroitin sulfate proteoglycans (CSPGs), 
respectively. Promising preclinical drugs that upregulate survival/anti-apoptotic 
pathways to promote survival of damaged neurons and upregulate axon growth 
pathways include purine nucleoside and inosine.(2) Several growth factors have 
been investigated for neural differentiation, neuroprotection, and promoting axon 
growth (e.g., brain-derived growth factor (BDNF), nerve growth factor (NGF), 




Finally, there are promising preclinical drugs and biologics that have been 
investigated to reduce inflammation (e.g., minocycline, interleukin 4 (IL-4), and 
CD95),(53) reduce secondary damage initially after SCI, and/or polarize 
macrophages toward an M2-like regenerative phenotype. Inflammation is 
complex and may be beneficial in the early stages post-injury for aiding debris 
removal and limiting tissue damage, but inhibitory in the later stages as the 
inflammation persists and prevents regeneration.(2, 35) We recommend three 
excellent reviews for further reading on inflammation after SCI.(54-56)  
The main translational challenges of using drugs and biologics to treat SCI 
are targeted delivery and delivery of a therapeutic dose. Systemic delivery of 
drugs and biologics is difficult due to the low permeability of the blood-spinal cord 
barrier (BSCB), which only allows compounds less than 400 Da to cross.(53) The 
low diffusion of molecules across the BSCB necessitates high doses to be 
delivered to achieve therapeutic effects at the site of injury, which can result in 
systemic cytotoxicity and off-target effects.(33) To bypass the BSCB, 
therapeutics can be delivered locally, but injection into the intrathecal space 
around the spinal cord is hindered by the rapid clearance by the cerebral spinal 
fluid (CSF).(33) Furthermore, biologics such as growth factors are susceptible to 
enzymatic cleavage and have short circulation times(44) (e.g., NT-3 has a half-
life of 30 minutes after systemic injection,(57) ChABC loses enzymatic activity in 
3-5 days(58)). Injection of biologics can be further limited in clinical translation 




donor human or bacterial origins, and potentially high cost of isolation and 
purification from tissues. Overall, the local delivery of drugs and biologics both 
typically require repeated injections or continuous delivery by infusion to achieve 
the desired therapeutic effects,(44, 58) which is inconvenient and/or painful for 
patients and costly to produce.  
In summary, drugs and biologics have been developed to neutralize 
extrinsic factors and/or be neuroprotective, which may lead to less long-term 
damage; however, by only reducing the secondary injury and not promoting 
regeneration, there may be limited functional recovery. Nevertheless, modulating 
the inhibitory environment with neuroprotective/neutralizing drugs to create a 
permissive environment for axon growth in a combination strategy may improve 
the efficacy of regenerative approaches. Drugs and biologics will need to 
overcome the translational limitations of delivering a therapeutic dose and 
targeted delivery to the injury. However, in the future, drugs and biologics may 
have the advantage of oral or intravenous administration for earlier treatment 
(e.g., in the acute stage) than a cellular or material-based therapy that requires 
transport to a hospital and surgery. Combining acutely delivered drugs/biologics 
to create a permissive environment combined with regenerative approaches 
delivered in the later stages could leverage the advantages of both approaches 





The development of biomaterials typically aims to provide a physical and 
permissive environment that enables or promotes axon growth. There are two 
main areas of focus: 1) delivering and enhancing cell therapies, drugs, and 
biologics, and 2) controlling scaffold architectures to guide neurite outgrowth. 
Several types of scaffolds (e.g., extracellular matrix-based polymers, non-
mammalian natural polymers, synthetic polymers) have been developed and 
investigated in vitro and in vivo (we refer readers to two reviews(59, 60) for more 
comprehensive reviews of biomaterials for SCI), with few clinical studies or trials. 
Of the eight current (i.e., active, recruiting, not yet recruiting) clinical trials with 
biomaterials for SCI (as of July 2020, clinicaltrils.gov, see Table 2.4), most focus 
on combining biomaterials with cells. Only two of the eight current clinical trials 
that we identified are investigating a material alone, and are both investigating a 
poly(lactic-co-glycolic acid) (PLGA) scaffold called “Neuro-Spinal Scaffold” 
(ClinicalTrials.gov Identifiers: NCT02138110, NCT03762655)), which has shown 
moderate improvements in the first enrolled patient.(61) 
To overcome the translational limitations of cell therapies, drugs, and 
biologics, biomaterials have been widely employed in the literature to deliver 
these therapeutics. Five of the eight current clinical trials that use biomaterials 
focus on using scaffolds to deliver cells because the materials can protect cells 
from the shear stresses of being injected through a needle and protect cells from 




and functional recovery in animal models. There are two different scaffold 
approaches that have been presented in combination with cells. The first is a 
collagen scaffold with a sural nerve graft to deliver autologous OECs 
(ClinicalTrials.gov Identifier: NCT03933072). The other is a linearly ordered 
collagen scaffold from decellularized bovine aponeurosis (NeuroRegen Scaffold), 
which delivers umbilical cord-derived MSCs (UC-MSCs), mononuclear cells 
(ClinicalTrials.gov Identifiers: NCT02352077, NCT02510365, NCT02688062), or 
NSCs (ClinicalTrials.gov Identifier: NCT02688049). While improvements were 
moderate in eight chronic patients treated with the NeuroRegen Scaffold with UC-
MSCs (e.g., no change in ASIA classification, but some improved autonomic 
functions and motor evoked potentials),(62) two acute patients had significant 
functional voluntary motor improvements after 12 months.(63) Increased 
numbers of patients in the trial and proper controls in later phases are needed to 
confirm these promising initial results. Finally, the last trial is investigating the 
same collagen scaffold combined with ES (ClinicalTrials.gov Identifiers: 
NCT03966794). 
Outside of clinical trials, several other combinations of biomaterials with 
cells and/or with drugs/biologics have been investigated, and are covered in 
several reviews, of which we particularly recommend those by Katoh et al,(64) 
Wang et al,(60) and Ham and Leipzig.(65) For example, genetically modified 
cells, nano-sized, and micro-sized biomaterials have all been utilized for 




release, nanocarriers (e.g., carbon nanotubes (CNTs), polymeric nanoparticles) 
still have translational limitations similar to delivering drugs and biologics alone 
in terms of needing further characterization of clearance, getting past the BSCB, 
the large initial release of drugs on or near the surface, and/or attaining high 
payloads within the nanocarriers. Therefore, combinations of encapsulating drug-
loaded nanocarriers within macro-scale biomaterials (e.g., particles or fibers in 
hydrogels or electrospun scaffolds) have been investigated to achieve local 
delivery, sustained release, and mitigation of the burst effect, as reviewed by 
Song et al.(53) 
In addition to acting as a carrier for cells, drugs, and biologics, some 
biomaterials have a 3D structure that has been engineered for guided axon 
growth in vitro and in vivo (e.g., aligned nanofibers, hollow channels, patterned 
nanotubes). Specifically, aligned nanofibers have been shown to increase in vitro 
neurite outgrowth and orientation in the direction of nanofibers more than 
randomly aligned fibers.(53) Additionally, aligned nanofibers have been 
fabricated into 3D tubular shapes by rolling electrospun films into multi-layered 
tubes,(66) or dispersing aligned fibers in hydrogels(67) or made into composite 
guidance channels(68) for in vivo studies. Besides architectures, incorporating 
CNTs into hydrogels (e.g., Matrigel®, chitosan, polyethylene glycol-diacrylate 
(PEG-DA)) has shown greater in vitro neural cell adhesion and neurite outgrowth 
than the material alone and aligned CNTs have shown greater in vitro cell 




Although several of the translational limitations that are associated with 
cell therapies, drugs, biologics, and biomaterials have been overcome, there are 
still additional translational limitations that need to be addressed before 
widespread utilization in clinical studies can be expected. Preformed conduits 
and fibers may be easy to trim and surgically implant into a gap created by the 
transected or hemi-section SCI model; however, surgically implanting a 
preformed scaffold into human SCIs, most of which are contusion or 
compression-type injuries is more challenging. Preformed scaffolds would need 
to be trimmed and shaped to fit within the cyst-like injury in the operating room, 
or need to be fabricated in the shape of the defect, which may not be able to be 
determined at a sufficient resolution via current imaging techniques. Alternatively, 
glial scar tissue in the spinal cord would need to be removed to create a gap 
(although occasionally a transection-type injury and gap may exist)(69). As we 
mentioned earlier, removal of spinal cord tissue to implant preformed biomaterials 
during the acute stage has a higher risk that may compromise spontaneous 
recovery. In contrast, implanting preformed biomaterials during the chronic stage, 
after spontaneous recovery plateaus, is less risky because spontaneous recovery 
is not compromised, although introducing additional damage to the cord by 
removing tissue still has inherent risks. Injectable biomaterials are less invasive 
and less risky, which may be more translational for contusion SCIs. Any 




shape memory polymers,(70) cryogels(71)), but hydrogel precursors could be 
injected into an injury prior to gelation. 
Several reviews(33, 72-75) and other original research(76-79) have 
discussed the need for hydrogel precursors to be injectable for better clinical 
translation. To be injectable, precursor solutions would ideally be low-viscosity 
and/or shear-thinning. For other characterizations of precursor rheology, see our 
recent review in Townsend et al.(80) Although liquid hydrogel precursors may be 
capable of conforming and forming in situ inside the injury cavity, these liquids 
may be difficult to surgically place in a bleeding, fluid-filled environment. To 
overcome the placement and fitting challenges, a shear-thinning viscous or 
paste-like hydrogel precursor would be able to be surgically placed while still 
conforming to an injury of any shape. As we have previously investigated with 
hyaluronic acid-based(81, 82) and cartilage matrix-based hydrogels,(83) shear 
thinning paste-like precursors can be injected and enable easy surgical 
placement in irregularly-shaped defects.(80) While a paste-like hydrogel 
precursor may be easier to surgically deliver for cartilage defects where a 
surgeon could inject the paste-like biomaterial into the defect and press-fit the 
material to conform into the defect, an injured spinal cord in the late 
subacute/chronic stage in contrast may be more of an enclosed fluid-filled cyst 
rather than an open cavity, and injection of a viscous precursor to fill the space 




In summary, biomaterials have been developed for delivering cell 
therapies, drugs, and biologics to overcome translational limitations of each, and 
the added benefits of the tunable 3D architecture has been further engineered to 
guide neurite outgrowth. While preformed scaffolds may be more difficult to apply 
to the most common contusion SCIs due to necessary shaping in the operating 
room, injectable and viscous biomaterials that could fill and conform to the shape 
of a contusion SCI may be less invasive and more clinically translatable. 
Current therapeutic approaches: rehabilitation 
Given that even the most severely injured patients usually retain some 
axonal pathways and sensorimotor circuits in the spinal cord below the injury, 
most will go through activity-based rehabilitation therapies to promote 
reorganization of neural pathways, but motor training alone typically does not 
enable patients to produce movements voluntarily. To augment motor training, 
clinical research has investigated two methods to increase the excitability of 
spared axons and/or intact spinal circuits: 1) ES and 2) pharmacological 
stimulation. One of the proposed mechanisms of stimulation is that the increased 
excitability makes it easier for motor and sensory inputs to reach the action 
potential threshold of neurons, resulting in subsequent firing and continuation of 
the signal. Repetitive usage of a neural pathway encourages synaptic formation 
and maintenance, and thus re-organization through spared tracts, interneurons, 
motor neurons, and neural circuits which can improve voluntary function. The use 




by Shah and Lavrov.(84) For an overview of other stimulation techniques in a 
broader review of SCI, we refer readers to Hutson and Di Giovanni.(4)  
Electrical stimulation 
ES can be delivered at various locations to stimulate different parts of the 
spinal cord. Electrical epidural stimulation (EES) is investigated the most, and 
typically uses surgically implanted electrode patches on the spinal dura to directly 
deliver ES to the dorsal spinal cord right below the injury. However, non-invasive 
stimulation techniques are being developed as alternatives. These include 
transcutaneous stimulation, where electrodes are placed over the skin and injury 
site, and transcranial magnetic stimulation, which uses an electric current in a coil 
to generate a magnetic field that stimulates the brain and descending tracts to 
the SCI. Given the extensive field of ES for SCI, we briefly discuss ES in rats and 
cats, the challenges of translation to humans, and provide a few illustrative and 
recent clinical studies that have achieved encouraging clinical functional recovery 
to date.  
Rehabilitation approaches in rats and cats with incomplete SCIs can 
induce stepping that is most likely due to promoting neural 
plasticity/reorganization in spared tissue and/or activating intact spinal locomotor 
circuits. However, in transected rats and cats with no spared tissue, it is thought 
the stepping motions that can be elicited by rehabilitation approaches are due to 
activation of the intact spinal circuits. In cats with complete spinal transections 




stimulation, or various combinations can produce step-like motions.(85) Similarly, 
rats with complete spinal transections can achieve step-like motions with ES 
and/or pharmacological stimulation but stimulation without motor training resulted 
in stepping that was not full-weight bearing, and rats tended to drag their feet and 
produced uncoordinated, inconsistent stepping. With ES, pharmacological 
stimulation, and locomotor training, full weight-bearing locomotion and stepping 
motions indistinguishable from voluntary stepping have been achieved in 
rats.(86) While rodents may not need the motor cortex for locomotion, humans 
may have a higher dependence on supraspinal input during locomotion, such as 
for balance, and translation of such rehabilitation approaches has been slower to 
humans. EES alone has enabled human patients with complete injuries (i.e., AIS 
grade A) to produce volitional movement, but not independent stepping so 
far.(87) As reviewed by Shah et al,(84) there are several EES parameters being 
investigated to improve recovery of a stepping motion. These parameters include 
multisite vs. single-site stimulation with electrode arrays, locations of stimulation 
(lumbosacral), frequencies, pulse intervals, and relative timing of stimulation 
pulses in different segments.  
Similar to rats, combining motor training and ES has had encouraging 
functional recovery in terms of enabling over-ground independent stepping (with 
assistive devices). In one study, patients were treated with intensive motor 
training at the same time as task-specific spatiotemporally-controlled EES 




sequences at specific intervals.(88) The results were that the use of specific 
spatiotemporal activation patterns enabled over-ground walking with assistive 
devices ~15-85 weeks after electrode implantation in two patients with 
incomplete injuries (i.e., AIS grade B).(88) However, for two other patients with 
complete injuries (i.e., AIS grade A), over-ground walking was not achieved, and 
instead only stepping with body-weight support on a treadmill was achieved.(88) 
None of the four participants could step at all without the EES turned on.  
Another more recent study employed spatiotemporally-controlled EES 
with motor training for three patients. Two patients had incomplete injuries, and 
they experienced improved over-ground walking with EES turned on after only a 
week of training, and then had neurological recovery after only a few months of 
training to the point where they had improved over-ground walking with assistive 
devices without the EES on.(89) For the patient with the complete injury, over-
ground walking with a walker was achieved only when the EES was on. While 
the patient with the complete injury could not walk with the EES off, they could 
fully extend their legs against gravity, which they were not able to do prior to 
starting the treatment. A third study with a patient with a complete injury yielded 
similar task-specific EES-enabled independent over-ground stepping (with 
assistance) after 43 weeks of the EES combined with motor training.(90)  
Although these clinical studies offer promising results, the authors noted a 
limited number of patients were treated to determine feasibility, and larger studies 




involving EES with or without motor training are ongoing, but there are additional 
considerations (i.e., the timing and sequence of interventions, determining the 
subsets of patients that benefit the most) that are discussed further in a review of 
rehabilitation and ES for SCI and traumatic brain injury (TBI) by Hofer and 
Schwab.(91) The promising outcomes in complete patients are thought to be due 
to the activation of intact spinal networks for locomotion, and these methods may 
be a short-term approach to recover locomotion; however, tissue regeneration 
may still be necessary for full recovery of functions beyond locomotion until the 
spinal networks in humans are better understood and able to be leveraged for 
enhanced recovery.   
While EES is the most widely studied method of ES, there are 
disadvantages and limitations, such as the invasive electrode implantation into 
the spinal dura. Given that implanted electrodes can cause tissue damage and 
gliosis around the electrode, and can therefore reduce the ability of the electrode 
to stimulate the tissue,(4) non-invasive stimulation has been investigated. Two 
types of non-invasive stimulation are transcutaneous and transcranial 
stimulation. Transcutaneous stimulation involves electrodes placed on the skin 
over the spine at the level of the injury, instead of surgical implantation on the 
spinal dura with EES. Benefits of transcutaneous stimulation include that it is 
noninvasive, inexpensive, and readily available, and therefore very low risk. 
However, transcutaneous stimulation does not offer the precise control over 




The efficacy of transcutaneous stimulation is inconclusive and still needs to be 
demonstrated in larger clinical trials,(92) and indeed there are several ongoing 
clinical trials.  
Another noninvasive approach is brain stimulation via transcranial direct 
current stimulation or magnetic stimulation, which can induce a current and 
stimulate spared descending pathways using an electric current in an external 
handheld coil that generates a magnetic field. With repetitive task training, 
transcranial stimulation has been shown in small case studies to facilitate activity-
dependent voluntary motor function, particularly with fine motor hand function.(4, 
20) In other studies, however, effects of transcranial stimulation have been found 
to be small or inconclusive.(93, 94) Several clinical trials attempting to 
demonstrate clear treatment benefits are ongoing. 
The field of ES treatments used for SCI is vast, and recent clinical 
advancements in the use of spatiotemporally controlled EES simultaneously with 
motor training has shown significant promise to promote functional recovery of 
independent stepping with assistive devices. Larger studies are needed to 
confirm efficacy, and the parameter space must be fine-tuned in clinical studies 
to further enhance efficacy. Rehabilitation approaches may primarily promote 
reorganization through spared tissue in incomplete patients and activation of 
intact spinal circuits below the lesion in complete patients to enable locomotion. 
However, activation and control of spinal networks with sensory input to generate 




regeneration may still be necessary for full recovery. In addition, limitations with 
the implanted electrodes will need to be addressed in the future for EES. While 
noninvasive methods exist, such as transcutaneous stimulation and transcranial 
stimulation, they have less direct control over the site of stimulation and the 
efficacy shown so far has been limited. 
Pharmacological stimulation 
Stimulation can be achieved through pharmacological approaches as an 
alternative or in addition to electrical stimulation. Several pharmacological 
stimulants are FDA approved and have been widely employed to treat various 
neurological disorders, which enables easier translation to SCI.  
Neurotransmission is critical for controlling neural signaling in the spinal cord, and 
the use of pharmacological stimulation with EES aims to promote long-distance 
re-growth of axons in clinical trials for SCI. Pharmacological stimulation studies 
are limited to delivering monoaminergic molecules, and further limited to only 
those molecules that modulate neurotransmitters. For example, 5-
hydroxytryptophan (5-HTP) is the precursor to serotonin, which is known to 
stimulate serotonergic receptors, and has resulted in increased hindlimb activity 
in rat contusion models of SCI.(95, 96) As such, a phase II/III clinical trial for 5-
HTP (along with levodopa (L-DOPA), the precursor to dopamine) is ongoing 
(ClinicalTrials.gov Identifier: NCT04000919). Pharmacological stimulation with 
monoaminergic drugs has been explored in combination with EES. For example, 




combination of pharmacological stimulation and EES compared to animals 
treated with only one modality.(84, 97) The improved performance associated 
with combined EES and pharmacological stimulation justifies the ongoing clinical 
trials that are investigating pharmacological drugs paired with gait training. For 
example, a serotonin re-uptake blocker, Lexapro (escitalopram), and a serotonin 
agonist, buspirone (ClinicalTrials.gov Identifiers: NCT01753882, NCT04105114) 
are being investigated with gait training. Given the wide use of pharmacological 
stimulation in other neural diseases, the translation to SCI may be easier than 
other more complex methods of delivery for regenerative medicine approaches; 
however, systemic delivery of monoaminergic drugs may have potential off-target 
effects. Furthermore, the efficacy thus far has been limited and future 
investigations are needed to demonstrate the safety and efficacy of 
pharmacological stimulation with gait training. 
In current clinical trials, pharmacological stimulation has been applied in 
combination with gait training, and could similarly be combined with regenerative 
medicine approaches for SCI. As a form of stimulation that could enhance 
neuroplasticity, delivery of monoaminergic drugs could be a less invasive method 
than EES, which may translate better or combine well with regenerative medicine 
approaches in the future. However, outcomes of current clinical trials and future 




Conductive biomaterials: linking regenerative medicine and 
rehabilitation approaches 
Individually, regenerative medicine and rehabilitation approaches have yet 
to effectively promote locomotor recovery for SCI patients. The most successful 
examples of locomotor recovery in human clinical studies have arguably been 
from combinations of motor training with EES, which are both rehabilitation 
approaches; however, larger clinical trials are needed to confirm the extent of 
efficacy. Despite the encouraging clinical results, patients with more severe 
injuries have not yet benefitted as much as patients with incomplete injuries from 
rehabilitation approaches alone. As others have noted,(2-4) functional recovery 
from SCI may be improved by combining regenerative medicine and 
rehabilitation. Regenerative medicine approaches aim to modulate the inhibitory 
environment and promote axonal regeneration, and rehabilitation approaches 
aim to stimulate regenerated tissues and promote reorganization of neural 
pathways. There are only a few ongoing clinical trials for combined therapeutic 
approaches: a collagen scaffold with EES, and umbilical cord blood-mononuclear 
cells with lithium carbonate and locomotor training (ClinicalTrials.gov Identifiers: 
NCT03966794, NCT03979742). Similarly, there are few in vivo studies combining 
rehabilitation approaches and regenerative medicine approaches. One study by 
Lin et al.(8) demonstrated better in vivo motor recovery in rats when treated with 




phosphate) (PCLEEP) scaffold with rehabilitation, compared to rats treated with 
only the scaffold (no rehabilitation).  
The overarching problem of rehabilitation approaches, including ES, is the 
reliance on spared connections that patients with more severe injuries may lack, 
and therefore severely injured patients benefit less from rehabilitation. 
Regenerative medicine may be able to facilitate regeneration of neural pathways 
for rehabilitation approaches to elicit their effects on. In translation of combined 
regenerative rehabilitation treatments, several rehabilitation approaches are 
already in clinical trials. 
The pragmatic problem now is translating the regenerative medicine 
approaches of cells, drugs, biologics, and biomaterials for clinical use that 
complement rehabilitation approaches. Conductive biomaterials can link 
rehabilitation and regenerative medicine approaches by providing a medium for 
ES delivery to cells in addition to providing a platform for delivery of regenerative 
medicine approaches (e.g., cells, drugs, biologics) and/or pharmacological 
stimulants (see Fig. 2.1). The intrinsic structure of a neuron is designed to pass 
electrochemical signals, so it is not surprising that neurons and neural progenitors 
respond to ES in terms of proliferation, differentiation, and migration.(98) 
Conductive biomaterials have been thought to benefit SCI as a scaffold to bridge 
the lesion and provide immediate connectivity; however, there are variable in vitro 
results of the effects of conductive biomaterials alone.(10-12, 14) The synergy 




in vitro through improved neurite growth beyond what each approach can do 
alone.  
Given that many cell types respond to ES (e.g., fibroblasts, myoblasts, 
osteoblasts),(23) several types of conductive materials have been developed and 
investigated for a variety of applications, including nerve regeneration in general, 
spinal cord regeneration in particular, and additionally biosensors, drug delivery, 
and tissue engineering of cardiac and muscle tissues. There are three categories 
of conductive biomaterials: 1) conductive polymers, 2) carbon-based materials, 
and 3) metallic particle-based materials, and additionally there are combinations 
of each. In the following sub-sections, we discuss the fabrication methods used 
for each category of conductive biomaterial along with the associated 
translational advantages and disadvantages in the context of treating spinal cord 
injury. 
Methods for fabricating conductive composites 
As others have reviewed, the most commonly discussed methods of 
fabricating of conductive composites are 1) coating,(22) 2) in situ processes,(22, 
23, 99, 100) and most commonly, 3) blending.(22, 23, 99, 100) Coating methods 
usually involve coating the surface of a preformed non-conductive scaffold with 
the conductive component (e.g., covalent attachment, immersion/drying, spin-
coating). In the specific case of composites with conductive polymers, the 
polymer can be coated on a non-conductive scaffold through polymerization of 




deposition.(101) Electrochemical deposition typically involves application of an 
electric potential to oxidize a bulk solution of monomer and electrolyte, which 
results in polymerization onto the electrode in a thin film; however, the deposition 
can alternatively be onto the surface of a material.  
In situ processes are methods of forming conductive components (e.g., 
metal particle formation, polymerization to form conductive polymers) within other 
non-conductive scaffolds.  For conductive polymers, in situ polymerization utilizes 
methods that are similar to chemical synthesis methods for conductive polymers, 
where a strong oxidizing or reducing agent is added to a bulk solution of a 
monomer to cause polymerization. In situ polymerization is typically a two-step 
process. First, a preformed non-conductive scaffold is saturated with the 
monomer of the conductive polymer. Second, an oxidizing or reducing agent is 
then added to initiate polymerization of the conductive polymer within the 
preformed scaffold. Similar to the two-step process of in situ polymerization, in 
situ formation of metal nanoparticles involves saturation of a preformed non-
conductive scaffold, except with metal ions, followed by addition of a reducing 
agent to form nanoparticles within the scaffold.(102) Another two-step in situ 
formation method is to reduce the metal ions with a non-conductive polymer 
followed by scaffold formation of the non-conductive polymer.(103, 104) Less 
commonly, in situ polymerization has been accomplished via polymerization of 
the monomer to surround other nanoparticles.(99, 105) More recently, one-step 




of the conductive polymer was polymerized at the same time as non-covalent 
gelation of another polymer (i.e., semi-interpenetrating network (IPN)),(106) or 
whereby the conductive monomer was used to crosslink monomer-functionalized 
polymers (i.e., covalent semi-IPN).(107)  
The blending method is the most utilized of the three methods, and 
involves mixing of preformed conductive components (i.e., macro-, micro-, nano-
sized particles) with precursors of other non-conductive materials, followed by 
fabrication of the blended precursor through conventional methods (e.g., 
electrospinning, freeze-dried casting, hydrogel crosslinking). All three types of 
conductive materials (i.e., polymers, carbon-based, and metal-based) have been 
used with the blending method to make conductive composites. The conductivity 
of composites with conductive particles and an insulating polymer matrix are well 
described by percolation theory,(21) where at a critical volume of conductive filler 
(i.e., the percolation threshold) the conductivity increases by several orders of 
magnitude. Below the threshold, the electrical properties of the composite are 
dominated by the insulating matrix because electron paths are not formed, and 
above the threshold there is little effect on the conductivity with increasing 
concentration of the conductive component.  
Given that the addition of filler usually makes polymers stiffer and more 
brittle, different materials, sizes, and shapes of filler have been investigated to 
decrease the percolation threshold and reduce the amount of filler needed to 




thresholds than larger particles (e.g., microparticles), and therefore several types 
of nanoparticles have been developed to make conductive composites for a wide 
variety of applications that include tissue engineering and regenerative medicine. 
Furthermore, particles with higher aspect ratios have lower percolation thresholds 
than spherical particles, leading to several composites being made with 
nanotubes or nanowires. Spherical particles require shorter interparticle 
distances and thus higher concentrations to maintain a conductive network, but 
high-aspect ratio particles can maintain contact with greater interparticle 
distances to form a conductive network with lower concentrations.  
Each fabrication method has advantages and disadvantages. First, 
coating processes are simple and effective to impart conductivity to a non-
conductive scaffold. However, as noted in the review on conductive hydrogels by 
Min et al,(22) the independent layers of the conductive coating and scaffold could 
lead to cracking and delamination if there is not sufficient interaction and bonding 
between the layers. Second, those authors further discussed that in situ 
processes resulted in homogeneous distributions of the conductive component 
throughout the scaffold, which could improve conductivity and mechanical 
performance. The discussed disadvantage was that these in situ methods could 
be more complex than the other fabrication methods, in part by consisting of 
multiple steps. Third, the blending method is a simple and widely adaptable 
process that can be used with various conductive fillers (e.g., conductive polymer 




the conductive material is important for creating a conductive network without 
compromising mechanical performance, but homogenous distributions of 
nanoparticles can be difficult to achieve, as nanoparticles can aggregate quickly 
and irreversibly. Additionally, from the small size of nanoparticles, the blending 
method requires high concentrations of nanoparticles to reach the critical 
volumes of filler to form conductive networks.  
Given that the coating method takes place after the formation of a non-
conductive scaffold, conductive composites fabricated via this method are 
therefore not conducive to injectable delivery systems and by definition must be 
in a preformed solid form for implantation. The same is true for in situ 
polymerization methods that follow a conventional two-step process, which 
necessitate the creation of a preformed scaffold. The problem is that preformed 
scaffolds may not conform to the shape of contusion or cyst-like SCIs, and the 
scaffold may require trimming to fit within the injury or the spinal cord tissue may 
need to be surgically removed to enable the scaffold to fit. Overall, preformed 
scaffolds are less translational than composites that could be injected and form 
within the injury. For application in SCI, the most translational methods of forming 
composites are the one-step in situ processes or the blending method of high 
aspect ratio nanomaterials with a material capable of conforming to the shape 





Conductive polymers have traditionally been used in a wide range of 
applications in society including capacitors, flexible electronics, and organic light 
emitting diodes (OLEDs), but the lack of solubility in water, rigid mechanical 
performance, and poor processability after polymerization have limited the uses 
for biomedical applications. As such, conductive polymer composites have been 
developed to overcome some of these limitations by improving solubility and 
degradation, and thereby forming 3D scaffolds for biosensors, drug release 
systems, neural interfaces, and tissue engineering (e.g., bone, cardiac, nerve, 
muscle). For more comprehensive reviews on conductive polymers, there are 
multiple outstanding reviews that we recommend.(21-24, 100, 108-110) 
Conductive polymers typically have alternating single and double bonds that 
result in overlapping -orbitals, or a conjugated -system, which then allows 
electrons to be mobile along the polymer chain. However, these conductive 
polymers by themselves are not highly conductive relative to the broader 
materials spectrum (see Fig. 2.2), with conductivities in a range similar to 
insulators to semiconductors.(108, 111) Therefore, to improve conductivity, 
doping such polymers through oxidation (p-doping) or reduction (n-doping) with 
counterions provides charge carriers and can increase polymer conductivities 
into a range more on the order of semiconductors to metals. The most commonly 
known conductive polymers in order from the most common to the least common 




polythiophene (PT), a derivative of PT called poly(3,4-ethylenedioxythiophene) 
(PEDOT), and poly(p-phenylene vinylene) (PPV). The composites of each 
conductive polymer that have been investigated for biomedical applications, and 
specifically on nerve regeneration, are shown in Table 2.5.  
PPy is the most commonly investigated conductive polymer for SCI 
because of the high conductivity (up to 103 S/cm,(100) see Fig. 2.2), ease of 
synthesis, and ease of biomolecule incorporation.(21, 111) PPy composites have 
been formed by in situ polymerization,(112-116) coating,(101, 117) and blended 
polymer nanoparticles into films(118-120) or scaffolds.(121, 122) Only a few 
studies have used PPy in SCI animal models. For example, a few studies 
synthesized electrospun films made of blends of PPy particles with PLA, rolled 
up the films into tubes, and implanted them in rat transection SCI models.(118, 
119) Another study used a PPy hydrogel patch that was crosslinked with tannic 
acid and then implanted into a rat hemi-section SCI model.(123) While motor 
functional recovery in rats was better with PPy materials than sham controls, rats 
did not fully recover complete motor function.  
Conductive polymer films that are rolled into tube shapes are useful for 
peripheral nerve regeneration and perhaps for the niche group of patients with 
transection SCIs; however, the pre-defined shape may be a limiting factor in 
translating to the treatment of contusion SCIs. Tube-shaped scaffolds may not 
be able to conform well to the injury borders or may require resection of some 




be highly invasive and might only be feasible for patients with chronic injuries. 
Development of PPy hydrogel blends that consist of PPy crosslinked with other 
molecules,(123) or are non-conductive polymers conjugated to pyrrole and 
crosslinked via pyrrole polymerization,(107, 124) have been more promising in 
terms of clinical translation. However, these formulations still require 
prefabrication because crosslinking conditions are not biocompatible (e.g., use of 
oxidative initiator such as iron(III) chloride, which is toxic). A one-step self-
assembly between polymers (i.e., polypyrrole and sodium alginate)(106) has 
more clinical translatability, but these have yet to be used for SCI either in vitro 
or in vivo. 
After PPy, PANI is the second most investigated conducting polymer and 
is a polymer of aniline that exists in three oxidation states (i.e., fully oxidized 
pernigraniline base, half-oxidized emeraldine base, and fully reduced 
leucoemeraldine base).(100) PANI in the emeraldine form has good conductivity 
(up to 2x102 S/cm,(100) see Fig. 2.2), low cost, good stability, ability to switch 
between the conductive and resistive state, and potential antimicrobial and 
antioxidant activity.(99, 100) PANI by itself is non-toxic; however, the 
biocompatibility of different PANI composites depends on the composition, size 
and shape of nanoparticles, dopants, and preparation. The biocompatibility is 
decreased by low molecular weight compounds from the reaction byproducts and 
acids that form the PANI salts.(99) Similar to PPy, the poor processability and 




composites have been made into films using in situ polymerization(125-127) or 
blending PANI nanoparticles into film precursors.(128, 129) PANI films have been 
used for in vitro studies or for peripheral nerve regeneration in vivo, but not yet 
for SCI in vivo. 3D scaffolds are needed for SCI and recent in vitro studies made 
strides in developing composite PANI hydrogels that formed a 3D network with a 
variety of methods. For example, PANI hydrogels were made by crosslinking 
PANI with phytic acid,(105) or by blending PANI nanofibers and chitosan.(130) 
PANI oligomers have been grafted to natural polymers that were subsequently 
crosslinked into scaffolds,(131-133) or aniline was blended with a synthetic 
polymer followed by in situ polymerization and formation of a sponge-like 
cryogel.(127) Given that several of the three-dimensional scaffolds of PANI 
composites have non-biocompatible synthesis conditions, the scaffolds require 
prefabrication before implantation, such as the scaffold that have been coated 
with PANI.(134, 135) However, blends of PANI materials or grafted PANI 
oligomers with scaffolds that form under biocompatible conditions (e.g., 
gelatin)(131) and/or are injectable could be a promising approach to impart 
conductivity in established non-conductive biomaterials to create more clinically 
translatable options. 
Aside from the most commonly investigated PPy and PANI, newer 
conducting polymers, such as PT and PT derivatives, have been explored 
because of their similar electrical properties to PPy. PT films have been 




widely used in regenerative medicine. On the other hand, PEDOT, a derivative 
of PT, has high conductivity (up to 400 S/cm(100) or 1000 S/cm,(137) see Fig. 
2.2), better chemical stability than PT, and is transparent. PEDOT has gained 
considerable attention in biomedical engineering because the monomer is 
soluble in water, which makes blending with different materials in aqueous 
conditions easier. PEDOT is commonly doped with poly(4-styrenesulfonate) 
(PSS) and the resulting PEDOT:PSS combination is commercially available as a 
colloidal suspension; however, the downside is the need for additives (e.g., 
ethylene glycol) or post-processing (e.g., thermal annealing) to improve 
conductivity and stability in water for biomedical applications.(138) There are 
efforts to improve the solubility and conductivity of PEDOT without the need for 
additives by synthesizing monomer derivatives that self-dope.(137)  
Films of PEDOT have been synthesized via in situ polymerization,(139, 
140) but to form a 3D scaffold and treat a transection SCI in rats, one study 
coated carbon microfibers with PEDOT:PSS-co-maleic acid, and then rolled up 
30 of these coated microfibers in an alginate membrane.(141) Functional 
recovery was not assessed, but the functionalized PEDOT scaffold resulted in 
enhanced blood vessel formation and axonal regeneration, no increase in 
inflammation, and reduced scarring. Most PEDOT composites that have been 
employed in vitro for application to nerve regeneration have been fabricated via 
the blending process.(141-145) PPy and PANI have water-insoluble monomers 




easier to blend with other materials in aqueous conditions in comparison to PPy 
and PANI.  
Another method to fabricate PEDOT composites for in vitro studies was a 
method similar to two-step in situ polymerization, except the PEDOT scaffold was 
synthesized first via copper ion gelation, followed by swelling in of the non-
conductive polymer and polymerization to form an IPN.(146) Regardless of 
whether PEDOT:PSS composites were fabricated via an IPN, the coating 
method,(11, 147) or blending, in each case these methods required the scaffolds 
to be preformed, which has limited translatability to contusion SCIs. Despite the 
use of preformed PEDOT:PSS composites, the most significant advantage of 
PEDOT:PSS over other conductive polymers is the improved solubility. The 
improved solubility of PEDOT:PSS has resulted in the bioprinting community 
developing composites of PEDOT:PSS together with other materials that have 
biocompatible gelation processes for extrusion (e.g., methacrylated gelatin 
(GelMA)),(143) ink-jet,(138) and stereolithography (SLA) bioprinting (e.g., PEG-
DA).(148, 149) In the future, the regenerative medicine field in general, and for 
SCI in particular, may benefit from applying some of the bioprintable PEDOT:PSS 
composites that could be more clinically translatable. 
Similar to PEDOT:PSS, PPV is a newer polymer with water-soluble 
monomers; however, without doping, it is considered an insulator. There have 
been older studies investigating different dopants to improve the conductivity of 




studies with aloin and FeCl3 (up to 10-4 S/cm, see Fig. 2.2).(12) There is a paucity 
of PPV studies for tissue engineering applications and nerve regeneration thus 
far. In one in vitro study, poly[2-methoxy-5-(2-ethyl-hexyloxy)1,4-phenylene 
vinylene] (MEH-PPV) and polycaprolactone (PCL) were blended and electrospun 
into films that supported neural cell viability the same as tissue culture plastic.(12) 
The MEH-PPV:PCL meshes were electrically stimulated and neural cells had 
enhanced neurite formation compared to non-stimulated controls. In another 
study, a PPV composite hydrogel was developed with polyacrylamide for 
controlled drug release.(151) While the PPV hydrogel was not specifically for 
nerve regeneration, the methods of grinding a PPV film into a powder for blending 
could be applied and incorporated into other polymers with biocompatible 
formation conditions for application to SCI. PPV has been minimally applied to 
regenerative medicine and has not been applied to SCI yet, but one of the limiting 
factors of all conductive polymers is the low conductivity when blended (see Fig. 
2.2). To improve the conductivity, other conductive polymers have been 
combined with carbon-based materials,(152-156) or metallic particles.(157, 158) 
If the low conductivity can be improved, the water-soluble polymer may enable 
future development of blends with PPV into more clinically translational materials 
for SCI. 
In summary, several conductive polymers have been developed and 
tested in vitro with promising neurite outgrowth, especially when coupled with ES; 




the few in vivo studies with conductive polymers, the functional recovery of rats 
treated with conductive polymers has been better than shams but has not yet 
resulted in full functional recovery. For translation of conductive polymers for SCI 
in the future, the most promising fabrication method is the blending method to 
incorporate the conductive polymers into injectable materials that can form within 
the injury. The bioprinting field has developed several ‘bioink’ formulations of 
biomaterial precursors containing PEDOT:PSS, which are injectable and form 
after printing under biocompatible conditions. The formulations that can serve as 
bioinks for extrusion-based bioprinting can additionally serve as injectable 
materials for regenerative medicine applications.(80) In the future, it may be 
beneficial for the regenerative medicine and SCI field to adapt bioprintable 
materials for contusion SCIs. Using the blending method, several of the 
conductive polymers could be integrated with injectable materials that can form 
in the injury, but the most promising conductive polymers that have been 
developed and tested in vitro are polymer-grafted PANI oligomers and the water 
soluble, PEDOT:PSS polymer, both of which could be enable future development 
of conductive polymer blends for application to SCI. 
Carbon-based materials 
Carbon-based materials include graphene, graphene oxide (GO), and 
CNTs and have been explored for nerve regeneration because they are highly 
conductive (103 to 104 S/cm, see Fig. 2.2) and have large surface areas for 




several reviews for additional information about graphene-based composites for 
biomedical applications,(159) stem cells,(160) in SCI,(161) and about 
biofunctionalized CNTs(162) and CNTs in the central nervous system 
(CNS).(163) In this section, we cover GO, CNTs, and the blends of each that 
have been used to fabricate conductive biomaterials for nerve repair, along with 
their translational advantages and disadvantages (see Table 2.6).  
Graphene is a single 2D sheet of sp2-hybridized graphite, and graphene-
based materials come as a colloidal suspension of sheets (0.5 to 5 nm thick, 10 
nm to 5 µm lateral size).(159) Graphene has been shown to be biocompatible as 
an immobilized surface for neural cell growth(164) and able to promote greater 
differentiation when coated in laminin compared to control surfaces.(165) Even 
so, the hydrophobicity and aggregation of graphene have limited the biological 
applications, and therefore pristine graphene is rarely used. On the other hand, 
the oxidized state of graphene, GO, contains several hydroxyl groups that 
increase the hydrophilicity, decrease aggregation, and increase the ability to 
adsorb biomolecules, but unfortunately decrease the conductivity. Reduction of 
GO via thermal, chemical, or electrical treatments produces reduced GO (rGO), 
with fewer hydroxyl groups, thereby achieving conductivities closer to pristine 
graphene.  
To make 3D scaffolds to treat SCI in vivo, rGO-only scaffolds have been 
formed via freeze-drying,(166, 167) thermal crosslinking,(168) or both with 




preformed, as opposed to injectable delivery with in situ polymerization, due to 
the scaffold formation conditions being non-biocompatible. Functional recovery 
was not evaluated in any of these SCI studies to date, but these studies did report 
positive outcomes such as new microvasculature, evidence of myelination, 
reduced gliosis, and reduced inflammation. Blends of other materials with GO 
and rGO have been fabricated to improve mechanical performance and for easier 
functionalization during in vitro and in vivo SCI studies. During a few in vitro 
studies, the coating method was used to coat GO on electrospun polymers and 
evaluated with neural cells(170) or oligodendrocytes,(171) but the formed 2D 
scaffolds may be less translational for SCI.  
3D scaffolds for in vivo studies have been made, but similar to in vivo 
studies with graphene, the non-biocompatible formation conditions made 
prefabrication necessary for all scaffolds implanted in rat SCI models. In one 
example, blended PLGA/GO nanofiber mats were electrospun and functionalized 
with growth factors before being implanted in a rat SCI model. This approach 
resulted in better functional recovery, reduced cavity formation, and more 
neurons compared to PLGA alone.(172) In another study, scaffolds were 
preformed by embedding rGO microfibers in gelatin and crosslinking in 
paraformaldehyde for 7 days before implantation in a rat SCI model. The 
rGO/gelatin scaffold resulted in new microvasculature and decreased gliosis, but 
there was no evaluation of functional recovery.(173) Further in vivo studies are 




terms of clinical translation, all preformed scaffolds were implanted because the 
crosslinking methods for GO and rGO scaffolds are not biologically compatible, 
but future methods that are more translational could involve blending GO or rGO 
into materials that can undergo gelation in the injury and conform to the size and 
shape of the injury.  
In contrast to graphene and GO, CNTs are sheets of graphite rolled into a 
cylinder as single-walled (SWCNTs) or multi-walled CNTs (MWCNTs) with 
enormous aspect ratios. These high aspect ratios are due to CNTs being 
hundreds of nanometers to microns in length and only 1-3 nm or 10-200 nm in 
diameter for SW- and MWCNTs, respectively. CNTs have been used in 
biomedical applications because of the high aspect ratio, high conductivity (up to 
105 S/cm),(22) ease of functionalization to deliver therapeutics, and improved 
mechanical performance when combined in composites. The biggest 
disadvantages of CNTs are the insolubility in water and the aggregation, which 
causes cytotoxicity. In the CNS, CNTs can cause inflammation, reactive oxygen 
species overproduction, and mitochondrial dysfunction.(163)  
Despite the cytotoxicity, CNTs are still widely used in biomedical and 
neural applications because the large surface area can easily be functionalized 
to 1) deliver high loads of biomolecules compared to other nanoparticle delivery 
systems and 2) improve hydrophilicity, dispersion, biocompatibility, and the ability 
to form composite materials. CNTs have been employed in vitro with some 




surface coating to improve neuronal adhesion,(174) and in another example, 
CNTs were delivered to cells as a suspension, which resulted in better delivery 
of NGF that promoted cell differentiation and growth.(175) However, delivery of 
CNT suspensions in vivo resulted in modest functional recovery in a rat SCI 
model.(176)  
3D scaffolds of CNTs and CNT composites have been developed mostly 
for peripheral nerve applications but have non-biocompatible synthesis 
conditions, which require prefabrication and limit translation for treating SCI. For 
example, methods that are often non-biocompatible include chemical vapor 
deposition,(177) coating methods,(178, 179) electrospinning,(15, 180-182) oven 
drying,(183) UV crosslinking for extended amounts of time,(16) coagulation in 
ethanol,(184) freeze drying,(185-187) electrodeposition,(188) and Matrigel®.(13) 
For application to SCI, CNT composites formed via the blending method with 
biocompatible formation conditions may be more translational. Examples of CNT 
composites with biocompatible formation conditions include UV-crosslinked 
polyacrylamide/thiolated PEG (PEG-SH) hydrogel,(14) crosslinkable PEG-DA 
hydrogel,(189) UV-crosslinked GelMA hydrogel.(190) CNT composites that can 
form under biological conditions may have improved translation for contusion SCI 
and should be further investigated in vivo. 
In summary, there have been some pioneering in vivo SCI studies 
involving graphene-based scaffolds and composites that have established 




needed to establish the efficacy and functional recovery after SCI with graphene-
based conductive composites. Furthermore, composites of graphene with other 
materials that can form under biological conditions will need to be developed for 
translation to contusion SCIs. While functionalized CNTs can overcome 
hydrophilicity, aggregation, and cytotoxicity problems, the preformed scaffolds 
will limit translation to SCI. Additional CNT composites that can form under safe 
biological conditions are needed for translation to contusion SCIs.  
Metallic particle-based materials 
Metal nanoparticles have been highly attractive to fabricate conductive 
composites for a variety of applications because of the tremendous conductivities 
of metals. Conductive composites using gold, silver, platinum, and/or metal 
oxides (e.g., iron oxide) have been fabricated and investigated for biomedical 
applications such as hydrogels with gold nanoparticles (AuNPs) or iron oxide 
nanoparticles (IONPs). However, there are limited studies applied to neural tissue 
engineering in vitro and even fewer applied to treat SCI in vivo. Among the metal 
particles, AuNP composites are the most widely developed for tissue engineering 
and have been applied in cardiac, muscle, and peripheral nerve applications.  
Silver nanoparticles (AgNPs) are advantageous for their antibacterial, 
optical, and photo-thermal properties, but were shown to disrupt the neural 
cytoskeleton and reduce neurite length and differentiation in cultured NSCs in 
vitro.(191) Furthermore, in one in vivo rat study, AgNPs exacerbated neuronal 




In a review on the inflammatory response to silver in the CNS by Wu et al,(193) 
AgNPs were implicated in stimulating reactive oxygen species and nitric oxide 
production, thereby causing neuroinflammation.  
In terms of other metals, platinum nanoparticles are another available 
option, but these have mostly been used for catalysts and biosensors,(194) and 
not yet for nerve regeneration. As another metal example, IONPs have been used 
for SCI, but mostly to leverage their magnetic and optical properties and not to 
form conductive composites. The use of conductive composites has been limited 
for SCI, so in the remainder of this section, we now return our focus to composites 
made with AuNPs for cardiac and skeletal muscle applications, and then later will 
address IONPs that have been used for SCI (see Table 2.7).  
AuNPs are attractive because they are highly conductive (up to 105 S/cm, 
see Fig. 2.2), easy to scale up, easy to functionalize, and can be made into a 
variety of shapes, including nanorods and nanowires. Gold is usually considered 
to be non-toxic and several studies using larger particles (30-100 nm) did not find 
acute side effects from systemic delivery. However, there could be size-
dependent long-term toxicity of small AuNPs (<1.4 nm), which are thought to 
aggregate inside cells and be cytotoxic, and there are varying cytotoxicity results 
for medium-size AuNPs (8-37 nm).  
The easy functionalization of AuNPs has been leveraged to fabricate 
several composite materials for drug delivery, particularly for delivering cancer 




engineering scaffold studies using AuNPs to crosslink polymer scaffolds.(195, 
197, 198) There are a precious few AuNP composites that have been tested in 
vivo for SCI. In one example, AuNPs were employed for fibroblast growth factor 
(FGF) delivery with a scaffold composed of agarose and poly(N-
isopropylacrylamide) (PNIPAM) with bone marrow-derived MSCs.(199) The 
composite scaffold resulted in better functional recovery than sham controls after 
6 weeks, but the AuNPs were intended for FGF delivery, not conductivity.  
Aside from composites using AuNPs for drug delivery, most conductive 
gold composites have been fabricated for cardiac and skeletal muscle tissue 
engineering, not neural regeneration. Several of the AuNP composites were 
preformed and synthesized by methods that are not biologically compatible, 
which included in situ formation of AuNPs,(102) coating,(200, 201) freeze-
drying,(199, 202, 203) and electrospinning.(204) The blending method has been 
used to fabricate AuNP conductive composite scaffolds that form under 
biocompatible conditions. There are three examples: gelation via laponite 
nanoparticle interactions,(205) GelMA photopolymerization,(206, 207) and Schiff 
base-mediated collagen/cellulose crosslinking.(208) Additionally, in situ 
processes have been used to fabricate composite scaffolds with biologically 
compatible conditions where HAuCl4 was reduced in chitosan to form chitosan-
stabilized AuNPs, followed by scaffold formation via thermogelation at 37°C by 





Another advantage of AuNPs is the ability to control the shape of the 
nanoparticle during synthesis. As discussed earlier, spherical nanoparticles in 
conductive composites have higher percolation thresholds than high aspect ratio 
nanoparticles, which means higher concentrations of spherical nanoparticles are 
needed to attain the critical volume fraction for conductivity. High enough 
concentrations of nanoparticles can be challenging to obtain. Therefore, high 
aspect ratio nanoparticles (e.g., nanorods, nanowires) have been investigated to 
make composites because they have lower percolation thresholds and lower 
concentrations can be used. A disadvantage of gold nanorods (GNRs) and gold 
nanowires is that a toxic surfactant, hexadecyltrimethylammonium bromide 
(CTAB), is required for shape-controlled synthesis and further stabilization. The 
cytotoxicity is linked to the CTAB, but has been mitigated by coating the CTAB 
bilayer on the surface of the AuNP with non-toxic biomolecules (e.g., 
GelMA).(203) Complete replacement of the CTAB is difficult with normal ligand-
exchange methods because of the high affinity of CTAB to gold. However, 
indirect ligand exchanges on different AuNP sizes and shapes through deposition 
and etching of a silver layer have been successful in completely removing CTAB 
and replacing it with a non-toxic citrate coating, making the GNR more suitable 
for biomedical applications.(209)  
GNRs(203, 206, 207, 210) and nanowires(202) have been incorporated 
into composites via the blending method for in vitro cardiac tissue engineering or 




composites with GNRs for peripheral nerve tissue engineering. One example for 
peripheral nerve tissue engineering was a blended GNR and silk fibroin 
composite that promoted better neural adhesion and proliferation than silk fibroin 
controls in vitro.(212) For SCI, GNR composites have not yet been investigated 
to the best of our knowledge, but GNRs alone have been delivered in vitro to 
neural cells. For example, GNRs delivered to neural cells with laser stimulation 
resulted in longer neurite growth than laser stimulation alone,(213) and in a 
follow-up study, GNRs induced intracellular calcium transients.(214) GNRs have 
additionally been used to improve the stability of ChABC for future application to 
SCI.(215) While there are few studies with conductive GNR composites for nerve 
regeneration, the composites used in cardiac tissue engineering that form under 
biological conditions could be adapted and highly translational for SCI. Several 
AuNP or GNR composites have been developed to be injectable(103, 104, 205, 
208) or bioprintable,(197, 203) enhancing their translatability. 
While AuNPs have been used to fabricate conductive composites, IONPs 
have been applied in SCI for their magnetic properties and not for conductivity. 
Additionally, IONPs have low cytotoxicity, are a magnetic resonance imaging 
(MRI) contrast agent that can label cells, and fabricate minimally invasive, aligned 
scaffolds. For example, IONPs have been used to label and track cells via MRI 
after in vivo delivery of cell suspensions,(216) or within a hydrogel in vitro.(217) 
In addition, functionalized IONPs have been used for imaging cells and releasing 




blended into hydrogels, implanted in a SCI rat model, and subjected to 
electromagnetic fields to facilitate axonal regeneration via mechanical stretching 
of neuronal membranes and attenuation of oxidative damage.(219) There was 
no detectable functional recovery, but there was less demyelination and more 
sprouting from neurons than sham controls.  
For aligned topographies, IONPs have been blended and fabricated into 
microparticles, aligned in a magnetic field before hydrogel crosslinking, and finally 
dissolved to make aligned tubular microstructures to guide axon regeneration for 
peripheral nerve regeneration.(220) In addition to a templating technique, 
injectable hydrogels with aligned topographies have been made by magnetically 
aligning rod-shaped microgels made from PEG/IONPs(221) or macro-sized 
tubular fiber conduits made from electrospun IONPs with poly (L-lactic acid) 
(PLLA)(222) or PLGA(223) in hydrogel precursors (i.e., fibrin, fibrin/Matrigel®, 
collagen/Matrigel®). For all studies, the aligned tubular structures promoted in 
vitro guided neurite outgrowth within the hydrogels. In the future, the developed 
injectable hydrogels could be injected into a contusion SCI as a minimally 
invasive approach. 
In summary, composites utilizing metal particles are not widely used for 
spinal cord injury, but gold and iron oxide may be the most promising metals for 
SCI. From cardiac tissue engineering studies, several AuNP or GNR conductive 
composites have been developed that are injectable and can form under 




gold nanowires) have advantages of needing lower concentrations than spherical 
nanoparticles to obtain a conductive scaffold. Finally, non-conductive IONP-
based composites are promising because of the magnetic properties and ability 
to non-invasively align IONP nanoparticles or micro-sized rod-shaped scaffolds 
or fibers in an injectable natural polymer for guided axon growth.  
Discussion 
The integration of regenerative medicine and rehabilitation approaches, or 
regenerative rehabilitation, may be necessary for full functional recovery in 
patients with complete injuries. Rehabilitation approaches have showed clinical 
promise in achieving better functional recovery than current treatments, but full 
functional recovery has not yet been achieved. The key limitation of rehabilitation 
approaches is the reliance on spared tissue that patients with a severe SCI; 
however, regenerative medicine may be able to overcome this problem by 
promoting regeneration of the spinal cord tissue. Combined together, 
rehabilitation approaches may facilitate reorganization of the regenerated neural 
pathways for meaningful functional improvements. 
Despite the wide variety of regenerative medicine approaches for SCI 
(e.g., cells, drugs, biologics, scaffolds), the field has been limited by translational 
challenges to the clinic. With one in vivo SCI study(8) using the “regenerative 
rehabilitation” terminology and several additional studies and reviews utilizing the 
principles, the SCI field has been combining these fields to improve functional 




approaches, the compatibility of the approaches must be considered, as one 
approach could negatively affect the other. There is a need for regenerative 
medicine approaches that are designed specifically to synergize with 
rehabilitation approaches. Conductive biomaterials are strategically poised to 
integrate regenerative medicine and rehabilitation through use of the conductive 
biomaterial to deliver regenerative medicine approaches for regenerating the 
spinal cord tissue while facilitating transfer of ES through the injury to promote 
neural plasticity.  
Common to all categories of conductive composites, the most translational 
method was blending to mix conductive particles/materials into scaffold 
precursors that can subsequently form in an injury (e.g., via photocrosslinking, 
self-assembly, thermogelation). Furthermore, conductive composites developed 
for bioprinting are injectable and could be highly translational for SCI. One 
consideration of conductive composites that contain non-conductive materials is 
that the conductivity is lower than the pristine conductive component. Attaining 
sufficient concentrations of conductive particles can be difficult because of high 
percolation thresholds for spherical shapes. Fortunately, high aspect ratio 
particles such as gold nanorods or nanowires decrease the percolation threshold 
and can be used to achieve conductivity at lower concentrations. Another avenue 
that has been used to enhance the conductivity of composites was to combine 
two or more conductive components, and most of the combinations have included 




multiple conductive fillers may be another avenue for future development of 
highly conductive composites. 
In application to SCI, there are currently no in vivo studies using 
conductive biomaterials with ES or with ES/motor training. Additionally, there are 
limited numbers of in vivo SCI studies using only conductive biomaterials. 
However, for decades, in vitro studies have drawn on the fundamental principles 
underlying both regenerative medicine and rehabilitation by using conductive 
biomaterials with ES to deliver ES to neural cells, resulting in increased neurite 
outgrowth, neural differentiation, and proliferation. Complex combinations can be 
cumbersome for regulatory approval and hinder translation; therefore, proper 
controls are warranted to evaluate each component alone to identify the most 
influential component(s) to simplify translation or demonstrate a compounded 
and synergistic effect. While the combined effect of conductive materials with ES 
has been well characterized in vitro, the independent effect of conductive 
materials on neural cells is variable. Some conductive materials alone enhance 
neurite growth, but some materials have the same neurite growth compared to 
non-conductive materials. Unfortunately, non-conductive controls are not often 
included and conductive biomaterials with ES are compared to the same material 
without ES, which does not elucidate the effects of conductive materials. Future 
in vitro and in vivo investigations will be needed to elucidate the effects of 
conductive biomaterials by themselves and determine whether the effects of ES 




Evidence exists that rehabilitation approaches may be most effective when 
combining two separate neuromodulation approaches: ES and motor training, but 
the dependence of rehabilitation techniques on spared tissues may not be 
sufficient for severely injured SCI patients. By developing regenerative medicine 
strategies to overcome the limitation of rehabilitation approaches and linking the 
two fields, conductive biomaterials with ES and motor training may be a promising 
new direction for regenerative rehabilitation to improve functional outcomes for 




Chapter 3 : Development and Quantitative Characterization of 




Bioprinting technologies have tremendous potential for advancing 
regenerative medicine due to the precise spatial control over depositing a 
printable biomaterial, or bioink. Despite the growing interest in bioprinting, the 
field is challenged with developing biomaterials for extrusion-based bioprinting. 
The paradigm of contemporary bioink studies relies on trial-and-error methods 
for discovering printable biomaterials, which has little practical use for others who 
endeavor to develop bioinks. There is pressing need to follow the precedent set 
by a few pioneering studies that have attempted to standardized bioink 
characterizations for determining the properties that define printability. Here, we 
developed a pentenoate-functionalized hyaluronic acid hydrogel (PHA) into a 
printable bioink and used three recommended, quantitative rheological 
assessments to characterize the printability: 1) yield stress, 2) viscosity, and 3) 
storage modulus recovery. The most important characteristic is the yield stress; 
we found a yield stress upper limit of ~1000 Pa for PHA. Measuring the viscosity 
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was advantageous for determining shear-thinning behavior, which aided in 
extruding highly viscous PHA through a nozzle. Post-printing recovery is required 
to maintain shape fidelity and we found storage modulus recoveries above ~85% 
were sufficient for PHA. Two formulations had superior printability (i.e.,1.5 MDa 
PHA - 4 wt%, and 1 MDa PHA - 8 wt%), and increasing cell concentrations in 
PHA up to 9 x 106 cells/mL had minimal effects on the printability. Even so, other 
factors such as sterilization and peptide modifications to enhance bioactivity may 
influence printability, highlighting the need for investigators to consider such 
factors when developing new bioinks.(1) 
Introduction 
Bioprinting is a revolutionary technology that has empowered tissue 
engineers to recapitulate the native structure of tissues by allowing for spatial 
control over the deposition of printable materials, or bioinks, in addition to 
controlling cell distribution and the location of bioactive molecules within printed 
materials.(224-228) Conventional regenerative medicine research has 
investigated biomaterials containing homogeneous distributions of cells and 
biomolecules; however, native tissues are complex shapes with hierarchical 
structures from the macroscale down to the nanoscale, and homogeneous 
biomaterials that lack structured cues may not be capable of fully regenerating 
complex tissues. Bioprinting greatly increases the number of possibilities for 
physical arrangements of different biomaterials, cells, and biomolecules to mimic 




While there are a growing number of bioprinters commercially available, 
the bottleneck for research is the lack of printable bioinks.(227, 230, 231) Bioinks 
must satisfy traditional criteria for biomaterials in regenerative medicine such as 
promoting cell functions (e.g., migration, proliferation, differentiation), but must 
additionally ensure cell survival throughout the printing process and any post-
modifications (e.g., hydrogel crosslinking). Along with the biological 
requirements, bioinks are challenging to develop because of their physical 
requirements.(231, 232) Hydrogels are a commonly used platform for 
regenerative medicine because hydrogels facilitate cell survival and fulfill the 
biological requirements of a bioink; however, many hydrogel precursors are non-
viscous liquids that are incapable of being deposited as a 3D structure without a 
mold, thus rendering them useless for extrusion-based bioprinting.(233) 
Fortunately, the development of new printable bioinks has emerged as a 
promising subdiscipline within the bioprinting community, but less fortunately, 
much of the research depends on trial-and-error of different material formulations 
to determine printability, with limited characterization of the material’s physical 
properties or correlation of the characterization to the printability.(234-239) 
Currently, there are no standardized methods to characterize a material’s 
printability,(231, 233) and the development of new bioinks is limited by time-
consuming trial-and-error methods. Standardized characterization would stand to 
benefit from focusing on defining ‘printability windows’ for the properties that 




bioinks must 1) flow through a needle or nozzle as a stable filament, 2) ‘instantly’ 
retain its 3D shape after deposition on a platform, and 3) support the weight of 
additional deposited material without collapsing. A few of the rheological 
properties that relate to the process of bioprinting are the viscosity, yield stress, 
and storage modulus recovery, but only a handful of reviews and studies have 
attempted to standardize the characterization,(240-246) and few new bioink 
papers have characterized their bioink with any of the suggested standardized 
methods, which include viscosity/shear thinning,(233, 244, 247) yield stress,(233, 
241, 242) recovery,(244, 247) and storage/loss modulus.(243) Between the 
limited number of characterization studies, the viscosity has been well-
characterized in a few ways to define quantitative ‘printable windows’ for the loss 
tangent or predicting printing parameters; however, the printability windows for 
yield stress and storage modulus recovery have not been quantitatively defined 
for universal comparison. Reproducible methodology is a key step toward 
developing protocols that can accelerate the development of new bioinks 
globally, and facilitate comparisons among groups, thus, there is a need for a 
continued effort to follow the precedent set by the aforementioned pioneering 
studies that began using uniform characterizations for bioinks.(243, 244) 
Several types of bioinks are currently being investigated for extrusion-
based bioprinting, such as hydrogels, cell aggregates, and decellularized 
extracellular matrix.(226, 233, 248) Hydrogels are advantageous because of their 




(e.g., Pluronic®, poly(ethylene glycol) (PEG)) and natural polymers (e.g., 
collagen, gelatin, hyaluronic acid (HA), chitosan, alginate, agarose) that have 
been bioprinted. Furthermore, there are chemically modified versions of both 
natural and synthetic hydrogels (e.g., methacrylated or diacrylated polymers) and 
blends of different types of hydrogels (e.g., gelatin/chitosan or PEG-
diacrylate/alginate). HA is advantageous because it leverages benefits of both 
natural and synthetic hydrogels.(249) Similar to other natural polymers, HA is an 
extracellular matrix polymer found in several tissues (e.g., cartilage, epithelium, 
nerve) and is non-immunogenic. Similar to synthetic materials, HA is 
commercially available from microbial fermentation and can be easily chemically 
modified. The high viscosity of HA and chemical tunability for crosslinking 
capabilities enabled us to previously develop HA into a paste-like precursor for 
cartilage and bone regeneration,(82, 250-252) which had translational 
advantages for surgical placement. Our initial focus on surgical placement 
organically dovetailed into repurposing hydrogel precursor rheological 
characterization for identifying necessary physical properties for bioprinting.(253) 
In our previous work, we used a methacrylated HA hydrogel, but our work has 
evolved to using a pentenoate-functionalized HA (PHA) because of the rapid 
photocrosslinking of the thiol-ene click chemistry compared to the methacrylate 
chemistry.(254)  
The purpose of the current study was to demonstrate the utility of standard 




characterizations by developing PHA, a known biomaterial,(254) into a bioink as 
an example. The current study examined the yield stress, viscosity, and storage 
modulus recovery as standard, quantifiable characterizations that can be 
compared between groups. Furthermore, we compared the parameters of the 
printable PHA formulations to the non-printable formulations in effort to define a 
window of printability for each parameter. Given that bioinks are commonly used 
to bioprint cells, we evaluated the rheological effects of different concentrations 
of rat bone marrow-derived mesenchymal stem cells (rBMSCs) within PHA, in 
addition to evaluating the cell viability of two cell types, rBMSCs and rat neural 
stem cells (rNSCs), after bioprinting. The goals of the experiments presented 
here were to develop a hyaluronic acid-based hydrogel precursor as a bioink and 
to characterize three vital rheological parameters to continue defining printability 
parameters to ultimately aid the development of new bioinks.  
Materials and Methods 
Materials 
Unless otherwise stated, all materials were purchased from Sigma-Aldrich 
(St. Louis, MO). 
Synthesis of pentenoate-functionalized hyaluronic acid 
PHA was synthesized from two different molecular weights of hyaluronic 
acid, 1.5 MDa and 1 MDa (actual MW: 1.55 MDa and 823 kDa; Lifecore 
Biomedical, Chaska, MN). PHA was synthesized as we described 




HA was dissolved in deionized water (DI) at a concentration of 0.5% (w/v) at room 
temperature before N,N-Dimethylformamide (DMF) was added at a 3:2 water to 
DMF ratio. In an additional step beyond our previous work, we added a catalyst, 
4-(dimethylamino)pyridine, for the purpose of increasing the reaction efficiency of 
conjugating the pentenoate groups to the hydroxyls on the HA. Specifically, the 
catalyst was added to the HA in the water and DMF solution at a ratio of 0.25 g 
per g of HA and allowed to dissolve. 4-pentenoic anhydride was added in a 5-fold 
molar excess to HA and the pH was maintained between 8 and 9 with 1M sodium 
hydroxide for approximately 1 hour. After reacting overnight at room temperature, 
sodium chloride was added to achieve a final concentration of 0.5 M. Four times 
the reaction volume of acetone was added to precipitate the PHA and the solution 
was centrifuged at 7000 x g to separate the PHA from the acetone. The 
centrifuged PHA pellets were collected and dissolved in DI water before being 
transferred to dialysis tubing (MWCO: 6-8 kDa, VWR, Radnor, PA) to remove 
impurities. PHA was dialyzed in DI water for 48 hours with water exchanges every 
12 hours before the solution was brought to a physiological pH of 7.4, frozen, and 
lyophilized. Dry PHA was stored at -20C.  
Characterization of PHA 
The degree of substitution, or percent of repeating disaccharide units in 
PHA that were functionalized with a pentenoate group, was quantified using a 
Varian VNMRS-500 MHz NMR Spectrometer equipped with a 5 mm indirect 




mM (i.e., concentration of the repeat unit) was prepared in deuterium oxide (D2O; 
Cambridge Isotope Laboratories, Inc., Andover, MA) as a solvent. For all batches 
of PHA, a proton was collected at 80°C with 16 scans, a recycle delay of 35 
seconds, a 90-degree pulse width, and a 60-second pre-acquisition delay. NMR 
was performed at 80ºC to compare to the reported 1H-NMR spectrum of PHA, 
which was collected at 80ºC.(254) Furthermore, the higher temperature of 80ºC 
shifted the D2O peak to 4.163 ppm,(255) which limited overlap with the majority 
of the proton peaks of PHA, and after performing NMR on 1.5 MDa PHA at 
different temperatures (i.e., 25, 50, and 80ºC), proton peaks were more resolved 
at 80ºC than at 25 or 50ºC and provided more accurate integrations. The percent 
functionalization was determined by integration of the alkene peaks (2.46 and 
2.29 ppm) on the pentenoate group, normalized to the acetyl methyl group (1.91 
ppm) of the disaccharide repeat unit. 24-33% of the repeating disaccharide units 
of HA were functionalized with a pentenoate group for all the 1 MDa and 1.5 MDa 
batches of PHA synthesized and used in the current study.  
Cell culture 
All cell culture supplies were purchased from Thermo Fisher Scientific 
(Waltham, MA) unless otherwise stated. The rNSCs were purchased (Thermo 
Fisher Scientific; originally isolated from the cortex of Sprague Dawley rats at day 
14 of gestation) and were cultured according to manufacturer protocols. Tissue 
culture flasks were coated with 1% CTS™ CELLstart™ Substrate in Dulbecco’s 




37°C, 5% CO2 incubator. The rNSCs were cultured on coated flasks and in 
KnockOut DMEM/F-12 Basal Medium supplemented with StemPro Neural Stem 
Cell Serum Free Medium (NSC SFM) Supplement (2%), recombinant human 
basic fibroblast growth factor (bFGF; 20 ng/mL), recombinant human epidermal 
growth factor (EGF; 20 ng/mL), GlutaMAX™-I supplement (2 mM), and penicillin-
streptomycin (Pen/Strep; 1%). The rNSCs medium was changed every 2-3 days 
and cells were passaged at 80% confluency using StemPro™ Accutase™ Cell 
Dissociation Reagent. 
The rBMSCs were purchased (ScienCell, Carlsbad, CA; originally isolated 
from the bone marrow from adult Charles River Sprague Dawley rats) and 
cultured in DMEM (low glucose, pyruvate) supplemented with fetal bovine serum 
(FBS; certified, US Origin; 10%) and Pen/Strep (1%). The rBMSCs medium was 
changed every 2-3 days and were passaged at 80% confluency using Trypsin-
EDTA (0.25%) phenol red. 
Hydrogel precursor preparation 
Different PHA precursor formulations of each molecular weight of PHA 
were prepared for rheological testing by varying the concentration of PHA (i.e., 
6-9 weight percent (wt%) for 1 MDa PHA and 3-6 wt% for 1.5 MDa PHA). 
Additionally, precursor formulations with 1.5 MDa PHA (4 wt%) with varying 
concentrations of cells were prepared for rheological testing and cell viability 
testing. For all precursors, PHA was dissolved overnight at a 2X concentration in 




2959 (I2959) for a photoinitiator, dithiothreitol (DTT) at a 1:1 thiol:ene molar ratio 
for a crosslinker, and the remaining volume of PBS or PBS with cells. PHA 
precursors were left for 15-30 minutes in the dark to fully incorporate the added 
liquids. Due to the paste-like consistency of PHA precursors, letting the precursor 
mix completely was vital to achieve a homogeneous paste. PHA precursors were 
mixed once more and loaded into UV-shielding cartridges and centrifuged with a 
short-spin cycle for 30 seconds to eliminate air bubbles.  
Rheological testing 
The viscosity (n = 5), yield stress (n = 3), and storage modulus recovery 
(n = 3) of the PHA precursors without cells and the viscosity (n = 5) and yield 
stress (n = 5 for 7 x 106 cells/mL and n = 3 for all other groups) of PHA precursors 
with rBMSCs (passage 9-12, 106 to  9 x 106 cells/mL) were evaluated on a 
Discovery Hybrid Rheometer-2 (TA Instruments, New Castle, DE) equipped with 
parallel 20-mm crosshatched plates. Cellink® Start (Cellink®, Gothenburg, 
Sweden) is a commercially-available, bioprintable support material and was used 
as a control group in rheological studies because of its optimized printability. 
Additionally, Colgate Total® toothpaste (Colgate-Palmolive, New York City, NY) 
was used as a comparator group to put the results into a more understandable 
context. All tests were conducted at 25C and with a gap of 500 m. Viscosity 
curves were determined by a logarithmic shear rate sweep from a shear rate of 
0.1 s-1 to 100 s-1 with 3 points per decade.  The yield stress was determined by 




defined as the shear stress at the crossover point of the storage (G’) and loss 
(G”) moduli, as we have done previously.(83, 251, 252, 256) The storage 
modulus recovery was determined by three phases of oscillatory shearing at a 
frequency of 1 Hz after a 5-minute soak time where no stresses were applied, 
similar to what has been done previously in our group.(82) Materials underwent 
5 minutes of a constant shear stress of 10 Pa to determine an initial storage 
modulus, 30 seconds of high shear stress of 3000 Pa (i.e., above the material’s 
yield stress to mimic extrusion and flow through a bioprinter nozzle), and another 
5 minutes of a constant shear stress of 10 Pa. The initial storage modulus was 
defined by the average storage modulus of the initial 5 minutes of the material 
being exposed to 10 Pa of shear stress. The recovered storage modulus was 
defined by the storage modulus 5 seconds after the shear stress transitioned from 
3000 Pa back to 10 Pa. The percent recovery was defined as the recovered 
storage modulus divided by the initial storage modulus and multiplied by 100%. 
Printability assessment 
The g-code for a grid structure was generated from a 10 x 10 x 1.2 mm 
(LxWxH) rectangular prism using Repetier-Host software (Hot-World GmbH & 
Co. KG, Willich, Germany). The object was sliced in Repetier-Host into three 0.4 
mm layers, with 43% rectilinear pattern infill to create 6 parallel lines, no perimeter 
or shells, and a printhead speed of 10 mm/s to generate a distinct path and 
structure for assessing the printed materials. PHA precursors in bioprinter 




(Cellink®) and the 3-layer grid structure was bioprinted through a sterile 27G (i.e., 
0.21 mm diameter) polypropylene conical nozzle (Cellink®) onto a glass 
microscope slide (24 mm x 76 mm, L x W). The pressure used (40-180 kPa) to 
extrude the material was adjusted for each material to achieve a consistent flow 
and the best print possible. Images of printed materials were captured on a DSLR 
camera (Nikon D5500, B&H Photo Video, New York City, NY) with a macro lens 
(Nikon AF-S Micro-NIKKOR 60mm f/2.8G ED Lens, B&H Photo Video). 
The printability of each PHA precursor was qualitatively assessed by 
evaluating the shape fidelity of the printed grid within 1 minute after printing prior 
to any crosslinking and scoring it on a scale of 0 to 3, based on a review presented 
by Malda et al.(233) where 0 was no shape fidelity, 1 was poor shape fidelity with 
low undefined structure, 2 was medium shape fidelity with intermediate irregular 
patterns, and 3 was high shape fidelity with well-defined building potential. 
Factors that affected shape fidelity were the edge shape of the individual printed 
strands (e.g., no edges, soft/undefined edges, clean/stable edges, 
fragmented/irregular edges), and overall stability of the printed structure shortly 
after it was printed (e.g., retainment of the grid structure after printing, or 
relaxation of the material into a puddle after printing). ImageJ was used to 
measure the strut size of bioprinted grid structures and the particle analysis 





Cell viability analysis 
To determine the cell viability after bioprinting, 1.5 MDa PHA was sterilized 
by ethylene oxide gas (AN74i, Anderson Anprolene, Haw River, NC) before a 4 
wt% solution was prepared with 106 cells/mL of rBMSCs (passage 5; n = 3) or 
rNSCs (passage 3, n = 3) using the methods previously described. Hydrogel 
precursors of each cell type were bioprinted into rectangular prisms (8 x 6 x 0.3 
mm, LxWxH), not the same grid structure as was used for the shape fidelity 
assessment, onto microscope slides (Fig. 3.1A). Each slide of hydrogels was 
crosslinked under a 312 nm handheld UV light at 9 mW/cm2 (EB-160C, 
Spectroline, Westbury, NY) for 2 minutes (Fig. 3.1B). While 365 nm light is 
perceived to be safer than 312 nm light for cells, we used 312 nm light because 
the photoinitiator used (I2959) has an absorbance peak around 311 nm, which 
increased the crosslinking efficiency compared to 365 nm light. With 312 nm light, 
the amount of time needed for crosslinking PHA was only 2 minutes, which limited 
the amount of time cells were exposed to UV and did not have detrimental effects 
in previous studies.(82, 83, 250, 257) An 8-well removable silicon chamber (Ibidi, 
Martinsried, Germany) was sealed on top of the printed and crosslinked 
hydrogels and each cell’s respective medium was added to each well (Fig. 3.1C). 
Cells were cultured for 7 days with medium changes every other day. 2 hours 
after bioprinting, and after 7 days of culture, hydrogels were stained with the 
LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells for 20 minutes using 2 




Representative images of each group were taken on a Leica TCS SP8 confocal 
microscope (Leica Microsystems, Wetzlar, Germany) by taking a z-stack of 501 
slices throughout the entire hydrogel. An approximate cell viability was 
determined from the images by comparing live and dead cell counts obtained 
with the Analyze Particle feature in ImageJ. We noted the cell densities between 
rBMSCs and rNSCs appeared to be slightly different in the confocal images 
taken. Based on the printability assessments of PHA with cells showing minor 
effects on printing from the addition of varying concentrations of cells, we did not 
anticipate a slight variation in cell density to significantly affect the viability. 
Therefore, the cell viability data still provided a reasonable representation of the 
effect of bioprinting on cell viability for both cell types. 
Statistical methods 
GraphPad Prism (Graphpad Software Inc, La Jolla, CA) was used to 
perform all statistical analyses. All groups were analyzed with a one-way analysis 
of variance (ANOVA), followed by Tukey’s post-hoc test. Results were 
considered significant at a level of p < 0.05. All results were reported as mean  
standard deviation.  
Results 
Printability assessment 
All hydrogel precursors were printed into a 3-layer grid (Fig. 3.2A), given 
a shape fidelity score (Fig. 3.2B), and imaged from above (Fig. 3.2C). Images 




measurements below each image in Fig. 3.2C). Cellink® Start was used as a 
control group because of its optimized printability and good shape fidelity (shape 
fidelity score = 3) after printing (Fig 3.2A). Cellink® Start printed with clean edges, 
was well-matched to the original grid file, and retained its shape after being 
printed. Toothpaste was included as a comparator group (Fig. 3.2A) to provide a 
more understandable context but failed to extrude through a 27G nozzle. Even 
with a larger 22G nozzle, toothpaste only printed with medium shape fidelity 
(score = 2). While the printed structure matched the model decently, it had soft 
edges (i.e., curved turns instead of 90 degree turns) and relaxed over time into a 
less defined structure. The pore area and strut size of Cellink® Start were 0.13 
mm2 and 1.07 mm, respectively, while toothpaste had a pore area of 0.32 mm2 
and a strut size of 0.92 mm. 
For the 1 MDa PHA groups (Fig. 3.2C, top row), the 5 wt% had no shape 
fidelity and immediately lost its shape after being deposited, resulting in a puddle 
(score = 0). The 6 wt% performed better than the 5 wt%, where the original 
structure of the 6 wt% was still visible after printing; however, the edges were 
soft, and the shape fidelity was still poor (score = 1). The 7 and 8 wt% groups 
both printed with clean and defined edges similar to the Cellink® Start but given 
that the 7 wt% relaxed within a few minutes into an undefined shape, the 7 wt% 
had medium shape fidelity (score = 2) while the 8 wt% had good shape fidelity 
(score = 3). While the 9 and 10 wt% groups had structures that imitated the 




that were irregular, which resulted in a medium shape fidelity (score = 2) for the 
9 wt% group and a poor shape fidelity (score = 1) for the 10 wt% group. For pore 
area there generally appeared to be a trend of increased pore area with increased 
PHA concentration, ranging from 0.05 mm2 (7 wt% PHA) to 0.71 mm2 (10 wt% 
PHA), with the exception of the 6 wt% PHA (0.22 mm2). For strut size, there 
generally appeared to be a trend of decreased strut size with increased PHA 
concentration, ranging from 1.48 mm (6 wt% PHA) to 0.45 mm (10 wt% PHA). 
For context, the inner diameter of the nozzle used to bioprint the formulations 
was 0.21 mm and therefore, we anticipated the minimum strut size would be 0.21 
mm. Out of the 1 MDa PHA groups, the 8 wt% appeared to have the closest pore 
area and strut size to Cellink® Start. 
For 1.5 MDa PHA groups (Fig. 3.2C, bottom row), the 3 wt% group was 
similar to the 1 MDa - 6 wt% group with no shape fidelity (score = 0) because of 
the immediate loss of structure upon deposition. The 4 wt% group was most 
similar to the 1 MDa - 8 wt%, with well-defined edges and good shape fidelity 
(score = 3). The 5 and 6 wt% groups were akin to the 1 MDa - 9 and 10 wt% 
groups, respectively, with medium (score = 2) and poor (score = 1) shape fidelity 
from the fractured edges and irregularity of the printed lines. Similar to the 1 MDa 
PHA, there appeared to be the same general trends of increased pore area and 
decreased strut size with increased PHA concentration for the 1.5 MDa PHA. The 
pore areas ranged from 0.14 mm2 (4 wt% PHA) to 0.59 mm2 (6 wt% PHA) and 




of the 1.5 MDa PHA groups, the 4 wt% appeared to have the closest pore area 
and strut size to Cellink® Start. 
Shape fidelity scores were plotted against the PHA concentration for the 1 
and 1.5 MDa PHA groups (Fig. 3.2B). For both molecular weights, as the 
concentration of PHA increased, the shape fidelity increased, reached a peak, 
and decreased. The groups that printed with medium, poor, or no shape fidelity 
had two distinct sets of characteristics, depending on if the PHA concentration 
was greater than or less than the previously mentioned ideal concentrations. The 
precursors that had a lower PHA concentration either had soft edges or relaxed 
into a puddle after printing. On the other hand, the precursors with a higher 
concentration had sharper or fractured edges that printed more irregularly. 
Overall, the concentration for each molecular weight of PHA that printed with best 
shape fidelity were 1 MDa - 8 wt% and 1.5 MDa - 4 wt% (Fig. 3.2B-C, red boxes).  
Rheological testing 
Viscosity evaluation 
All of the materials displayed decreasing viscosities with increasing shear 
rates from 0.1 to 100 s-1 (i.e., shear thinning) (Fig. 3.3A-B), with viscosities 
ranging from 410 to 11,600 Pa-s at 0.1 s-1 and from 1 to 18 Pa-s at 100 s-1. The 
Cellink® Start appeared to have a linear decrease in viscosity from 1510 Pa-s at 
0.1 s-1 to 5 Pa-s at 100 s-1 on the log-log plot of viscosity versus shear rate, but 
the toothpaste viscosity, which ranged from 570 at 0.1 s-1 to 13 Pa-s at 100 s-1, 




shear rates and a sharper decrease at higher shear rates. Overall, increasing the 
PHA concentration generally appeared to have increased the viscosity behavior 
but at the highest shear rate, all materials had viscosities under 18 Pa-s. 
Toothpaste had viscosity behavior similar to the PHA groups, but the toothpaste 
shear thinning behavior appeared to not decrease as quickly as the PHA groups.  
Yield stress evaluation 
None of the 1 MDa PHA groups had a yield stress, but all the 1.5 MDa 
PHA groups did have a yield stress (Fig. 3.3C). For reference, toothpaste had a 
yield stress of 105  6 Pa. For the 1.5 MDa PHA, there was a trend of increased 
yield stress with increased PHA concentration. Specifically, the yield stresses of 
the 3 and 4 wt% groups were 320  90 Pa and 380  17 Pa, respectively, and 
were not significantly different from Cellink® Start, which had a yield stress of 
217  5 Pa. The 5 wt% group had a yield stress of 1140  150 Pa that was 
approximately 5.3 times greater than Cellink® Start and 3.5 times greater than 
the 3 wt% group (p < 0.005). the yield stress of the 6 wt% group was 2010  360 
Pa, which was greater than all other groups (p < 0.005).  
Storage modulus recovery evaluation 
Because the 1 MDa PHA groups did not have a yield stress and the loss 
modulus, G’, was higher than the storage modulus, G”, at all shear rates, there 
would be no loss or recovery of the storage modulus after shearing and the 




1.5 MDa groups. Cellink® Start and PHA 3 wt% and 4 wt% all had recovered 
storage moduli that were not significantly different from their initial storage moduli 
(Fig. 3.3D). Specifically, Cellink® Start had an 87  1% storage modulus 
recovery, 3 wt% had an 89  2% recovery, and 4 wt% had an 85  6% recovery. 
Toothpaste and the 5 wt% and 6 wt% had decreased recovered storage moduli 
from their initial storage moduli (p < 0.0001), where the percent recoveries of the 
storage modulus were 32  2%, 76  5%, and 68  5%, respectively.  
Printability and rheological assessments of PHA with encapsulated cells 
The 1.5 MDa - 4 wt% PHA precursor with varying cell concentrations (i.e., 
106, 3 x 106, 5 x 106, 7 x 106, and 9 x 106 cells/mL) was evaluated for shape 
fidelity after bioprinting (Fig. 3.4A), yield stress (Fig. 3.4B), and viscosity (Fig. 
3.4C). The bioprinted 3-layer grid of all PHA groups with cells, despite the 
increasing cell concentrations, printed with high shape fidelity (i.e., score = 3) with 
clean and defined edges that maintained their structure after printing. The pore 
areas and strut sizes of the PHA with varying cell concentrations were similar to 
PHA without cells and fell within the range of 0.09 to 0.22 mm2 for pore area and 
0.94 to 1.14 mm for strut size (listed under each respective image in Fig. 3.4A). 
The yield stress of the PHA with 106 cells/mL (580  15 Pa) was approximately 
1.5 times greater than PHA with no cells (380  17 Pa), 1.4 times greater than 
the PHA with 5 x 106 cells/mL (410  20 Pa), and 1.75 times greater than the 
PHA with 9 x 106 cells/mL (330  60 Pa). The yield stresses of the PHA with 3, 5, 




respectively, and were not different from the yield stress of PHA without cells (380 
 17 Pa). The viscosities of all the PHA with cells groups at shear rates ranging 
from 0.1 to 100 s-1 generally appeared to show similar shear thinning behavior to 
PHA without cells. Overall, the PHA groups with cells displayed similar shear 
thinning behavior compared to the PHA alone.  
Viability assessment 
1.5 MDa - 4 wt% PHA was separately bioprinted into the rectangular 
scaffolds (8 x 6 x 0.3 mm) with 100% infill, not the grids previously used for shape 
fidelity assessments, and were crosslinked with encapsulated rBMSCs or rNSCs 
(Fig. 3.1). Live/Dead staining showed live cells in green and dead cells in red on 
the day hydrogels were bioprinted (day 0) and after 7 days of culture (Fig. 3.5). 
From the cell counts of the representative image of each group, the rBMSCs had 
a viability around 100% after the bioprinting and hydrogel crosslinking process. 
After 7 days of culture, the viability only decreased to 83%. On the other hand, 
the rNSCs had a viability of about 87% after the bioprinting and crosslinking 
processes. After 7 days of culture, the viability dropped to approximately 55%. 
We noted that the size of the rNSCs at day 7 appeared larger than they were at 
day 0, and we speculate the increased cell size could be due to a small amount 
of cell spreading or spontaneous differentiation. 
Discussion 
We have established a quantitative range of printability, or printability 




an example. In the experiments performed here, we have not only developed a 
known crosslinkable hyaluronic acid hydrogel into a printable material, but we 
quantified three rheological assessments that are universally comparable (i.e., 
yield stress, storage modulus recovery, and viscosity) and determined two 
printability windows of yield stress and storage modulus recovery for PHA. While 
the ranges of printability determined from the experiments presented here are 
specific for PHA, the application of the methods are standard rheological 
experiments that can be employed by any group to define the printability of other 
materials and develop new bioinks. Toothpaste and a commercially available 
bioink, Cellink® Start, were tested alongside the PHA here to further demonstrate 
the applicability of the rheological experiments, but one limitation of the studies 
here was that other potentially printable biomaterials were not tested. Even so, 
the data provided here provides a quantitative point of comparison or starting 
point for the development of new bioinks, especially for other HA-based materials 
or similar natural polymers.  
To provide a link between the qualitative trial-and-error methods and the 
quantitative rheological measures of viscosity, yield stress, and storage modulus 
recovery, a shape fidelity assessment was employed to determine the printability 
of different PHA formulations. From previous work, we found that lower molecular 
weight (i.e., 60 kDa) PHA precursor solutions had a low viscosity, even at higher 
concentrations (i.e., 10 wt%); therefore, we investigated higher molecular weights 




fidelity assessments, the formulations that printed with good shape fidelity were 
the 1 MDa - 8 wt% PHA and the 1.5 MDa - 4 wt%. Comparing the two groups that 
printed with good shape fidelity, the 1.5 MDa - 4 wt% contained half the 
concentration of PHA compared to the 1 MDa - 8 wt%, which made the higher 
molecular weight PHA a more practical material source for a bioink because the 
lower concentration uses less material. In the current study, we used a simple 
qualitative scale for evaluating shape fidelity. There are other methods of 
quantifying the shape fidelity, such as using image analysis software to measure 
pore area, circularity of pores,(258) strut size,(245) printed area,(237) or filament 
fusion/filament collapse.(242) As Ribeiro et al. (242) emphasized, there is a need 
for a universal testing method of bioink shape fidelity, or correlation of shape 
fidelity with another quantitative measure (e.g., yield stress) to compare between 
different bioinks. 
The viscosity of a bioink is an important parameter to characterize 
because it determines how much pressure is necessary to keep the material 
extruding at a desired flow rate. Higher viscosity materials or materials with a 
yield stress maintain their shape after printing better than low viscosity materials 
or materials without a yield stress; however, a material experiences high shear 
forces when flowing through a needle, and viscous bioinks necessitate shear 
thinning behavior, or having lower viscosities at high shear rates, to be able to 
flow through a needle.(245) The relevant shear rates for needles have been 




nozzles had higher estimated shear rates around 200-3000 s-1 localized to just 
the nozzle tip.(244, 259) In the current study, PHA failed to extrude through a 
22G blunt-tip needle (i.e., 0.413 mm diameter), but was extrudable through a 27G 
nozzle tip (i.e., 0.21 mm diameter), making nozzles a more practical choice for 
extrusion of materials with high viscosity.  
As others have found,(233, 241-244, 247) the viscosity measurement 
alone is insufficient for determining printability. In these studies, we found that the 
PHA formulations that printed the best did not have a distinct viscosity behavior 
that differentiated them from the groups that did not print well. Comparing the 
viscosity curve of the Cellink® Start to the printable 1.5 MDa - 4 wt% group, both 
groups had shear thinning behavior and converged to viscosities below 18 Pa-s 
at a shear rate of 100 s-1, which is in the neighborhood of the relevant shear rates 
through a nozzle; however, the Cellink® Start followed a different, more linear 
decrease with increasing shear rates when compared to the PHA groups. 
Therefore, there was not a “printable” viscosity range and the viscosity alone 
could not be used to determine printability. The most important information the 
viscosity data provided was determining whether the material was shear thinning, 
which was vital for the extrusion of viscous materials through a nozzle. Others, 
such as Paxton et al.(244) found similar results and demonstrated additional uses 
for viscosity data in predicting other printing parameters. Specifically, they used 
the viscosity data to determine the shear thinning coefficients from a Power Law 




and nozzle geometry. They found that the higher viscosity materials would 
require higher pressures and larger diameter nozzles for successful extrusion.  
The yield stress is the most important parameter to characterize because 
a yield stress is required for a material to hold its shape after bioprinting and 
support the weight of added layers. Comparing the yield stresses of the PHA 
formulations that had good shape fidelity to the formulations that did not, printable 
materials had yield stresses below a maximum threshold value of around 1000 
Pa, where PHA with a yield stress above the threshold printed with fractured and 
irregular lines. The upper limit of the yield stress determined from our results 
specifically applies to extrusion of PHA through a 27G (i.e., 0.21 mm) nozzle at 
the pressures used here, and the yield stress limits for different size nozzles or 
materials may deviate from that value (see Table 3.1). For example, Paxton et 
al.(244) found that the printable formulation of poloxamer 407 through a 0.25 mm 
nozzle had a yield stress of 227 Pa, but the formulation with a 348 Pa yield stress 
was not printable, indicating a yield stress limit around 300 Pa. While there may 
be different yield stress limits for different materials to print with good shape 
fidelity, a material with high viscosity may be sufficient for printing with good 
shape fidelity under the right conditions. Among these conditions for good shape 
fidelity for high viscosity materials, the most important is time, and specifically the 
time elapsed from printing from the nozzle to crosslinking for a given layer. Given 
enough time, even the highest viscosity bioink in theory can flow (i.e., change 




 In the current study, none of the 1 MDa PHA groups had yield stresses, 
but the 1 MDa - 8 wt% printed with good shape fidelity. The 8 wt% group had a 
high enough viscosity (i.e., 4 times greater than the 1.5 MDa - 4 wt%) to 
compensate for the lack of a yield stress within the time period given for 
crosslinking. Similarly, Paxton et al.(244) found a printable formulation of 
alginate-gelatin that did not have a yield stress, but was still able to be printed 
with good shape fidelity, which was accomplished by lowering the print bed 
temperature to increase the viscosity of the material upon deposition. While a 
high viscosity is not a substitute for a yield stress, we found that a material with a 
high viscosity may delay the movement of the material after printing, and aid in 
shape retainment, especially if a crosslinking mechanism is employed directly or 
soon after printing. Overall, the existence of a yield stress is the most important 
parameter to characterize for evaluating whether the material can retain a printed 
shape and the yield stress limit for a particular material and nozzle size can be 
used to determine printable formulations. 
Given that the yield stress does not account for a material’s exposure to 
high shear stresses during the extrusion process, the storage modulus recovery 
is necessary to characterize to determine how well the yield stress and original 
properties are recovered after printing. In the current study, we demonstrated that 
PHA formulations that printed with good shape fidelity and the Cellink® Start 
material had storage modulus recoveries above 85%, similar to others.(240, 260) 




printable PHA formulations. While the recovery data may not be entirely relevant 
for other polymer systems, we believe the 85% target is a reasonable starting 
point and guideline for novel bioinks entering the literature. We additionally found 
that higher viscosities could mitigate the impact on the shape fidelity of materials 
with low recovery. Even though the 1.5 MDa - 3 wt% and 4 wt% PHA had similar 
recoveries of their storage modulus, it is possible that because the 3 wt% was 
less viscous, the shape fidelity started out with soft edges and deteriorated to no 
edges, where the 4 wt% printed with rigid edges and relaxed to normal defined 
edges. Crosslinkable hydrogels can additionally overcome low recoveries by 
initiating crosslinking throughout the printing process to conserve the printed 
structure immediately upon deposition.(261) The PHA hydrogels used here are 
advantageous for overcoming low recoveries because of the quick crosslinking 
time (~2 min) compared to other previously used methacrylated HA chemistries 
with longer crosslinking times (~5-30 min).(82, 250) Overall, for the PHA 
formulations, groups with good shape fidelity had storage modulus recoveries 
above 85%. 
Given that many bioinks are used to bioprint cells in constructs that mimic 
native tissues or even print multiple cell types in different locations on the same 
structure, it is important to investigate the effects that cells have on the printability 
of bioinks and how well cells survive the printing and post-printing processes 
(e.g., UV crosslinking). To illustrate and quantify this point, we demonstrated that 




increased the yield stress but otherwise had minimal effects at higher cell 
concentrations up to 9 x 106 cells/mL on the printed shape fidelity, yield stress 
and viscosity when compared to PHA with no cells. Other studies found opposite 
trends of decreasing bioink viscosity when 2.5 x 106 cells/mL or less were 
encapsulated.(258, 259) Given the discrepancy, for development of future 
bioinks, it will be important to take into account the effects of encapsulated cells 
on the printability of the bioinks and characterize bioinks accordingly. Given that 
the tested cell concentrations did not diminish printability, cell viability studies 
were conducted with 106 cells/mL. Even though exposure to UV light may be 
harmful to cells, we have previously shown high viability of cells after hydrogel 
encapsulation and exposure to 312 nm light.(82, 250, 257) PHA has a fast thiol-
ene crosslinking chemistry and only requires a short duration of UV exposure 
(i.e., 2 minutes) and a low concentration of photoinitiator I2959 (i.e., 0.05% w/v) 
for sufficient crosslinking, thus, we did not anticipate the UV exposure to 
significantly increase cell death. In support of our hypothesis, there was good 
viability of rBMSCs and rNSCs (i.e., greater than 87%) after exposure to UV light 
and additionally being extruded through a nozzle. Altogether, the high cell 
viabilities indicated that the 1.5 MDa - 4 wt% PHA precursor met the minimum 
biological requirement of keeping cells alive throughout the bioprinting process. 
The rBMSCs maintained a good viability after 7 days of culture; however, the 
rNSCs began to lose viability. Even though rNSCs initially survived the stresses 




negative long-term effects from the bioprinting process. Several studies showed 
that cell viability after printing decreases as the viscosity of the material increases 
and as the nozzle diameter decreases because of the high shear stresses.(262, 
263) The rNSCs may have been more susceptible to damage from the high shear 
stresses compared to the rBMSCs. Low pressures and larger nozzles are 
favorable for printing cells, (262, 263) but larger nozzles reduce the resolution of 
the print. Low-viscosity crosslinkable materials may be able to overcome the 
limitations by simultaneously depositing and crosslinking the material to form 
stable structures.(261)  
Another consideration that may affect printability is the effect of different 
sterilization techniques on material composition and mechanical performance. 
Ethylene oxide was used as a sterilization technique for PHA to be used in cell 
viability studies and because ethylene oxide can participate in addition reactions 
with amines, carboxylic acids, hydroxyls, and sulfhydryl groups,(264) preliminary 
studies with NMR showed there was most likely residual ethylene oxide in the 
sample, which could be eliminated by sample aeration after sterilization. Further, 
we found there was most likely an addition reaction of the ethylene oxide onto 
the carboxylic acids or hydroxyls present on the PHA backbone. Other studies 
found similar addition reactions occurring on materials with carboxylic acids.(264, 
265) In terms of rheological performance, preliminary studies with sterilized PHA 
showed that the ethylene oxide sterilization could have affected the yield stress 




A few other studies found effects on other scaffolds after ethylene oxide 
sterilization in terms of yield strength, swelling, pore morphology, and molecular 
weight, but the effects were not the same among all the materials tested,(264, 
266, 267) which highlights the need for each material to be characterized 
individually, as the effects vary. Overall, we emphasize the need to characterize 
the effects on compositional and mechanical performance from the sterilization 
technique used because of the potential influences on the printability.  
We have developed the printability of the PHA material in these studies; 
however, HA materials lack motifs for cell attachment, reducing the applicability 
for regenerative medicine. In preliminary studies, we found that rNSCs do not 
adhere or spread well when encapsulated or are seeded on PHA hydrogels. The 
same challenges arise with other inert synthetic polymers, but polymer 
modifications with adhesive peptides are used to overcome this challenge. 
Similar to synthetic polymers, PHA can be modified with thiolated bioactive 
factors, such as adhesive peptides, which can enhance the bioactivity for better 
regeneration of tissues. While the overall bioactivity may be enhanced, such 
modifications could influence or alter the printability. Preliminary studies involving 
bioprinted PHA modified with laminin-based adhesive peptides for enhancing 
rNSC adhesion resulted in similar printability, but the specific rheological effects 
need to be further investigated. We speculate the rheological performance could 
be dependent on peptide concentration, size, and interactions. At lower 




PHA and similar to that of PHA alone; however, the conjugation of a high 
concentration or longer peptides may cause more peptide “branches” on PHA 
and thus, more physical entanglements and a potentially higher yield stress. On 
the other hand, the ability of peptides to interact with other peptides or the 
polymer via charge or hydrogen bonding may influence the interactions with 
neighboring peptides, causing aggregations or repulsions, and further influencing 
the bulk rheological properties and printability. From the immense variety of 
peptides that can be synthesized, the influence of peptide modifications to 
polymers on printability is another topic in need of further investigation by the 
bioprinting field. 
Conclusions 
There are several physical properties, printing parameters, and biological 
requirements that all influence the printability of a material from an extrusion-
based bioprinter. In terms of physical properties, we assessed the printability of 
varying formulations of a hyaluronic acid-based hydrogel precursor, PHA, and 
characterized the formulations with three rheological tests: viscosity, yield stress, 
and storage modulus recovery. We found that the viscosity alone did not 
determine printability, but the viscosity behavior was valuable in determining if 
PHA had shear thinning behavior and would be extrudable through a nozzle 
during bioprinting. Further, possession of a yield stress was a critical 
characteristic for maintaining a printed shape; however, the yield stress upper 




PHA formulations with yield stresses beyond 1000 Pa printed with irregular lines. 
While the yield stress could be a direct indicator of printability, a material could 
print with high shape fidelity if the viscosity was high enough to delay the material 
relaxation and a crosslinking mechanism was employed directly or soon after 
printing to retain the printed shape. Similarly, good storage modulus recovery 
after shearing was necessary for preventing material relaxation and maintaining 
the printed shape fidelity after being extruded, but materials with high viscosity 
could reduce the relaxation effect of PHA formulations that had low recovery 
through use of a quick UV crosslinking mechanism. Bioprinting has significant 
advantages for controlling the spatial location of different cell types to mimic the 
native hierarchy of tissues, but bioprinting cells comes with additional challenges. 
We found minimal effects of cell concentration on the printability of PHA, but 
others have found that it decreased viscosities. Additionally, we found that the 
carboxylic acid and hydroxyl-containing PHA may be susceptible to 
compositional changes from ethylene oxide sterilization, which may in turn 
influence the printability. Another parameter that may influence printability is the 
use of peptide modifications on PHA or other inert polymers to overcome the lack 
of motifs for cell attachment. Overall, cell concentration, sterilization methods, 
and peptide modifications are important considerations to account for during 
future bioink development. To demonstrate the feasibility of using PHA as a 
bioink, we found that two stem cell types each had good viabilities after printing. 




bioink, characterized different formulations with three quantifiable rheological 
assessments, and determined printability windows for the yield stress and 
storage modulus recovery of PHA. We hope to accelerate future bioink 
development by recommending the rheological evaluation of the viscosity, yield 
stress, and storage modulus recovery to promote the use of standardized 
characterizations for more efficient, quantitative, and reliable methods to develop 




Chapter 4 : Injectable Hyaluronic Acid/Gelatin Hydrogel for 
Application to Spinal Cord Injury3 
 
Abstract 
The combination of regenerative medicine and rehabilitation approaches, 
known as regenerative rehabilitation, may be necessary for functional recovery 
after contusion spinal cord injury (SCI). Regenerative medicine approaches are 
needed to regenerate axonal pathways and work synergistically with 
rehabilitation approaches. The bottleneck for developing regenerative medicine 
approaches to treat SCIs in the context of rehabilitation is that biomaterials for 
SCI treatments tend to be pre-formed solids. Implantation of preformed solids 
into a spinal cord may cause serious risk for a rehabilitating patient and is thus 
undesirable. This inherent risk may be overcome by the use of hydrogel bioinks 
for injectable delivery and retention in contusion SCIs. The bioprinting field is a 
fertile ground for injectable biomaterials, as fluid mechanics (i.e., rheology) and 
cytocompatibility are paramount to success. In the current studies, a new 
pentenoate-functionalized gelatin (PGel) hydrogel was developed, and 2D 
nuclear magnetic resonance (NMR) spectroscopy on PGel was used to confirm 
and quantify the degree of functionalization. Rat neural stem cells lacked 
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adhesion to a previously developed fast-crosslinking, pentenoate-functionalized 
hyaluronic acid (PHA) bioink, and in the current studies, some PGel formulations 
degraded within 14 days. Therefore, the PGel and PHA were combined to solve 
the problem of the other, where the PGel improved rNSC adhesion and PHA 
improved the precursor printability and long-term stability of the post-crosslinked 
hydrogels. The 4%/5% and 3%/10% PHA/PGel formulations were adhesive for 
rNSCs and had improved long-term stability. Finally, the 4%/5% PHA/PGel 
hydrogel precursor (i.e., before UV-crosslinking) had more desirable rheological 
properties for bioprinting/translation to SCI compared to the 3%/10% formulation. 
While both formulations were injectable (i.e., shear thinning), the 4%/5% 
formulation had better shape retention after extrusion (i.e., higher yield stress and 
storage modulus recovery), which may translate to better material retention in a 
SCI, until the rapid formation of the hydrogel (2 minutes). The injectability, paste-
like rheology, and fast UV-crosslinking (2 minutes), and of the 4%/5% PHA/PGel 
bioink may be leveraged as a translational platform for future application to SCI. 
Introduction 
Spinal cord injury (SCI) affects 17,800 people in the United States every 
year, with 294,000 current patients.(25) Current clinical treatments (e.g., 
rehabilitation) have not yet been able to promote full functional recovery, but 
recent human studies have made significant progress in achieving independent 
stepping (with assistive devices) when coupling motor training with electrical 




neuroplasticity.(88, 90) However, the majority of SCI patients that have severe 
injuries with minimal spared pathways may experience little benefit from 
rehabilitation-based therapies alone. Regenerative medicine approaches are 
needed to help regenerate the damaged spinal cord tissue and form new axonal 
pathways. The combination of regenerative medicine and rehabilitation 
approaches, termed regenerative rehabilitation,(5-7) may be the most promising 
approach to regenerate the spinal cord tissue and promote plasticity to maximize 
functional outcomes.  
There are far fewer regenerative medicine approaches that have made it 
to clinical trials for SCI than rehabilitation approaches. Of the regenerative 
medicine approaches that are in clinical trials for SCI, most are cell-based 
therapies, which have key translational limitations (e.g., limited proven efficacy, 
low cell survival, the need for good manufacturing practice facilities). Biomaterials 
have been used to overcome some of the limitations that cell therapies face, but 
biomaterials themselves have different translational limitations when applied to 
SCI. For example, most biomaterials have non-biocompatible formation 
conditions, requiring the pre-fabrication and fitting of the material into the injury. 
While prefabricated materials may be appropriate for transection-type SCIs, they 
may be challenging to apply to the most common type of SCI, which is a cyst-
like, contusion injury. Most preformed materials would require trimming to fit 
within the injury or removal of spinal cord tissue to make space for the material, 




and that can form within the injury may be better suited to augment rehabilitation 
approaches, and may therefore be more translatable than preformed scaffolds 
for SCI.  
A fertile ground for exploring injectable materials is the bioprinting field, 
where fluid mechanics (i.e., rheology) and cytocompatibility are paramount to 
success. Several bioinks developed for extrusion-based bioprinting are injectable 
and form under biologically compatible conditions for cell encapsulation. The 
development of bioprintable materials, or bioinks, typically involves developing 
the rheology (e.g., viscosity, yield stress, storage modulus recovery) of 
biomaterials to be injectable, retain their shape after extrusion, and form under 
biocompatible conditions. The inherent rheology of bioinks and other paste-like 
materials are advantageous for surgical delivery and retainment of biomaterials 
in several areas of regenerative medicine,(80, 82, 83, 251) and could more 
specifically be advantageous for treating SCI. Other studies have utilized the high 
viscosity of hyaluronic acid (HA) to make HA-based bioink formulations or 
injectable hydrogels.(197, 268) We previously adapted a pentenoate-
functionalized hyaluronic acid (PHA) hydrogel as a bioink;(81) however, our 
preliminary in vitro studies with rat neural stem cells (rNSCs) showed that PHA 
did not support rNSC adhesion, similar to what others have found with fibroblasts 
or oligodendrocyte progenitors on HA-based hydrogels.(197, 268) Those studies 
incorporated gelatin to promote cellular adhesion (e.g., via the RGD sequences); 




may not be sufficiently retained if injected into a hemorrhaging SCI with constant 
cerebral spinal fluid flow around the cord, and thus unrealistic for translation. 
Therefore, there is an unmet need for injectable hydrogels with faster gelation 
times for better retention within the injury. The purpose of this study was to adapt 
the fast-crosslinking PHA bioink to support neural stem cell growth through the 
inclusion of the newly developed pentenoate functionalized-gelatin (PGel), while 
maintaining the paste-like and injectable rheology for bioprinting and translation 
for application to SCI.  
Materials and Methods 
Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise 
stated.  
Pentenoate-functionalized hyaluronic acid (PHA) and gelatin (PGel) 
synthesis 
PHA was synthesized from 1.5 MDa hyaluronic acid (HA, actual MW: 1.56 
MDa; Lifecore Biomedical, Chaska, MN) as we previously described.(81) PGel 
was synthesized using a similar protocol using gelatin from porcine skin (Type A, 
~300 g Bloom). Briefly, HA or gelatin were fully dissolved in deionized (DI) water 
(HA: 2 g into 150 mL (0.5 w/v%) at 25°C, gelatin: 5 g in 100 mL at 37°C (5 w/v%)). 
A catalyst, 4-(dimethylamino)pyridine (HA: 500 mg, gelatin: 250 mg) was then 
added. Once dissolved, N,N-Dimethylformamide (DMF) (HA: 200 mL (3:1 




to mix. 4-pentenoic anhydride (12 mL) was added slowly and the pH was 
maintained between 8.5-9 with dropwise addition of sodium hydroxide (1 M) for 
1 hour, until the pH remained constant. The PHA reaction was left to react 
overnight before dry sodium chloride was added (10 g, 0.5 M). In contrast, the 
PGel solution (5 mL) was immediately precipitated. Both PHA and PGel were 
precipitated in acetone with four- or eight times the reaction volume, respectively 
(40 mL). While PHA was precipitated directly in the glass beaker and then 
transferred to 50-mL plastic tubes, the PGel (5 mL) was transferred to 50-mL 
plastic tubes and then precipitated with acetone to prevent adherence to glass 
upon precipitation. PHA or PGel were centrifuged (6000 x g, 3 min) on a 
Centrifuge 5430R (Eppendorf®, Hamburg, Germany) to pellet the precipitate. 
The acetone was decanted PHA pellets were collected in a glass beaker with a 
stir bar and dissolved in DI water (400 mL) overnight. For PGel, DI water was 
added to each tube with a pellet (20 mL per tube) and placed on a tube rocker 
(~1 h) until dissolved. PHA or PGel were then dialyzed in DI water (MWCO: 6–8 
kDa, VWR) for 48 hours with water exchanges every 12 hours to remove 
impurities. After dialysis, PHA (at room temperature) or PGel (heated to 37°C on 
a stirring hot plate) solutions were adjusted to a physiological pH of 7.4 with 
dropwise addition of sodium hydroxide (1 M), frozen at –20°C, and lyophilized. 




1D and 2D NMR of PHA and PGel  
The functionalization of PHA was determined using NMR Spectroscopy 
on a Varian VNMRS-500 MHz NMR Spectrometer equipped with a 5 mm indirect 
detection room temperature probe (Varian, Palo Alto, CA), as we previously 
described.(81) NMR samples were prepared by dissolving 2-3 mg of PHA or PGel 
in 0.7 mL of deuterium oxide (D2O; Cambridge Isotope Laboratories, Inc., 
Andover, MA). The PGel sample was dissolved with an internal standard, 3-
(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TMSP) at 1 mg/mL. To 
ensure accuracy in the integration, a long recycle and pre-acquisition delay were 
employed to allow for full relaxation of the protons. Therefore, the integrated 
proton spectrum of PHA was collected at 80°C (16 scans, 35 s recycle delay, 90-
degree pulse width, 60-s pre-acquisition delay). The integrated proton of PGel 
was collected at 25°C with identical parameters. The percent functionalization of 
PHA was determined through integration of an alkene peak corresponding to one 
proton of the pentenoate group (5.82 ppm) and normalization to the acetyl methyl 
group (1.91 ppm) on the repeating disaccharide. The molar concentration of 
pentenoate functionalization of PGel was determined through integration of the 
alkene peak corresponding to one proton of the pentenoate group (5.84 ppm) 
and quantified using an internal standard (TMSP, 0 ppm), as has been done 
previously for methacrylated gelatin.(269)  
The 1H resonances for the HA, gelatin, PHA, and PGel were assigned by 




experiments were run on gelatin and PGel at 25°C and HA and PHA at 80°C: 1H-
1H Total Correlation Spectroscopy (TOCSY), 1H-1H homonuclear correlation 
spectroscopy (COSY), 1H{13C} heteronuclear single quantum coherence 
spectroscopy (HSQC), phase edited to distinguish CH2 and CH3 signals, and 
1H{13C} heteronuclear multiple bond correlation spectroscopy (HMBC). 
MestReNova software v.12.0.1 (Mestrelab Research, Santiago de Compostela, 
Spain) was used to process all 1D spectra with a baseline correction, phase 
correction, and a 1 Hz exponential weighting function. The 2D spectra were 
collected with 1024 points in f2, 128 points in f1, and a three second recycle 
delay. Non-uniform sampling was used to reduce data collection time by 50%. 
The data were then processed with a cosine squared and a gaussian function in 
the f2 dimension, and a cosine function in the f1 dimension. Zero filling and linear 
progression were also applied in the f1 dimension to increase the processed data 
size to 2048 points in f1. 
Hydrogel formation 
For in vitro studies, ethylene oxide gas was used to sterilize dry PHA and 
PGel (AN74i, Anderson Anprolene, Haw River, NC). Hydrogels made for 
characterization and in vitro studies and were formed as follows. PGel hydrogels 
were dissolved at 2X in phosphate buffered saline (PBS) at 37°C for 5-10 
minutes. PHA/PGel hydrogels were formed by first dissolving PGel in PBS at 2X 
(37°C for 5-10 min), before adding to PHA to dissolve (4°C, overnight). PGel or 




concentration in the hydrogel) and crosslinker, DL-Dithiothreitol (DTT, ≥98%). 
Final concentrations of PGel, PHA, and DTT were varied for the in vitro and 
characterization studies and are defined in the subsequent Experimental Design 
sub-section. The PGel hydrogel precursors were mixed via pipetting. A metal 
spatula was used to mix PHA/PGel hydrogel precursors and were left for 15–30 
min in the dark to fully incorporate the added liquids. Air bubbles were eliminated 
by centrifugation with a short-spin cycle (30 s). 
PHA/PGel hydrogels for all characterization and in vitro studies were 
formed by depositing precursor solutions into a rectangular rubber mold (1 mm 
thickness) between 2 glass slides followed by crosslinking with a handheld UV 
light (312 nm, 9 mW/cm2; EB-160C, Spectroline, Westbury, NY) for 2 minutes. 
Hydrogels were swollen in PBS overnight at 37°C and cylindrical hydrogels were 
punched out of the swollen hydrogel with a 6-mm biopsy punch. For in vitro 
studies, all materials aside from PHA and PGel were sterilized via autoclaving or 
ethylene oxide prior to use and hydrogels were prepared under sterile conditions. 
PGel hydrogels for mechanical characterization were formed with the 
same methods as PHA/PGel hydrogels, except the glass slides were coated with 
a siliconizing reagent (Sigmacote®) prior to hydrogel formation to prevent the 
adherence of PGel hydrogels to the glass. PGel hydrogels for in vitro studies 
were fabricated directly in sterile flat-bottomed 96-well or 48-well plates where 33 
µL or 100 µL, respectively, of hydrogel precursor was pipetted into each well to 




Hydrogels were swollen in sterile PBS overnight at 37°C with 2 PBS exchanges 
(1 and 12 hours after fabrication) to swell out excess DTT.  
Experimental Designs 
For PGel in vitro studies (n = 6-8), mechanical testing (n = 5-6), and 
swelling/absorption characterization (n = 6), PGel hydrogels were fabricated with 
varied PGel concentrations (i.e., 5, 10, 15 wt%) and DTT concentrations (i.e., 
0.25, 0.5 xDTT, where xDTT is the mmol of DTT per g of PGel). The mass 
concentrations of DTT for each group were as follows: 5 wt% PGel-0.25 xDTT 
(1.93 mg/mL), 5 wt%-0.5 xDTT (3.86 mg/mL), 10 wt%-0.25 xDTT (3.86 mg/mL), 10 
wt%-0.5 xDTT (7.71 mg/mL), 15 wt%-0.25 xDTT (5.78 mg/mL), and 15 wt%-0.5 xDTT 
(11.57 mg/mL).  
For PHA/PGel in vitro studies (n = 5-7), mechanical testing (n = 5-6), and 
swelling/absorption characterization (n = 6), PHA/PGel hydrogels were fabricated 
with varied PHA (i.e., 3, 4, 5 wt%) and PGel concentrations (i.e., 5, 10 wt%). The 
amount of DTT was determined by the summation of the amount needed to 
crosslink 10% of the repeat units on PHA (given that 34% of the repeat units had 
pentenoate groups, determined via NMR) and the amount needed for the 0.25 
xDTT condition for the PGel. DTT concentrations for each group were as follows: 
3%/5% (PHA wt%/PGel wt%) (2.52 mg/mL), 3%/10% (4.45 mg/mL), 4%/5% (2.72 





For rheological studies, the viscosity (n = 3), yield stress (n = 3 or 5), and 
storage modulus recovery (n = 3) were characterized of PHA/PGel precursors 
(i.e., 3%/10%, 4%/5% (PHA wt%/PGel wt%)). For bioprinting and the shape 
fidelity assessment, the 4%/5% precursor was tested (n = 4). 
Mechanical testing and swelling characterization 
The compressive elastic modulus of the hydrogels was determined on a 
Discovery Hybrid Rheometer-2 (DHR-2; TA Instruments, New Castle, DE) using 
8-mm parallel plates to compress samples at a 5 µm/s rate (~0.25% 
strain/second) until 20% strain at 25°C under dry conditions, as previously 
described.(270) A micrometer was used to measure hydrogel diameters prior to 
testing and used to calculate the cross-sectional area. A 0.01 N tare load was 
used to ensure the parallel plates were in contact with the hydrogel before 
compression and determine the hydrogel height. A custom MATLAB® script was 
used to calculate the stress by dividing the force by the initial cross-sectional area 
and to then calculate the slope of the linear portion of the stress-strain curve (i.e., 
5-15% strain) to determine the compressive modulus. 
For absorption and swelling measurements, hydrogels were immediately 
punched after gelation into cylindrical hydrogels to measure the fabricated mass. 
After swelling in PBS (24 h, 37°C), the swollen mass was measured, and then 
after freezing (–20°C) and lyophilization, the dry mass was measured. The 
swelling ratio was calculated as the swollen mass divided by the dry mass. The 





The rheology of PHA/PGel precursors was measured on a DHR-2 
rheometer with parallel 20-mm crosshatched plates (25°C, 500 µm gap), as we 
previously described.(81) Viscosity curves were obtained by a logarithmic shear 
rate sweep from 0.1 s-1 to 100 s-1 (3 points per decade). The storage (G’) and 
loss (G”) moduli were measured over an oscillatory shear stress sweep from 1 to 
1000 Pa, and the yield stress was determined by the crossover point of these 
storage and loss moduli. After a 5-minute soak time, the storage modulus 
recovery was measured during three phases of oscillatory shearing at a 1 Hz 
frequency (i.e., 5 min of 10 Pa shear stress, 30 s of 1000 Pa shear stress, 5 min 
of 10 Pa shear stress). The initial storage modulus was calculated from the 
average storage modulus of the initial phase, and the recovered storage modulus 
was the first recorded storage modulus in the third phase (5 s after the transition 
from 1000 Pa to 10 Pa). The storage modulus recovery was the recovered 
storage modulus divided by the initial storage modulus, multiplied by 100%.  
The printability was assessed by bioprinting PHA/PGel precursors on an 
Inkredible+ bioprinter (Cellink®, Gothenburg, Sweden) as we previously 
described.(81) Briefly, the g-code was generated for a 10 x 10 x 1.2 mm 
rectangular prism in Repetier-Host (Hot-World GmbH & Co. KG, Willich, 
Germany) with three layers, 43% rectilinear infill, 10 mm/s printhead speed, and 
no perimeter. The precursors were back-loaded into a bioprinter cartridge, 




polypropylene conical nozzle (27G) (Cellink®) using pressures of 60-80 kPa to 
reach a consistent flow and print. Images were taken on a Nikon D5500 camera 
(Nikon, Tokyo, Japan) with a macro lens (Nikon AF-S Micro-NIKKOR 60 mm 
f/2.8G ED Lens, Nikon). The printability was assessed using a qualitative shape 
fidelity score as previously described (scale of 0 to 3, where 0 is no shape fidelity 
and 3 is high shape fidelity with well-defined building potential.(81) ImageJ 
(National Institutes of Health, Bethesda, MD) was used to analyze the strut size 
and pore area of the bioprinted precursors. The strut size was determined from 
several measured widths of horizontal and vertical struts from each sample, and 
the pore area was determined using the Analyze Particle feature to measure 
several pores per sample. 
Cytotoxicity in vitro studies 
Unless otherwise stated, all cell culture supplies were purchased from 
Thermo Fisher Scientific (Waltham, MA). Rat neural stem cells (rNSCs) (Thermo 
Fisher Scientific) were cultured on tissue culture flasks coated with CTS™ 
CELLstart™ Substrate (1% diluted in Dulbecco’s phosphate-buffered saline with 
calcium and magnesium (DPBS)) for 1 hour in a 37°C incubator. Cells were 
cultured with KnockOut DMEM/F-12 Basal Medium supplemented with StemPro 
Neural Stem Cell Serum Free Medium (NSC SFM) Supplement (2%), 
recombinant human basic fibroblast growth factor (bFGF; 20 ng/mL), 
recombinant human epidermal growth factor (EGF; 20 ng/mL), GlutaMAX™-I 




was changed every 2-3 days and cells were dissociated with StemPro™ 
Accutase™ Cell Dissociation Reagent for passaging once they reached 80% 
confluency. For all in vitro studies, rNSCs were seeded on hydrogels at 50,000 
cells/cm2 (passage 3) and cultured for 7 days with medium changes on day 1 and 
every other day afterwards. 
PGel hydrogels were formed in 96-well plates for assays and 48-well 
plates for imaging. PHA/PGel hydrogels were formed and punched out as 
described in the previous Hydrogel Formation sub-section and were placed at the 
bottom of 96-well plates using a sterile metal spatula for both assays and imaging. 
Additional hydrogels for each group were fabricated without seeded cells to serve 
as material controls (n = 2 for the PGel study, n = 3 for the PHA/PGel study). 
Additional wells were coated with CTS™ CELLstart™ as described above and 
seeded with the same density of cells for a comparator group of normal plated 
cells (n = 8 for the PGel study, n = 7 for the PHA/PGel study). 
The metabolic activity of rNSCs on day 1 and day 7 was measured using 
the alamarBlue Cell Viability Reagent (Thermo Fisher Scientific), according to 
manufacturer’s instructions. Briefly, after the removal of medium from each well, 
the alamarBlue reagent (10X) was diluted in pre-warmed medium (1X solution) 
and 150 µL was added to each well and incubated (6 hours). A BioTek Cytation™ 
5 plate reader (BioTek, Winooski, VT) was used to measure the fluorescence 
(excitation: 540 nm, emission: 590 nm). The fluorescence was normalized to the 




assay, the total DNA content of the same samples was quantified. The 
alamarBlue/medium was removed from each well and the cells were digested in 
150 µL of papain solution (125 µg/mL papain from papaya latex, 5 mM N-acetyl 
cysteine, and 5 mM (ethylenedinitrilotetraacetic acid disodium salt dihydrate 
(EDTA) in PBS) overnight at 60°C, as previously described.(257) Samples were 
stored in tubes in the freezer at –20°C. To prepare samples, tubes were thawed, 
vortexed, and centrifuged to pellet the polymer (10,000 rpm or 9391 x g, 5 min). 
The total DNA content in the supernatant of each sample was quantified using 
the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific), according 
to manufacturer’s instructions. A BioTek Cytation™ 5 plate reader (excitation: 
485 nm, emission: 528 nm) was used to measure the fluorescence and the total 
DNA was determined with a DNA standard curve. To determine the metabolic 
activity normalized to the total DNA content, the alamarBlue fluorescence of each 
sample was divided by the total DNA content, with further normalization to the 
average of the plated cells group or to the 3%/5% (PHA wt%/PGel wt%) group 
for the PHA/PGel study. 
On day 1 and 7, rNSCs on PGel hydrogels in the 48-well plate were 
stained with the LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells (calcein 
AM (2 µM), ethidium homodimer-1 (4 µM) in PBS; Thermo Fisher Scientific) for 
20 minutes before replacing the solution with PBS. Images of each hydrogel were 
taken on a Keyence BZ-X800 Automated Fluorescence Microscope (KEYENCE 




microscope software. Given the aggregations of the cells and the limitations of 
the LIVE/DEAD stain (i.e., the dead stain intercalating with the DNA without 
distinct separation between aggregated cells), direct quantification of the viability 
from counting live and dead cells may be an inaccurate estimate of viability and 
was not performed. 
On day 1 and 7, rNSCs on PHA/PGel hydrogels in 96-well plates were 
fixed with 10% neutral buffered formalin (VWR) and stored in PBS at –4°C until 
imaged. Scanning electron microscopy (SEM) images were taken on a Hitachi 
TM3000 Tabletop SEM (Hitachi, Schaumburg, IL).  
Statistical methods 
GraphPad Prism (GraphPad Software Inc., La Jolla, CA) was used to 
perform all statistical analyses. A two-way analysis of variance (ANOVA) was 
used to analyze results from hydrogel mechanical, swelling, and absorption 
testing, metabolic activity, DNA content, metabolic activity normalized to DNA 
content, followed by Tukey’s post-hoc test. A two-tailed t-test was used to analyze 
yield stress and storage modulus recovery tests. A two-way ANOVA with 
repeated measures was used to analyze viscosity curves with Bonferroni’s post-
hoc test to determine the simple effects between the viscosities for each material 
for each shear rate. p < 0.05 was considered significant. Results were reported 





Confirmation and quantification of pentenoate functionalization on PHA 
and PGel 
The proton spectra of HA, PHA, gelatin, and PGel were fully assigned (Fig. 
4.1, Tables 4.1-4) by 2D NMR methods, using the 1H-1H 2D TOCSY, COSY, 
HSQC, and HMBC correlations. The 1H-1H 2D TOCSY separates amino acid 
residues by correlating protons within a single spin system. The COSY 
experiments identified the 1H resonances on adjacent carbon atoms within a spin 
system for sequential assignment (data not shown). The phase edited HSQC 
experiments correlated the 1H resonance to the 13C resonance of the attached 
carbon and distinguished CH and CH3 signals from CH2 signals (data not shown). 
The HMBC experiments correlated the 1H resonances with 13C resonances that 
were separated by 2-3 bonds, effectively placing the amino acid residues within 
the compound (data not shown).  
  Each sugar ring of HA is a distinct spin system allowing the 1H-1H 2D 
TOCSY spectra (Fig. 4.1A) to distinguish between the unique sugar ring 
resonances (Table 4.1). The 1H-1H 2D TOCSY peaks of the N-acetyl-D-
glucosamine spin system (highlighted in red) showed correlation of the proton 
signals of the 2, 3, 4, and 5 ring protons (refer to the HA structure in Fig. 4.1A for 
numbering scheme) to the proton signal of ring position 6, correlations to each 
other and to the ring’s anomeric proton at 4.47 ppm. Additionally, weaker 




were observed. The of D-glucuronic acid spin system (highlighted in light blue) 
showed the proton signals (4 to 5 ppm) of the 2’, 3’, 4’, and 5’ ring carbons 
correlated to each other and to the anomeric 1’ carbon signal (4.33 ppm). Each 
amino acid of the gelatin sample is a distinct spin system, and therefore, readily 
observed in the 1H-1H 2D TOCSY spectra (Fig. 4.1B). The proton signals of the 
following amino acids that were greater than 3 wt%(269) were assigned (Table 
4.3) and highlighted in Fig. 4.1B: arginine (green), lysine (dark blue), proline 
(orange), hydroxyproline (yellow), alanine (pink), glycine (red), glutamic acid 
(gray), aspartic acid (dark purple), and serine (light purple).  
Pentenoate conjugation occurred at hydroxyl groups in HA. When 
compared to the HA 1H-1H 2D TOCSY (Fig. 4.2A), the PHA 1H-1H 2D TOCSY 
(Fig. 4.2B) showed a new spin system that consisted of four new peaks: two 
alkenes and two alkanes of the pentenoate group (highlighted in red at 5.82, 5.0, 
2.46, 2.29 ppm). The assigned PHA proton signals (Table 4.2) from the sugar 
rings were similar to the signals in HA. 
Pentenoate conjugation occurred at hydroxyl and amine groups in gelatin. 
When compared to gelatin (Fig. 4.2C), the PGel spectra showed a new spin 
system that consisted of four new peaks (Fig. 4.2D, highlighted in red at 2.33, 
2.51, 5.04, 5.84 ppm) of the pentenoate group. The proton resonances of PGel 
were assigned (Table 4.4) and the pentenoate group in PGel had similar 
resonances as the pentenoate group of PHA. While two of the amino acid spin 




shifted signals from the functionalized lysine were detected (called modified 
lysine in Table 4.4).  
 Quantification of the pentenoate functionalization of PHA (Fig. 4.2E), 
revealed that 38% of the repeat units were functionalized with a pentenoate 
group, which was ~0.108 millimoles of pentenoate per gram (mmol/g) of PHA. 
The quantification of the pentenoate functionalization of PGel (Fig. 4.2F), 
revealed that there was ~0.025 mmol/g of PGel.  
PGel mechanical testing and swelling characterization 
The compressive moduli of PGel ranged from 4 ± 2 kPa up to 153 ± 18 
kPa, where the moduli increased with increased PGel concentration and DTT 
concentration (Fig. 4.3A). The modulus of the hydrogel with the highest PGel and 
DTT concentrations (i.e.,15%/0.5, PGel wt%/xDTT) was 1.5, 2.9,7.6, 25.9, and 
39.7 times greater (p < 0.0001) than the 15%-0.25, 10%/0.5, 10%/0.25, 5%/0.5, 
and 5%/0.25 hydrogels, respectively. The modulus of the 15%/0.25 hydrogel was 
1.9, 4.9, 17, and 26 times greater (p < 0.0001) than 10%/0.5, 10%/0.25, 5%/0.5, 
and 5%/0.25 hydrogels, respectively. The modulus of the 10%/0.5 hydrogel was 
2.6 greater (p < 0.001) than the 10%/0.25 hydrogels, and 8.9 and 13.7 times 
greater (p < 0.001) than 5 wt% PGel hydrogels with 0.5 and 0.25 xDTT, 
respectively.  
The absorption of all PGel hydrogels ranged from 0.80 ± 0.07 to 0.97 ± 
0.03, which are all less than 1 and indicated that the hydrogels contracted and 




highest PGel concentration and lowest DTT concentration (i.e.,15%/0.25) were 
about 12-21% greater than the hydrogels with the same PGel concentration and 
highest DTT concentration, 15%/0.5 (p < 0.01), and the hydrogels with the lowest 
PGel concentrations, 5%/0.5 (p < 0.0001) and 5%/0.25 (p < 0.001). The 
absorption of the middle PGel concentrations, 10%/0.25 and 10%/0.5 hydrogels, 
were 14-15% greater than that of the 5%/0.5 hydrogels (p < 0.001).  
The swelling ratio decreased from 15.4 ± 0.5 to 4.4 ± 0.4 as the PGel 
concentration increased, with a smaller effect from the DTT concentration (Fig. 
4.3C). The swelling ratio of hydrogels with the lowest PGel concentrations, 
5%/0.25 and 5%/0.5, were 1.9-3.4 times higher (p < 0.0001) than all the 
hydrogels with 10 and 15 wt% PGel. The swelling ratio of the 10%/0.25 hydrogel 
was 21, 39, and 78% greater than the 10%/0.25 (p < 0.01), 15%/0.25 (p < 
0.0001), and 15%/0.5 (p < 0.0001) hydrogels, respectively. The swelling ratio of 
the 10%/0.5 and 15%/0.25 hydrogels were each 47% (p < 0.0001) and 28% (p < 
0.01) greater than the 15%/0.5 hydrogel, respectively. 
PHA/PGel mechanical testing, swelling, and rheological characterization 
The compressive moduli of the PHA/PGel hydrogels ranged from 63 ± 4 
kPa to 172 ± 20 kPa (Fig. 4.3D). The hydrogel with the highest PHA and PGel 
content (i.e., 5%/10%, PHA wt%/PGel wt%) had the highest compressive 
modulus, which was 1.6-2.7 times greater than all the other tested hydrogels (p 




37-70% greater than the hydrogels with the lowest PHA and PGel content, 
4%/5% (p < 0.05) and 3%/5% (p < 0.01).  
The absorption of PHA/PGel hydrogels ranged from 1.31 ± 0.03 to 1.51 ± 
0.03 (Fig. 4.3E). Absorption was higher with greater PHA concentrations, where 
the 4%/5%, 5%/5%, and 5%/10% hydrogels were 10-16% greater than the 
3%/5%, 3%/10%, and 4%/10% hydrogels (p < 0.0001).  
As seen in Fig. 4.3F, the swelling ratios ranged from 10.3 ± 0.2 to 14.7 ± 
0.2. Hydrogels with the lower PGel concentration (i.e., 5 wt%) had swelling ratios 
that were 16-42% higher (p < 0.0001) than those of the hydrogels with the higher 
PGel concentration (i.e., 10 wt%). PHA concentration had less of an effect on the 
swelling ratio, except the swelling ratio of 3%/10% hydrogels were 15% greater 
than the 5%/10% hydrogels (p < 0.01). 
The rheology the 4%/5% and 3%/10% PHA/PGel hydrogel precursors was 
characterized in Fig. 4.4. Both formulations had similar shear thinning viscosity 
curves (Fig. 4.4A) and the viscosities of the 4%/5% and 3%/10% precursors were 
4.3 ± 1.2 and 0.9 ± 0.1 Pa-s at the highest tested shear rate of 100 s-1, 
respectively. The viscosities were not significantly different. At lower shear rates 
(i.e., 0.10, 0.22, 0.46 s-1), the 4%/5% hydrogel precursor (lighter blue line, circle 
markers) was 2.4-3.0 times more viscous (1,260 ± 150, 1,100 ±160, 650 ± 110 
Pa-s, p < 0.0001) than the 3%/10% hydrogel precursor (darker black line, square 
markers) (520 ± 200, 380 ± 170, 210 ± 130 Pa-s). The yield stress (Fig. 4.4B) of 




than the 3%/10% hydrogel precursor (93 ± 20 Pa). The storage modulus recovery 
(Fig. 4.4C) of the 4%/5% hydrogel precursor (79 ± 2%) was 95% greater (p < 
0.001) than the 3%/10% hydrogel precursor (41 ± 5%). After bioprinting (Fig. 
4.4D), the 4%/5% hydrogel precursor had good shape fidelity (score = 3) with a 
strut size of 1.07 ± 0.08 mm and pore area of 0.24 ± 0.03 mm2. The 3%/10% 
precursor had poor shape fidelity and did not hold the bioprinted shape (strut size 
and pore area not able to be measured). Overall, the 4%/5% formulation 
precursor printed with better shape fidelity and had a higher yield stress and 
storage modulus recovery than the 3%/10% formulation. 
PGel hydrogels promoted rNSC adhesion at lower PGel concentrations 
The metabolic activity of the rNSCs seeded on PGel hydrogels for 7 days 
and normalized to seeded cells is shown in Fig. 4.5A. On day 1 the normalized 
metabolic activity ranged from 0.13 ± 0.05 to 0.19 ± 0.11, which was less than 
20% of the metabolic activity of the plated cell control. Cells on the 15%/0.25, 
10%/0.25, and 5%/0.5 hydrogels had 2.6 (p < 0.01), 2.3 (p < 0.05), and 2.3 (p < 
0.05) times greater metabolic activity than cells on the 15%/0.5 hydrogels. After 
7 days, the metabolic activity of cells on all PGel groups ranged from 0.01 ± 0.01 
to 0.64 ± 0.07, which was less than 70% of the metabolic activity of the plated 
cell control, but the cells on the 5%/0.5 hydrogels had 2.3 (p < 0.0001), 1.7 (p < 
0.0001), 1.3 (p < 0.01), 4.4 (p < 0.0001), and 53.4 (p < 0.0001) times higher 
metabolic activity than cells on all other hydrogels: 5%/0.25, 10%/0.25, 10%/0.5, 




the second highest metabolic activity that was 1.7, 1.3, 3.4, and 40.8 times 
greater than the metabolic activity of cells on the 5%/0.25 (p < 0.0001), 10%/0.25 
(p < 0.05), 15%/0.25 (p < 0.0001), and 15%/0.5 (p < 0.0001) hydrogels. The third 
highest metabolic activity belonged to the cells on the 5%/0.25 and 10%/0.25 
hydrogels, which were not significantly different from each other, but were ~2.2 
and ~25 times higher than cells on the 15%/0.25 and 15%/0.5 hydrogels (p < 
0.0001), respectively. Finally, the metabolic activity of the cells on the 15%/0.25 
hydrogels was 12.1 times greater than for the 15%/0.5 hydrogels (p < 0.05). The 
greatest to least metabolic activity of cells on PGel hydrogels on Day 7 was 
5%/0.5 > 10%/0.5 > 5%/0.25, 10%/0.25 > 15%/0.25 > 15%/0.5 and is denoted by 
A-E on the right panel of Fig 4.5A, where each letter denotes statistical 
significance of that group relative to groups with all other letters. 
The DNA contents of the seeded rNSCs ranged from 53 ± 50 ng to 147 ± 
30 ng and are shown in Fig. 4.5B. On day 1, four of the hydrogel groups had 2.1-
2.8 times greater DNA content than the 5%/0.25 hydrogels: 5%/0.5 (p < 0.0001), 
10%/0.25 (p < 0.0001), 10%/0.5 (p < 0.001), and 15%/0.5 (p < 0.01). Additionally, 
the 10%/0.25 hydrogels had 62% more DNA than the 15%/0.25 hydrogels. After 
7 days, the DNA content ranged from 97 ± 8 ng to 146 ± 13 ng. The 5%/0.5 
hydrogels had the greatest DNA content, which was ~41% greater than the 
5%/0.25 (p < 0.05), 10%/0.25 (p < 0.05), 15%/0.25 (p < 0.05), and 15%/0.5 (p < 




To evaluate the metabolic activity on a per cell (i.e., per ng of DNA content) 
basis, the metabolic activity was normalized to the DNA content. For context to 
normal plated cells and to allow comparisons between the in vitro studies 
presented here, the data was further normalized to the plated cells group (where 
1.0 represents the metabolic activity of the plated cells). The normalized 
metabolic activity of rNSCs on a per cell basis on PGel hydrogels is shown in Fig. 
4.5C and ranged from 0.06 ± 0.06 to 0.20 ± 0.14. On day 1, the normalized 
metabolic activity for all groups was below 20% of the plated cell controls, but the 
cells on the 15%/0.5 hydrogels had 3.3 times the metabolic activity of the cells 
on the 15%/0.25 hydrogels (p < 0.01). After 7 days, the normalized metabolic 
activity ranged from 0.03 ± 0.02 to 1.12 ± 0.16 and the cells on the 5%/0.5 and 
10%/0.5 hydrogels exceeded the plated cell controls (i.e., normalized metabolic 
activity > 1.0). Cell on hydrogels with the 5 and 10 wt% PGel had higher metabolic 
activity than the cells on the 15 wt% PGel hydrogels. Specifically, the hydrogels 
with the higher DTT concentration, 5%/0.5 and 10%/0.5, had 3.5 times greater 
normalized metabolic activity than the 15%/0.25 hydrogels (p < 0.001), and 33-
35 times greater activity than the 15%/0.5 (p < 0.0001) hydrogels. On the other 
hand, the lower DTT concentrations, 5%/0.25 and 10%/0.25, had less of an effect 
with 2.7 times greater normalized metabolic activity than the cells on the 
15%/0.25 hydrogels (p < 0.05), and 26 times greater activity than the cells on the 




The LIVE and DEAD stains of rNSCs seeded on PGel hydrogels are 
shown in Fig. 4.6, along with plated cell controls (right column). There was 
qualitatively similar cell adhesion to all hydrogels after 1 day (~12 h) with the 
presence of live and dead cells (Fig. 4.6A). A magnified image of the white inset 
box is shown to the right of the wider field-of-view image and qualitatively showed 
that the cells on hydrogels had rounded morphologies. In comparison, plated cell 
controls qualitatively had more cells with elongated morphologies. After 7 days 
(Fig. 4.6B), several of the 5%/0.5 hydrogels were too soft to handle and were 
often aspirated into the pipette tips during gentle medium and staining solution 
exchanges. Few images were able to be obtained, but the visible cells had formed 
into neurospheres instead of adhering to the hydrogel. In all other groups on day 
7, qualitatively similar densities of cells and cell spreading were seen in all 
hydrogel groups and in the plated cell control. There appeared to be more dead 
cells on the 15 wt% PGel hydrogels than the 5 or 10 wt% PGel hydrogels. 
PHA/PGel hydrogels with less PHA promoted better rNSC adhesion 
The metabolic activity of rNSCs seeded onto PHA/PGel hydrogels for 7 
days was evaluated and normalized to the plated cells control group (Fig. 4.7A). 
On day 1, the metabolic activities ranged from 0.36 ± 0.01 to 0.83 ± 0.42. While 
the main effect of the PHA was significant (p < 0.01), none of the groups were 
different from one another other from the Tukey’s post-hoc test. On day 7, the 
metabolic activities ranged from 0.65 ± 0.41 to 1.30 ± 0.32. The cells on the 




times greater metabolic activity than the cells on the 3%/5% (p < 0.001), 5%/5% 
(p < 0.05), and 5%/10% (p < 0.01) hydrogels, respectively.  
The total DNA content of seeded rNSCs on day 1 (Fig. 4.7B) were not 
significantly different among hydrogel groups and ranged from 186 ± 12 ng to 201 
± 9 ng. On day 7, the DNA contents of the seeded cells ranged from 110 ± 29 ng 
to 220 ± 25 ng. All groups at day 7 had greater DNA contents than the 3%/5% 
group, where the 3%/10% group had 49% greater (p < 0.05) DNA content and all 
the 4% and 5% PHA containing groups had 1.8-2 times greater DNA content (p 
< 0.0001). Additionally, the 5%/5% hydrogels had 35% greater DNA content than 
the 3%/10% hydrogels (p < 0.05). 
The metabolic activity was normalized to the DNA content and further 
normalized to the 3%/5% hydrogels in Fig. 4.7C. On day 1, the main effect of the 
PHA was significant (p < 0.01); however, there were not any individual differences 
among groups from the Tukey’s post-hoc test. The range of normalized metabolic 
activity on day 1 was 0.44 ± 0.02 to 1.04 ± 0.52. After 7 days, the normalized 
metabolic activity ranged between 0.53 ± 0.10 to 1.16 ± 0.25 and the cells on the 
3%/10% hydrogels had the greatest normalized metabolic activity. Cells on the 
3%/10% hydrogels had 50-55% greater (p < 0.01) and 2.1-2.2 times greater (p < 
0.0001) normalized metabolic activity than the 4% and 5% PHA containing 
groups, respectively. Additionally, the cells on the 3%/5% hydrogel had 83-87% 





Given the opaque nature of the PHA/PGel hydrogels, SEM images were 
taken of the seeded cells on day 1 and 7 (Fig. 4.8). On day 1 (Fig. 4.8A), rNSCs 
were adhered to all PHA/PGel hydrogels at similar densities, qualitatively. After 
7 days (Fig. 4.8B), there were qualitatively fewer visible cells on the 3%/5% 
hydrogels, and the cells did not have spread morphologies. On all other 
PHA/PGel hydrogels, cells appeared to have spread morphologies and covered 
a greater portion of the hydrogel than on day 1.  
Discussion 
We developed and characterized a hyaluronic acid- and gelatin-based 
hydrogel bioink that supported the adhesion and proliferation of rNSCs. The 
rheology of the PHA/PGel bioink precursor (i.e., prior to crosslinking) establishes 
the injectability and paste-like handling properties, which may enable easy 
surgical placement and retainment within a cyst-like contusion SCI. The pre-
crosslinking rheology combined with the fast-crosslinking (~2 min) and post-
crosslinking compatibility with rNSCs make the developed PHA/PGel hydrogel a 
suitable candidate biomaterial for future application for nerve regeneration, 
specifically for treatment of SCI. 
In the current study, we found that PGel hydrogels promoted rNSC 
adhesion but lacked a printable precursor and degraded quickly in vitro. On the 
other hand, PHA hydrogels had a printable precursor and the hydrogels did not 
visibly degrade but were not adhesive for rNSCs. Combining PHA and PGel 




rNSC adhesion with better long-term stability. The PHA hydrogels had previously 
been evaluated with seeded rNSCs in preliminary studies and most cells failed 
to adhere to the PHA and instead formed neurospheres that washed off over the 
course of the experiment (data not shown). Other studies have similarly shown 
lack of fibroblast and oligodendrocyte progenitor cell adhesion to HA-based 
hydrogels, and improved cell adhesion with the inclusion of gelatin.(197, 268) 
However, the HA/gelatin hydrogels had long gelation times (2-3 days or 30-60 
min) which may not be able to be retained in a SCI before gelation. The 
pentenoate chemistry applied to HA and gelatin in the current study enabled fast 
UV-crosslinking of all hydrogels.  
From the lack of adhesion to PHA, rNSC adhesion was initially evaluated 
on PGel-only hydrogels with various concentrations of PGel (i.e., 5, 10, 15 wt%) 
and crosslinker, DTT (i.e., 0.25, 0.5 xDTT) to narrow down potential PHA/PGel 
formulations. All the PGel formulations supported rNSC adhesion after 1 day, 
except the softest formulation of the 5% PGel/0.25 xDTT, which were difficult to 
handle, and by day 7, those hydrogels were easily aspirated or destroyed. After 
7 days, the 5 and 10% PGel groups supported better rNSC viability than the 15 
wt% PGel groups and were similar to plated cell controls. The PGel hydrogels 
had similar compressive moduli to rat (7-8 kPa(271)) and human spinal cord (40 
kPa(272)), but the metabolic activity of rNSCs was not correlated with stiffness. 
There was similar metabolic activity per ng of DNA for all the 5% PGel and 10% 




20-53 kPa for 10% PGel). For the rheology, the PGel precursor was injectable, 
but the watery precursor did not have a yield stress and was not printable via an 
extrusion bioprinter. Despite the better cell response of rNSCs on 5% and 10% 
PGel hydrogels than PHA hydrogels, the PGel hydrogels ultimately lacked a 
printable precursor and showed signs of visible degradation after 7 days. 
To improve the integrity of the hydrogel, and to decrease the rate of 
degradation and improve precursor rheology, PHA was incorporated into PGel 
hydrogels.  Given the better rNSC adhesion and survival on the 5 and 10% PGel 
hydrogels, different PHA concentrations (i.e., 3, 4, 5 wt%) were incorporated into 
5 or 10% PGel hydrogels and evaluated for rNSC adhesion and viability. The 
PHA/PGel hydrogels showed minimal degradation over 7 days in the current 
study, and in preliminary studies, did not visibly degrade after 14 days (data not 
shown). In addition to improved stability, rNSCs had better adhesion to PHA/PGel 
hydrogels after 1 day (i.e., ~36 to 83%) compared to PGel only hydrogels (i.e., 
~13 to 19%), where each study was relative to plated cell controls. There was 
less rNSC adhesion and lower metabolic activity on the hydrogel with the lowest 
PHA and PGel concentrations (i.e., 3% PHA/5% PGel), but otherwise there was 
a trend that as the PHA concentration increased, the metabolic activity 
decreased. The addition of PHA to PGel hydrogels increased the compressive 
modulus because of the higher total mass content of polymer. Additionally, the 
compressive modulus of PHA/PGel hydrogels may have increased compared to 




IPN given that PHA and PGel can crosslink to each other in addition to 
themselves. However, similar to PGel, the normalized rNSC metabolic activity did 
not seem to be correlated with stiffness, as the metabolic activity for each PHA 
concentration was the same, irrespective of the PGel concentration and different 
stiffnesses. Given that PHA hydrogels alone did not support rNSC adhesion, the 
decreased adhesion with higher PHA concentrations on PHA/PGel hydrogels 
was most likely due to the lack of cell adhesion to PHA. The highest rNSC 
metabolic activity and cell adhesion was on the 3%/10% PHA/PGel formulation, 
followed by the 4%/5%, and 4%/10% formulations. 
Of the crosslinked PHA/PGel formulations that promoted the best rNSC 
adhesion, the rheological properties of 3%/10% and 4%/5% pre-crosslinked 
(precursor solutions) were tested to determine their printability as bioinks and 
thus their potential for injectable placement. While the 4%/10% formulation 
showed the same metabolic activity per DNA content as the 4%/5%, the hydrogel 
precursor was not tested because of the high PGel concentrations, which were 
twice the amount needed for the 4%/5% formulation. Previously, we 
demonstrated three rheological tests to quantify the printability for an extrusion-
based bioprinter: yield stress, viscosity, and storage modulus recovery.(81) From 
the viscosity curves, both formulations in the current study were shear-thinning 
and could be extruded through a tapered nozzle. Both formulations had a yield 
stress, which theoretically enables shape retention. The 4%/5% had a higher 




pneumatic bioprinter to extrude, but both used moderate pressures within the 
capabilities of the bioprinter.  
The most significant rheological difference between the two PHA/PGel 
formulations was the storage modulus recovery. After experiencing high shear 
stresses, similar to the high shear stresses of being bioprinted through a nozzle, 
the 4%/5% had good recovery of the storage modulus (i.e., ~80%); however, the 
3%/10% formulation had poor recovery (i.e., ~40%). While both formulations had 
a yield stress and theoretically could retain a shape, the poor storage modulus 
recovery resulted in the printed shape relaxing immediately after extrusion 
through a nozzle, or poor post-printing shape retention. For surgical placement, 
poor post-extrusion shape retention corresponds to potential leakage from the 
defect site after injection. Overall, the 4%/5% PHA/PGel hydrogel precursor 
printed successfully and retained high shape fidelity and the 3%/10% hydrogel 
precursor printed without retaining any shape fidelity. These results are 
consistent with the results from our previous study where 4% PHA hydrogel 
precursors printed with high shape fidelity and 3% PHA hydrogel precursor 
printed and immediately relaxed into a puddle with no retained shape.(81) In the 
current study, the high molecular weight of the HA (i.e., 1.5 MDa) may have 
influenced the printability of PHA/PGel more than the lower molecular weight 
gelatin (i.e., 50-100 kDa), as even the addition of 10 wt% gelatin did not improve 




In addition to the development of the 4%/5% PHA/PGel hydrogel as a 
printable bioink, the ability of the hydrogel precursor to be injectable has 
translational potential for application to SCI and in regenerative medicine in 
general. The injectability (i.e., shear thinning) of the PHA/PGel may enable 
injection of the material into a contusion type SCI, which may be easier for 
surgeons to use and less invasive compared to implantation of a preformed 
scaffold (although shape memory polymers in highly deformable hydrogels are 
one of the few examples of an injectable preformed scaffold(70)). In contrast to 
other less viscous and injectable HA or gelatin hydrogel precursors used for 
SCI,(70, 76, 78) the PHA/PGel hydrogels were paste-like to enable better 
retention in the injury. Besides paste-like materials, HA/gelatin hydrogels 
developed for bioprinting were pre-crosslinked to enable post-printing shape 
retention,(197, 253) which may translate to material retention within an SCI. A 
comprehensive review by Macaya and Spector(75) discussed other injectable 
scaffolds that can undergo gelation within an injury and that have been applied 
to SCI (e.g., agarose, collagen, fibrin/fibrinogen, hyaluronic acid/methylcellulose). 
While there were several injectable material precursors, there were other intrinsic 
disadvantages of several materials such as the limited degradation of agarose (> 
6 weeks in vivo) or too fast of degradation of fibrin (< 7 days in situ). As an 
additional example, these authors observed in several studies that collagen 
materials delivered as liquid precursors required a ‘clean’ hemi- or transection 




More homogeneous gelation may be achieved from immediate gelation 
(e.g., modified self-assembling peptides, peptide amphiphiles), or alternatively 
from more viscous or paste-like material precursors that can be retained in the 
injury until gelation. For a more comprehensive review of the necessary precursor 
rheology for material placement in surgical applications and bioprinting in a 
broader context outside of SCI, we refer readers to our recent review.(80) 
However, there are limited studies involving paste-like biomaterial precursors for 
SCI,(69) and the rheological characterizations of the material have not typically 
been performed. The significance of the PHA/PGel developed in the current study 
is the paste-like precursor rheology (i.e., possession of a yield stress) and good 
shape retention after extrusion (i.e., high storage modulus recovery). The 
rheological parameters not only enabled the precursor to be bioprinted with good 
shape fidelity, but may additionally enable translation for better material precursor 
retention after injection into a contusion SCI until gelation, which is rapid for 
PHA/PGel (2 minutes) with exposure to UV light.  
In addition to evaluating the rheology and cell adhesion, we demonstrated 
the utility of 2D NMR techniques in confirming and quantifying the 
functionalization of PHA and the newly synthesized PGel. Several polymers, 
including PHA and PGel, typically have several overlapping signals in the 1H 
spectra, which make characterization with conventional 1D NMR challenging. For 
PGel, the assignment of all the proton signals was more complex than PHA 




sequences, whereas hyaluronic acid is a repeating disaccharide unit. While 1D 
NMR methods have been commonly used to confirm functionalization of a variety 
of biomaterials, fewer studies have utilized 2D NMR characterizations of HA and 
gelatin.(269, 273) For more complex spectra of polymers, 2D NMR methods may 
be necessary to distinguish new signals of a functional group from shifted original 
polymer signals. Specifically for HA and gelatin, the assigned 1H{13C} 2D HSQC 
spectra have been used to show polymer functionalization.(269, 273) In the 
current study, we used an HSQC and other experiments (i.e., COSY, HMBC, 
TOCSY) to fully assign the signals in the HA and gelatin spectra, which had 
chemical shifts that were similar to those in the limited studies in the literature 
that reported the resonances. Furthermore, instead of showing the assigned 
HSQC experiment, we demonstrated the utility of a 1H-1H 2D TOCSY to confirm 
the functionalization by visualizing the distinct spin system of the pentenoate 
group in PHA and PGel and distinguishing the new signals from shifted original 
polymer signals.  
Quantification of gelatin functionalization can be challenging due to the 
inherent variable amino acid composition of gelatin. In studies using 
methacrylated gelatin, methacrylation occurs mostly at amines, and the most 
common methods to determine the degree of methacrylation are by measuring 
the corresponding decrease in amines/lysines. Measuring the decrease has been 
done qualitatively/quantitively with NMR (by observing the lysine methylene 




the Habeeb method/2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) assay).(274-
277) However, in the current study, there were two problems with measuring 
decreased lysine signals for determining the degree of functionalization of PGel. 
First, the assumption that functionalization only occurs on the free amine of 
lysines may not be valid for PGel, where both amines and hydroxyls on several 
amino acids (e.g., lysine, hydroxyproline, serine) could be functionalized by 
pentenoate groups. Second, lysine was not detected in the NMR spectra of PGel. 
Even though shifted signals from functionalized lysine was present, the modified 
lysine signals overlapped with arginine signals on the 2D spectra, which did not 
allow for an integration calculation of the functionalized lysine peak. Another more 
direct measure of the degree of functionalization that has been used is the 
integration of the methacrylate double bond normalized to the phenylalanine 
signal,(278) but this method requires the amino acid composition to be known. 
Finally, a simpler and more robust method by Claaßen et al.,(269) directly 
quantified the amount of methacrylate by normalizing the integrated signals of 
the methacrylate group to a new internal standard (i.e., TMSP), which was 
included in the sample at a known concentration. The method using TMSP as an 
internal standard was performed in the current study for determination of 
functionalization with the pentenoate group on gelatin (see Methods). The PHA 
was more functionalized per gram than PGel, which may be because PHA has 
more pentenoate modifiable groups (i.e., multiple hydroxyls per repeat unit) per 




context of the study that developed the TMSP method, which had several 
methacrylated gelatins with the functionalization ranging from 0.34 to 0.96 
mmol/g, the PGel developed in the current study had a lower pentenoate 
functionalization of 0.025 mmol/g. There is room for improvement to fabricate 
higher functionalized PGel for hydrogels with improved mechanical performance; 
however, in the current study we demonstrated that by adjusting the PGel 
concentration (i.e., 5 to 15 wt%) and crosslinker concentration (i.e., 0.25 or 0.5 
xDTT), the PGel hydrogels could achieve a wide range of compressive elastic 
moduli from 4 to 153 kPa. Overall, the 2D NMR enabled confirmation and 
quantification of the functionalization with the pentenoate group on PHA and 
newly developed PGel. 
Conclusions 
The previously developed PHA bioink had limited rNSC adhesion, thus, in 
the current study, a new functionalized gelatin, PGel, was developed, 
characterized with 2D NMR, and was found to promote cell adhesion. However, 
the PGel-only hydrogels lacked printability and degraded quickly in vitro. In the 
combination of PHA and PGel, each solved the problem of the other to formulate 
a printable hydrogel precursor before crosslinking and a post-crosslinked 
hydrogel that was adhesive for cells and stable over time. The shear thinning 
property of the precursor was important for extrusion of the paste-like PHA/PGel 
precursor for printing, and may additionally enable injection to a SCI. 




modulus was important for shape retention of the precursor after printing, which 
may translate to better material retention after injection in a SCI, until the rapid 
formation (2 minutes) of the PHA/PGel hydrogels. The 4%/5% PHA/PGel 
hydrogel was identified to meet our criteria of rNSCs adhesion and bioprintability. 
The significance of the current study was the development of the injectable and 
paste-like PHA/PGel rheology to overcome the typical challenges of a liquid 
hydrogel precursor and enable material retention in a future SCI application. We 
identified a platform with two common materials (i.e., HA and gelatin) that were 
combined, and determined the final formulation specifically for future application 
to SCI based on both the precursor rheology (pre-crosslinking) and the cell 
adhesion of the crosslinked hydrogel. Other investigators may apply the 
rheological characterizations in the current study to a variety of biomaterials for 






Chapter 5 : Conductive and Injectable Hyaluronic Acid/Gelatin 
Hydrogels for Treating Rat Spinal Cord Injury 4 
 
Abstract 
 In patients with spinal cord injury (SCI), full functional recovery is 
uncommon with current clinical treatments. Rehabilitation strategies have 
resulted in better functional recovery when motor training was combined with 
electrical stimulation (ES); however, patients with more severe injuries that do 
not benefit as much from rehabilitation strategies alone may require the 
incorporation of tissue regeneration for full functional recovery. There is growing 
evidence in the SCI literature indicating the need to combine the fields of 
rehabilitation and regenerative medicine to maximize functional recovery. 
Unfortunately, there are limited methods to synergistically combine rehabilitation 
and regenerative medicine, but conductive biomaterials could be the missing link 
that enables synergistic combination with ES. There are limited studies with 
conductive biomaterials for SCI. One problem is that many conductive 
biomaterials are pre-formed scaffolds, which may hinder clinical translation to a 
contusion-type SCI. Alternatively, an injectable biomaterial, such as those from 
the bioprinting field, may be more translational for contusion SCIs. In the current 
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work, a conductive and injectable/bioprintable hydrogel was developed by 
incorporating gold nanorods (GNRs) into a previously developed fast 
crosslinking, bioprintable pentenoate-functionalized hyaluronic acid (PHA) and 
pentenoate-functionalized gelatin (PGel) hydrogel. High aspect ratio GNRs were 
synthesized and the toxic CTAB coating was exchanged with non-toxic citrate. 
The GNR hydrogels were conductive and supported the adhesion and viability of 
seeded rat neural stem cells (rNSCs). Finally, the GNR, PHA/PGel, PHA, or PGel 
hydrogels were applied to a T8 lateral hemi-section rat spinal cord injury (SCI) 
model. While no significant differences in functional recovery or regeneration 
were found between any of the tested material groups, the feasibility and long-
term safety of implanting the GNR hydrogel was established. With no previous 
studies evaluating a GNR-based conductive hydrogel for application to SCI, this 
study filled that gap and, in the future, may provide a tunable translational 
platform for application to the more clinically relevant model of contusion SCIs 
with applied ES. 
Introduction 
Spinal cord injury (SCI) affects 294,000 people in the United States 
currently, with 17,800 new patients every year.(25) Functional recovery is 
uncommon after SCI with current clinical treatments. There are two main 
approaches to promote functional recovery after SCI: 1) rehabilitation 
approaches and 2) regenerative medicine approaches. Rehabilitation 




neurochemical stimulation to promote the plasticity and reorganization of the 
remaining axonal pathways. Regenerative medicine approaches include cells, 
drugs, biologics, and/or scaffolds to repair and regenerate axonal pathways. For 
SCI, rehabilitative and regenerative medicine approaches individually have not 
yet resulted in full functional recovery in humans, and each has limitations.  
Significant functional recovery, although not full functional recovery, has 
been made using rehabilitation approaches. For example, epidural ES (EES) is 
ES delivered through a surgically implanted electrode patch on the spinal dura at 
the injury site. In rats and cats, locomotor training and/or pharmacological 
stimulation have been able to produce a stepping response after incomplete SCIs 
by activating spinal locomotor circuits (also known as central pattern generators 
(CPGs)) and/or promoting neural plasticity and reorganization in spared tissue 
(covered in detail in a few excellent reviews by Shah et al.(84) and Rossignol et 
al.(85)). In rats with a complete transection and no spared tissue, a stepping 
motion can still be elicited and controlled through sensory feedback that activates 
the CPGs.(86) While rodents may not need the motor cortex to produce 
locomotion, the development of a stepping response in humans has been more 
difficult to achieve than in rats thus far. Activation of and control of CPGs with 
sensory input to generate locomotion in humans may be a more immediate 
approach to recover locomotion, but tissue regeneration may still be necessary 




Motor training alone does not typically result in full functional recovery in 
humans with complete injuries, but EES combined with motor training has been 
widely investigated in vivo and in clinical trials (clinicaltrials.gov) with promising 
results. In a few recent small clinical studies, electrode arrays were developed 
that delivered ES via spatially controlled patterns of activation in specific intervals 
for stepping motions (spatiotemporal control). Spatiotemporal ES with motor 
training together enabled independent stepping (with assistive devices) in 
patients with incomplete injuries (AIS grade B).(88-90) More recently, EES alone 
has been able to demonstrate volitional muscle control, but not yet stepping, 
while EES was active in the first seven patients with complete injuries in the 
Epidural Stimulation After Neurologic Damage (ESTAND) clinical trial.(87)  
Despite the promising results of rehabilitation approaches, patients with 
more severe injuries that do not benefit as much from rehabilitation approaches 
may need regenerative medicine strategies to first regenerate the tissue and 
axonal pathways for full functional recovery. However, there has been limited 
functional recovery seen with regenerative medicine approaches so far and there 
have been fewer regenerative medicine approaches in clinical trials compared to 
rehabilitation approaches. Therefore, the combination of regenerative medicine 
and rehabilitation, known as regeneration rehabilitation,(7, 19) may be needed 
for full functional recovery. Several in vivo studies(8, 279) and a few clinical trials 
for SCI have already applied regenerative rehabilitation principles (e.g., cells + 




achieved with rehabilitation approaches for SCI thus far, there is a need for 
regenerative medicine approaches to be translated for use in the clinic and to be 
developed to complement and enhance the rehabilitation approaches. One 
regenerative medicine solution may be to use conductive biomaterials to 
synergistically integrate regenerative medicine approaches and rehabilitation 
approaches.  
Conductive biomaterials combined with ES and motor training could better 
deliver ES directly to neurons, to simultaneously promote tissue regeneration and 
neural plasticity for enhanced functional recovery. We refer readers to three 
excellent reviews that cover conductive biomaterials with electrical 
stimulation.(21, 24, 44) In vitro studies with conductive materials and ES have 
improved differentiation and neurite growth,(98) and may be able to regenerate 
axons. Furthermore, clinical ES may facilitate reorganization of intact spinal 
networks with the regenerated axons and promote better functional recovery. The 
development of additional conductive biomaterials that can incorporate 
regenerative medicine approaches and possibly be synergistic with ES are 
needed.  
Given that most biomaterials are insulators, higher conductivities (i.e., 
semi-conductor range) have been achieved by creating composites by combining 
biomaterials with conductive components (e.g., carbon-based structures, 
conductive polymers, metallic-based particles). Composites with conductive 




materials or metallic particles. Carbon-based composites typically have 
cytotoxicity concerns.(22, 24, 161) However, metal nanoparticles, such as gold 
nanoparticles, impart high conductivities to composites and are known to be inert 
and biocompatible.(280) Gold nanoparticle-based composites have been widely 
investigated for tissue engineering purposes, particularly in cardiac, muscle, and 
peripheral nerve applications. However, the use of gold nanoparticles in 
hydrogels to treat SCI has been limited to using gold nanoparticles for growth 
factor delivery,(199) not to fabricate a conductive composite. To create a 
conductive composite by blending conductive nanoparticles, high concentrations 
are typically needed. In that context, the advantage of higher aspect ratio 
nanoparticles (e.g., nanorods, nanotubes, nanowires) is that the required 
threshold concentration to achieve conductivity is decreased.(21) A few studies 
by Navaei et al.(203, 206, 207, 210) fabricated conductive gold nanorod (GNR) 
hydrogels for cardiac and skeletal muscle applications. GNR biomaterials may 
be a promising approach for developing a conductive biomaterial for SCI; 
however, many biomaterials are preformed scaffolds that may be more 
challenging to implant into a human contusion SCI with ill-defined borders than 
into an animal model with a well-defined surgical defect.(10-16) There is a need 
for the development of biomaterials that are not only conductive, but also 
translational for SCI. While preformed scaffolds may be challenging to implant 
into a contusion SCI, injectable hydrogel precursors (i.e., before crosslinking) that 




may be well-suited for translation to SCI. Furthermore, a common clinical 
limitation of typically less viscous hydrogel precursors is leakage out of the injury 
before crosslinking, and a more viscous or paste-like rheology of the precursor is 
needed, such as bioinks from the extrusion bioprinting field. 
The purpose of the current study was to fabricate a translational 
biomaterial platform for SCI by developing a conductive hydrogel that had 1) an 
injectable and paste-like precursor, 2) biocompatible crosslinking conditions, and 
3) was conductive once crosslinked. Given that several conductive biomaterials 
have non-biocompatible crosslinking conditions and hydrogel precursors are 
typically less viscous, conductive, injectable, and paste-like hydrogel precursors 
are needed for minimally invasive delivery and enhanced material retainment in 
the injury. In the current study, we synthesized high aspect ratio, citrate capped-
GNRs (citrate-GNRs) and incorporated into a previously developed bioprintable 
hydrogel formulation comprised of pentenoate-functionalized hyaluronic acid 
(PHA) and pentenoate-functionalized gelatin (PGel). We evaluated the 
conductivity and ability of the GNR hydrogels to support adhesion and the viability 
of rat neural stem cells (rNSCs). We characterized the rheology of the GNR 
hydrogel precursor for evaluating the injectability and paste-like consistency for 
both, translatability and printability. Finally, we evaluated the feasibility, long-term 
safety, axon regeneration, and functional recovery after delivering a GNR 
hydrogel to an acute, lateral thoracic level (T8) hemi-section in a rat SCI model. 




a conductive GNR hydrogel as a translational platform that can be synergistically 
combined with ES in a regenerative rehabilitation approach to maximize 
functional recovery after SCI.  
Materials and Methods 
Materials 
Gold(III) chloride trihydrate (HAuCl4 , 99.9%), 
hexadecyltrimethylammonium bromide (CTAB) (99%), hydrochloric acid (HCl, 
37%), hydroquinone (99.0%), nitric acid (HNO3, 70%), polyvinylpyrrolidone 
(PVP, MW: 55,000), silver nitrate (AgNO3, 99%), sodium borohydride (NaBH4, 
99%), sodium hydroxide (NaOH, 98%), hydrogen peroxide (H2O2, 30%), L-
ascorbic acid (AA, 98%), sodium citrate tribasic dihydrate (99%) and all other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
noted. Acetone (99.5%) was purchased from VWR (Radnor, PA). All reagents 
for gold nanorod synthesis were prepared with nanopure water from a Purist Pro 
UV Ultrapure Water System (RephiLe Bioscience, Ltd., Boston, MA) and 
prepared fresh daily except for HAuCl4 and NaOH. All glassware and Teflon-
coated stir bars were cleaned with aqua regia (3:1 HCl:HNO3) and rinsed 15 times 
with nanopure water before each synthesis. 
GNR Synthesis 
High aspect ratio CTAB-capped GNRs (CTAB-GNRs) were synthesized 




ascorbic acid, to achieve high yields (~100%), high aspect ratios (~6-8), and 
minimal sphere contamination, according to a protocol established by Vigderman 
and Zubarev(281) (see graphic in Fig. 5.1A). The seed-mediated method 
involved a growth solution of CTAB, HAuCl4, AgNO3, and hydroquinone, where 
the latter is a weak reducing agent that reduced Au3+ to Au+. Subsequent addition 
of small gold seeds (1-2 nm in diameter) to the growth solution catalyzed the 
reduction of Au+ onto the surface of the seeds. The CTAB surfactant and silver 
block growth by preferentially adhering to the {110} facets of gold (i.e., the sides 
of the rods) and thus, encourage growth on the {001} plane (i.e., the ends of the 
rods), resulting in an anisotropic nanorod shape. 
For the seed solution, reagents were prepared as described here: NaBH4 
(0.01 M) was prepared in NaOH (0.01 M) and was placed at –20C for 20 
minutes, and CTAB (0.1 M) was fully dissolved in nanopure water on a stirring 
hotplate set to 30C. The seed solution was made in a 20-mL scintillation vial with 
a cleaned stir bar (5/8” x 5/16”) under vigorous stirring (setting 3) on a 30C, C-
MAG HS 7 hotplate (IKA Works, Inc., Wilmington, NC). The CTAB (5 mL, 0.1 M) 
solution was added to the vial followed by the addition of HAuCl4 stock (50 µL, 
50 mM), which led to a color change from clear to orange. The ice-cold (liquid, 
not solid) NaBH4 (230 µL, 0.01 M) was taken from the –20C freezer after 20 
minutes and added rapidly in one shot to the HAuCl4/CTAB solution, which was 
followed by an immediate color change to light brown. The solution was stirred 




Visible-Near infra-red (UV-Vis-NIR) spectroscopy on an Agilent Cary 5000 UV-
Vis-NIR spectrophotometer (Agilent, Santa Clara, CA) (described below) and 
Dynamic Light Scattering (DLS) on a Malvern ZetaSizer (Malvern Instruments, 
Worcestershire, UK) (described below). 
GNRs were synthesized in cleaned glass bottles (250 mL bottles, ~100 
mL batches) with a cleaned stir bar (1 ½” x 3/8”) under heavy stirring (setting 2) 
at 30C on a hotplate. The additional reagents were prepared as follows: AgNO3 
(0.1 M) and hydroquinone (0.1 M) were dissolved in nanopure water and wrapped 
in aluminum foil to protect from light. A growth solution in each bottle was 
prepared as follows: to 100 mL of CTAB (0.1 M), HAuCl4 stock (1 mL, 50 mM) 
was added, which led to a color change from clear to orange. AgNO3 (700 µL, 
0.1 M) was added, then hydroquinone (5 mL, 0.1 M) was slowly but continuously 
added, resulting in a color change from orange to clear. The growth solution was 
stirred for 5-10 minutes on the 30C hotplate before the seed solution (160 µL) 
was added. The growth solution with the seed solution was kept stirring for 15-
20 minutes on the 30C hotplate, and the solution started turning cloudy within 
the first 2-5 minutes. After the 15-20 minutes, the stir bars were removed and the 
bottles were transferred to a 30C water bath for 12 hours, where the solution 
gradually turned dark brown as GNRs formed. GNR formation was confirmed via 
UV-Vis-NIR, as described below. 
To purify the GNRs, the reaction solution from each bottle was centrifuged 




minutes in 50-mL tubes and carefully decanted. Each 50 mL tube was washed 
with 30 mL of PVP (112 mM, using the molecular weight of the repeat unit) as a 
steric stabilizer to prevent aggregation. GNRs were centrifuged a second time to 
remove most of the PVP, decanted, and each tube was washed in 50 mL of 
nanopure water. GNRs were centrifuged a third time to concentrate in ~3-5 mL 
of nanopure water.  
Citrate-GNRs via Indirect Ligand Exchange 
The cytotoxic CTAB on CTAB-capped GNRs was replaced with non-toxic 
trisodium citrate through an indirect ligand exchange protocol (see graphic in Fig. 
5.1B), as previously described.(209) The process involved coating GNRs with a 
thin (~4 nm) layer of silver to displace the CTAB, followed by the use of a 
hydrogen peroxide in a sodium citrate solution to etch away the silver and leave 
a clean GNR surface stabilized by citrate. The original protocol was adapted for 
longer and higher aspect ratio GNRs with the following minor modifications: initial 
GNR concentration (0.38 mg/mL) and the Ag:Au ratio (0.158:1).  
Briefly, the reagents were prepared as follows: PVP (112 mM) was diluted 
to 47 mM in nanopure water, sodium citrate (10 mM), and H2O2 (3%) were each 
prepared in nanopure water, AA (40 mM) was prepared in nanopure water and 
wrapped in aluminum foil to protect from light, and AgNO3 (10 mM) was prepared 
in nanopure water and diluted to 0.3 mM and protected from light with aluminum 
foil. The concentrated CTAB-GNRs (30 mL, 0.38 mg/mL) were diluted in 




(144 mL, 47 mM), CTAB-GNRs (30 mL, 0.38 mg/mL), and AA (3 mL, 40 mM) 
were mixed for ~2 minutes on a stir plate (setting 1.5-2). In one rapid addition, 
the AgNO3 (30 mL, 0.3 mM) was then added and the solution was stirred for 10 
minutes at room temperature. Acetone (414 mL) was added at a 2:1 ratio of 
acetone:solution volume and was mixed well (~3 min), followed by centrifugation 
(13,500 x g, 10 min) in 50-mL tubes. Acetone was decanted and the loose GNR 
pellets in the remaining acetone were sonicated (1 min) using a Branson 3800 
Ultrasonic Cleaner (Cleanosonic, Richmond, VA). Then the pellets were pipetted 
and combined into one 50-mL tube that was centrifuged (13,500 x g, 10 min), re-
dispersed in sodium citrate (6 mL, 10 mM), and transferred to a 100-mL glass 
bottle. To etch away the silver and CTAB and leave a clean surface on the GNRs, 
3% H2O2 (27 mL) was added to the sodium citrate solution and left for 3 hours at 
room temperature. The solution was then centrifuged (13,500 x g, 15 min) in a 
50-mL tube and re-dispersed in sodium citrate (3 mL, 10 mM) for 12 hours at 
room temperature to complete the ligand exchange. The solution was centrifuged 
(13,500 x g, 20 min), re-dispersed in nanopure water (30 mL), and sonicated (3 
min). Citrate-capping of GNRs (citrate-GNRs) was confirmed with zeta potential 
measurements and gel electrophoresis, as described below, to distinguish 
between the positive charge of CTAB and the negative charge of citrate. 
For in vitro and in vivo studies, citrate-GNRs were diluted to 100 mL before 
being sterile-filtered using a Steriflip® PLUS membrane (MilliporeSigma, 




water (6 mL). The sterile citrate-GNRs were confirmed via UV-Vis-NIR and TEM, 
and concentration/mass distribution were determined via ICP-MS. 
GNR Characterization 
UV-VIS-NIR 
UV-Vis-NIR samples were prepared by diluting centrifuged GNRs in 
nanopure water (~1:10 ratio GNRs to water) to bring samples into the 
concentration range of the instrument. UV-Vis-NIR spectra were collected in 
quartz cuvettes and scanned from 300-1300 nm on an Agilent Cary 5000 UV-Vis-
NIR spectrophotometer (Agilent, Santa Clara, CA) after collecting a baseline 
using nanopure water. 
Zeta Potential 
Surface charge of GNRs (pH 6.0-6.5) was determined with zeta potential 
measurements with a Malvern ZetaSizer (Malvern Instruments, Worcestershire, 
UK) in a disposable zeta potential cuvette. Samples for zeta potential of CTAB-
GNRs were taken directly after the second centrifugation from the 200 mL batch 
of GNRs that were resuspended in 100 mL of nanopure water (no dilution 
necessary). Samples of citrate-GNRs were taken after the final centrifugation of 
the indirect ligand exchange (no dilution necessary). 
Gel Electrophoresis 
Surface charge of GNRs was further confirmed with gel electrophoresis 




as follows: agarose (0.5 w/v%) was mixed in 0.5X Tris-Borate-EDTA (TBE) buffer 
(Fisher, Waltham, MA) in a 250 mL Erlenmeyer flask, heated in a microwave (2 
min total with swirling every 30 s) until dissolved, cooled until just warm, and 
poured into a gel tray with a comb in a casting apparatus. The agarose was set 
at room temperature for 1 hour. The gel was run in a gel box filled with TBE buffer 
(0.5X) at 50V for 1 hour. Samples of CTAB-GNRs or citrate-GNRs (10 µL) were 
mixed with 2 µL Ficoll 400 to keep the samples in the wells, and 10 µL of sample 
was loaded into each well.  
Transmission Electron Microscopy 
TEM samples were prepared by drying 2 µL of GNRs onto copper grids 
(Carbon Type-B 300 mesh Copper; Ted Pella Inc., Redding, CA) that were 
plasma-coated. TEM images were taken by a 200-kV field emission JEOL2010F 
analytical TEM (JEOL-USA, Peabody, MA) equipped with a Direct Electron DE-
12 camera. ImageJ software was used to determine the length and width from 
~250 GNRs from the collected TEM images. The aspect ratio was calculated from 
these images by dividing the length by the width of each rod. 
Inductively Coupled Plasma-Mass Spectrometry 
Elemental analysis measurements for total gold content and nanorod 
mass quantification were performed using a NexION2000 ICP-MS (Perkin Elmer, 
Waltham, MA) fitted with a High Efficiency Sample Introduction System, as 




dissolving 10 µL of GNRs (from the 200 mL batch resuspended in 3 mL of 
nanopure water) into 1 mL of aqua regia for 5 minutes. The GNRs in aqua regia 
were further diluted in nanopure water to obtain a concentration in range of the 
instrument and prepared standard curves. Final dilutions for batch ICP-MS 
ranged from 5x104 to 2.5x106-fold dilutions of the original GNR concentration 
(from a 200 mL batch resuspended in 3 mL). Single-particle ICP-MS samples 
were prepared using a 5x106-fold dilution into nanopure water.  
To determine the total dissolved gold in the digested nanorod samples, a 
prepFAST IC sample introduction system (Elemental Scientific Inc., Omaha, NE) 
was used and a dissolved gold calibration curve was made. The instrument was 
operated in standard peak hopping mode. Au195 signal was grouped to the 
signal from the internal standard-Ir193. 5 replicates were collected to ensure 
accuracy of the measurements. Synthesis yield was determined based on the 
mass concentration of Au measured by ICP-MS compared to the theoretical 
maximum amount of Au in a 200 mL batch of GNRs (19.7 mg). Yield from the 
indirect ligand exchange was determined by dividing the mass concentration of 
Au measured after the exchange by the amount of Au measured before. 
To determine the mass of intact individual nanorods, single particle ICP-
MS was employed.(284) The instrument was used in single-particle mode and 
the parameters/conditions are listed in Table 5.1. The introduction system 
consisted of a 2.0-mm quartz injector (PerkinElmer), an Asperon Spray Chamber 




Samples were delivered to the nebulizer at a flow rate of 10 µL min-1 using a 
Single Cell Micro DX Autosampler (Elemental Scientific Inc.). To maximize 
analyte signal and reduce interferences the ICP-MS was tuned with the NexION 
setup solution (PerkinElmer, N8145051). Fast sequential measurements of ion 
signals from atomized nanoparticles were obtained by sending nanoparticles 
through an argon plasma. All data were acquired and processed in Syngistix 
single-cell/single-particle Application Module Software V.1.5 (PerkinElmer). The 
SP-ICP-MS particle transport efficiency was determined using commercially 
available polystyrene microparticles (~3 µm in diameter) doped with Lu175 
(Fluidigm, South San Francisco, CA) according to a previously published 
procedure.(285) The transport efficiency was 58.5 ± 3.9%. The mass detector 
was configured to only analyze Au197 signal and the ICP-MS was calibrated with 
dissolved gold ion standards made from serially diluting a stock solution of 1000 
µg/mL (Au) ICP Single-Component Standard in 2% HCl (High Purity Standards 
100021-2-100, North Charleston, SC). With the dissolved Au calibration curve 
and the measured pulse intensity from a nanorod ion plume, the nanorod mass 
was back-calculated as described by Pace et al.(284) The Syngistix software was 
used to apply a threshold to all samples and enhance the signal to noise ratio via 





Pentenoate-functionalized hyaluronic acid (PHA) and gelatin (PGel) 
synthesis 
PHA was synthesized from hyaluronic acid (HA, actual MW: 1.56 MDa; 
Lifecore Biomedical, Chaska, MN) as we previously described.(81) PGel was 
synthesized using an adapted PHA synthesis protocol. PGel was made from 
gelatin from porcine skin (Type A, ~300 g Bloom, Sigma Aldrich). Briefly, HA (2 
g) or gelatin (5 g) were dissolved in deionized (DI) water (HA: 0.5 w/v%, 150 mL, 
gelatin: 5 w/v%, 100 mL, 37°C), and then a catalyst, 4-(dimethylamino)pyridine 
(Sigma Aldrich) (HA: 500 mg, gelatin: 250 mg), was added. N,N-
Dimethylformamide (DMF, Sigma Aldrich) was added (PHA: 3:1 water:DMF, 200 
mL, PGel: 2:1 water:DMF, 50 mL) and mixed before 4-pentenoic anhydride 
(Sigma Aldrich) (PHA: 2.4 mL per g of HA or gelatin) was slowly added. A pH of 
8.5-9 was maintained using dropwise addition of sodium hydroxide (1 M) for 30 
minutes to 1 hour. The PHA reaction was left to react overnight before sodium 
chloride was added (final concentration 0.5 M, 10 g). In contrast, the PGel was 
immediately precipitated. PHA or PGel were precipitated in acetone at a volume 
that was four- or eight times the reaction volume, respectively. PHA was 
precipitated directly in the glass beaker and PGel was precipitated in plastic 50-
mL tubes to prevent adherence to glass. PHA or PGel were centrifuged (6000 x 
g, 3 min) on a centrifuge 5430R (Eppendorf®) and the acetone was decanted. 
PHA pellets were transferred to a glass beaker before dissolving in DI water (400 




or PGel were then dialyzed in DI water (MWCO: 6–8 kDa, VWR) with water 
exchanges every 12 hours for a total of 48 hours. PHA or PGel were adjusted to 
a physiological pH of 7.4 using dropwise addition of sodium hydroxide (1 M) (PGel 
was additionally heated to 37°C). PHA or PGel were frozen at –20°C and 
lyophilized. Dry PHA and PGel were stored at –20°C. 
PHA and PGel characterization 
PHA and PGel functionalization were determined using Nuclear Magnetic 
Resonance (NMR) Spectroscopy using a Varian VNMRS-500 MHz NMR 
Spectrometer equipped with a 5 mm indirect detection room temperature probe 
(Varian, Palo Alto, CA), as we previously described.(81) Briefly, to prepare NMR 
samples, PHA (2-3 mg) or PGel (10 mg) were dissolved in 0.7 mL of deuterium 
oxide (D2O; Cambridge Isotope Laboratories, Inc., Andover, MA). PGel samples 
were additionally dissolved with 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid 
sodium salt (TMSP, 1 mg/mL, Sigma Aldrich) as an internal standard. The proton 
spectra of PHA and PGel were collected at 80°C and 25°C, respectively, with 16 
scans, a 35 s recycle delay, 90-degree pulse width, and a 60 s pre-acquisition 
delay to ensure accuracy in the integration and allow for full relaxation of the 
protons. The spectra were processed/analyzed in MestReNova software v.12.0.1 
(Mestrelab Research, Santiago de Compostela, Spain). The degree of 
functionalization of PHA was determined through peak integration of the alkene 
proton from the pentenoate group (5.82 ppm) and normalization to the acetyl 




study were functionalized with pentenoate groups, which was a molar 
concentration of 0.097 mM. The molar concentration of PGel was determined via 
integration of the alkene proton peak from the pentenoate group (5.84 ppm) 
compared to the internal standard, TMSP (0 ppm). PGel had 0.025 mM of 
pentenoate groups. 
Crosslinking to form hydrogels 
Four types of hydrogels were used in the current study for in vitro and in 
vivo studies: 1) PGel, 2) PHA, 3) PHA/PGel, 4) PHA/PGel/GNRs. The specific 
groups and concentrations that were investigated are specified in the 
corresponding sections below. Dry PHA and PGel were sterilized using ethylene 
oxide gas (AN74i, Anderson Anprolene, Haw River, NC) for in vitro and in vivo 
studies. PHA/PGel hydrogels made for all characterization, in vitro studies, and 
in vivo studies consisted of PHA (4 wt%, 40 mg/mL), PGel (5 wt%, 50 mg/mL), 
the photoinitiator Irgacure 2959 (I2959, 0.05 w/v%), the crosslinker dithiothreitol 
(DTT, 2.72 mg/mL), GNRs (varying concentrations, indicated in each methods 
section), and nanopure water. Hydrogels were formed as follows: PGel (61.8 
mg/mL) was dissolved in the sterile citrate-GNR suspensions or in nanopure 
water for 5-10 minutes. The PGel solution was used to dissolve the PHA (49.4 
mg/mL), which was further dissolved overnight at 4°C. The next day, I2959 stock 
(5 mg/mL) was dissolved in nanopure water in a 60°C bead bath for 20 minutes, 
and a DTT stock (30 mg/mL) was dissolved in nanopure water at room 




5 mg/mL stock added per mL of total hydrogel) and DTT (90.8 µL of 30 mg/mL 
stock added per mL of total hydrogel) at room temperature with a metal spatula. 
PHA/PGel precursors were left for 15–30 min in the dark to fully incorporate the 
added liquids. PHA/PGel precursors were mixed once more and centrifuged with 
a short-spin cycle (30 s) to eliminate air bubbles.  
Hydrogels for all characterization and in vitro studies (see graphic in Fig. 
5.2) were formed by placing precursor solutions into a rectangular cutout in a 
rubber mold (1 mm thickness) between 2 glass slides and were UV-crosslinked 
with a handheld 312 nm light at 9 mW/cm2 (EB-160C, Spectroline, Westbury, NY) 
for 2 minutes on each side. Hydrogels were swollen overnight at 37°C in 




For electrical conductivity testing, different concentrations of citrate-GNRs 
(i.e., 0, 0.4, 0.6, 0.8, 1.0, 1.2 mg/mL) were incorporated into PHA/PGel hydrogels 
(n = 5 or 6). Nanopure water was used to fabricate the hydrogels, as opposed to 
PBS, to minimize the ionic conductivity and to measure the direct electrical 
conductivity of the hydrogel. While PBS better mimics the in vitro and in vivo 
environments, the ionic conductivity of free ions in solution does not have the 
same cellular effects as electrical conductivity.(23) Given the sodium counterion 




included as baseline controls. Hydrogel resistance was measured using the two-
probe method with a 34401A Agilent Multimeter (Agilent, Santa Clara, CA) as 
adapted from previous methods.(287) Briefly, two wires from the multimeter were 
attached to copper tape on the top and bottom of paper-covered parallel plates 
on an Instron 5969 uniaxial tester (Instron, Norwood, MA). Excess surface 
moisture was removed from the hydrogels with a Kimwipe™ (but the hydrogel 
itself was still hydrated), the hydrogel was set on the copper tape, and the top 
plate was lowered until there was complete contact with the hydrogel. The 
resistance measurements were logged for 1-2 min (~400 data points) and the 
resistance of each sample was determined as the average of the stable data 
points (20th data point to the last data point). Prior to testing, the heights and 
diameters of the hydrogels were measured with a micrometer and the latter was 
used to calculate the circular cross-sectional area of each sample. The 
conductivity was calculated as the inverse of the resistivity, which was the cross-
sectional area multiplied by the resistance and divided by the length (i.e., height 
of the gel). 
Mechanical testing 
PHA/PGel hydrogels with (0.8 mg/mL) and without citrate-GNRs were 
tested for solid mechanics (n = 5 or 6), as previously described.(270) The 
compressive elastic moduli of the hydrogels were determined by compression at 
a strain rate of 5 µm/s (~0.25% strain/second) with 8-mm parallel plates until 20% 




Instruments, New Castle, DE). Prior to testing, a 0.1 N tare load was applied to 
hydrogels to ensure the geometry was in contact with the hydrogel surface and 
determine the hydrogel height. Hydrogel diameters were measured on a 
micrometer prior to testing to calculate the cross-sectional area. The compressive 
elastic modulus was calculated in a custom MATLAB® script as the slope of the 
linear portion of the stress-strain curve (i.e., 5-15% strain), where stress was 
calculated as the force divided by the initial cross-sectional area.  
Absorption and swelling characterization 
For absorption and swelling measurements, PHA/PGel hydrogels with (0.8 
mg/mL) and without citrate-GNRs were tested (n = 6). Hydrogels were formed 
and immediately punched into cylindrical hydrogels to measure the fabricated 
mass. The swollen mass was measured after swelling in nanopure water (24 h, 
37°C), and the dry mass was measured after freezing at –20°C and lyophilization 
overnight. The swelling ratio was calculated as the ratio of the swollen mass to 
the dry mass. The absorption was calculated as the ratio of the swollen mass to 
the fabricated mass. 
Rheology and shape fidelity of the hydrogel precursor 
For rheological characterization, the viscosity (n = 3), yield stress (n = 3), 
and storage modulus recovery (n = 3) were measured on a DHR-2 rheometer 
equipped with parallel 20-mm crosshatched plates, as we previously 




viscosity curves were evaluated using a logarithmic shear rate sweep (0.1 s-1 to 
100 s-1). The yield stress was determined from the crossover point of the storage 
(G’) and loss (G”) moduli, which were evaluated using an oscillatory shear stress 
sweep (1 to 1000 Pa). The storage modulus recovery was evaluated with a series 
of three phases of oscillatory shearing (1 Hz) after a 5-minute soak time: 5 min 
of 10 Pa shear stress (initial storage modulus), 30 s of 1000 Pa shear stress, and 
5 min of 10 Pa shear stress (recovered storage modulus). The storage modulus 
recovery was calculated as the recovered storage modulus divided by the initial 
storage modulus and multiplied by 100%.  
The printability of the PHA/PGel/GNR hydrogel precursor was assessed 
(n = 3) by bioprinting with an Inkredible+ bioprinter (Cellink®, Gothenburg, 
Sweden) as we previously described.(81) The hydrogel precursor were 
backloaded into a printing cartridge printed with a 27 G tapered nozzle (Cellink) 
into a 3-layer, 10 mm x 10 mm grid with 43% infill and no perimeter. 
PHA/PGel/GNRs required ~100-105 kPa of pressure for proper extrusion. A 
Nikon D5500 camera (Nikon, Tokyo, Japan) with a macro lens (Nikon AF-S 
Micro-NIKKOR 60 mm f/2.8G ED Lens, Nikon) was used to image the printed 
constructs. The strut sizes and pore areas of the bioprinted precursor constructs 
were analyzed in ImageJ (National Institutes of Health, Bethesda, MD). The 
average strut size from each print was determined from several measured widths 
of horizontal and vertical struts, which were then averaged across the samples. 




measure several pores from each sample, which were then averaged across the 
samples. 
Cytotoxicity in vitro studies 
For in vitro studies, PHA/PGel hydrogels with different concentrations of 
sterile citrate-GNRs (i.e., 0, 0.4, 0.6, 0.8 mg/mL) were formed and seeded with 
cells (n = 4 or 5) or were used as acellular material controls (n = 3). Hydrogels 
were formed as mentioned earlier, except under sterile conditions, and were 
placed into the bottom of a sterile 96-well flat-bottomed plate.  
All cell culture supplies were purchased from Thermo Fisher Scientific 
(Waltham, MA) unless otherwise stated. Rat neural stem cells (rNSCs) were 
purchased from Thermo Fisher Scientific. The rNSCs were cultured in tissue 
culture flasks that had been coated (1 h in a 37°C incubator) with CTS™ 
CELLstart™ Substrate (1% diluted in Dulbecco’s phosphate-buffered saline with 
calcium and magnesium (DPBS)). The medium was changed every 2-3 days with 
KnockOut DMEM/F-12 Basal Medium supplemented with StemPro Neural Stem 
Cell Serum Free Medium (NSC SFM) Supplement (2%), recombinant human 
basic fibroblast growth factor (bFGF; 20 ng/mL), recombinant human epidermal 
growth factor (EGF; 20 ng/mL), GlutaMAX™-I supplement (2 mM), and penicillin-
streptomycin (Pen/Strep; 1%). StemPro™ Accutase™ Cell Dissociation Reagent 
was used to dissociate cells for passaging once they reached 80% confluency. 
For the in vitro study, cells were seeded at 50,000 cells/cm2 (passage 2, 16,000 




The media from the cell-seeded hydrogels with 0.8 mg/mL GNRs and no 
GNRs were collected for quantification of released gold by ICP-MS (n = 3). Media 
samples were taken on day 1, 3, 5, and 7. Media samples (50 µL) were digested 
in aqua regia (10-fold dilution) for 1 hour in a 60°C water bath before 50 µL was 
diluted in nanopure water (100-fold dilution) and analyzed by batch ICP-MS 
according to the GNR Characterization methods section. The background from a 
media-alone sample was subtracted from all the other samples. The theoretical 
maximum gold content per GNR hydrogel was estimated to be 22.6 µg based on 
the GNR concentration and volume of the hydrogel. The gold content in the media 
samples was divided by the theoretical maximum gold content to estimate the 
amount of released gold as a percentage of the total gold in a hydrogel. 
To evaluate cell adhesion and viability on day 1 and day 7, the alamarBlue 
Cell Viability Reagent (Thermo Fisher Scientific) was used to measure the 
metabolic activity of rNSCs, according to manufacturer’s instructions. The 
medium from each well was removed, and the alamarBlue reagent (10X) was 
added to pre-warmed complete medium to obtain a 1X solution, which was added 
to each well and incubated for 6.5 hours. The fluorescence (excitation: 540 nm, 
emission: 590 nm) was measured on a BioTek Cytation™ 5 plate reader (BioTek, 
Winooski, VT). The fluorescence was normalized to the average fluorescence of 
the 0 mg/mL GNR hydrogel group for each day. After the alamarBlue assay, the 
same samples were used to measure the total DNA content. The 




overnight at 60°C in 150 µL of papain solution (125 µg/mL papain from papaya 
latex, 5 mM N-acetyl cysteine, and 5 mM ethylenedinitrilotetraacetic acid 
disodium salt dihydrate (EDTA) in PBS), as previously described.(257) Samples 
were stored at –20°C until further testing. For testing, samples were thawed, 
vortexed, and centrifuged (10,000 rpm or 9391 x g for 5 min) to pellet any 
polymer. The DNA content in the supernatant was quantified with the Quant-iT 
PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific), according to 
manufacturer’s instructions, and the fluorescence was measured on a BioTek 
Cytation™ 5 plate reader (excitation: 485 nm, emission: 528 nm). The metabolic 
activity of each sample was normalized to the DNA content by dividing the raw 
alamarBlue fluorescence by the total DNA content (ng), with further normalization 
to the average of the 0 mg/mL GNR hydrogel group.  
Experimental groups for in vivo study 
Five study groups were evaluated using a thoracic-level (T8) lateral hemi-
section SCI model in rats (n = 6-8). The sham group was defined in the current 
study as animals given a SCI with no treatment, and the other four groups were 
PGel, PHA, PHA/PGel, and PHA/PGel/GNRs (denoted the GNR hydrogel group). 
Concentrations used were 5 wt% PGel for all PGel-containing groups, and 4 wt% 
PHA for all PHA-containing groups. The concentration of GNRs in the GNR 
hydrogel group was 0.8 mg/mL. Hydrogel precursors were formed as described 





All animal experiments were approved by the Institutional Animal Care and 
Use Committee of the University of Oklahoma Health Sciences Center (protocol 
#19-005-SA). Adult female Sprague-Dawley rats (225-275 g) were purchased 
from Charles River Laboratories (38 total) and were acclimated for at least 72 
hours before surgery. Rats were anesthetized with 4% isoflurane with oxygen 
and maintained with 1-4% isoflurane as needed. Immediately prior to surgery, 
buprenorphine SR (1-1.2 mg/kg, subcutaneous (SC) injection, ZooPharm, 
Laramie, WY) was given as an analgesic, meloxicam SR (4 mg/kg, SC, 
ZooPharm) was delivered as an analgesic and anti-inflammatory, and 
oxytetracycline (50-60 mg/kg, SC, Covetrus, Portland, ME) was given for 
preventing infection, including bladder infection. Animals were on a heated pad 
during pre-operative, intra-operative, and postoperative periods to prevent 
hypothermia. The dorsal midline was shaved and aseptically prepared with three 
rounds of alternating chlorohexidine (Covetrus) with 70% alcohol. Immediately 
before surgery, animals received three scrubs of povidone iodine (Covetrus) and 
an ophthalmic lubricant (Covetrus) applied to both eyes. Surgery was performed 
under sterile conditions with intra-operative monitoring, as per IACUC guidelines.  
A single midline incision was made through the skin on the back from just 
above the scapulae and extended 3-4 cm in the caudal direction, followed by 
blunt dissection that exposed the muscular layer. Parallel cuts were made on 




cord were retracted. To expose the spinal cord, a multilevel dorsal laminectomy 
from T7-9 was performed using fine tipped rongeurs, and the dura mater was 
removed with fine-tipped forceps. To ensure a consistent T8 lateral spinal cord 
hemi-section, one midline cut and two medial to lateral cuts approximately 2.0-
2.5 mm apart were made on the right side of the cord followed by removal with 
forceps. Approximately ~50-100 µL of hydrogel precursor was injected through a 
tapered nozzle (1 mL syringe, 27G nozzle) into the spinal cord injury cavity and 
crosslinked in situ with a handheld UV light (312 nm, EB-160C, Spectroline). A 
sterile drape with a fenestration was placed over the animal to shield and protect 
the animal from UV light exposure during material crosslinking (~2 minutes for 
the hydrogel groups, except ~5 min for GNR hydrogel group). For the sham 
group, a hemi-section injury was performed but no material was implanted. 
Following the hemi-section and material implant, the muscular, 
subcutaneous, and subcuticular/skin layers were all closed with 4-0 Vicryl sutures 
in an interrupted pattern. Triple antibiotic ointment was given topically for infection 
prevention as needed. Additional doses of the buprenorphine SR and meloxicam 
SR were given every 72 hours if needed. Manual bladder expression was 
performed twice daily until bladder function recovered (~7-9 days post-injury).  
Tissue/organ processing 
8 weeks post-injury, animals were humanely euthanized according to 
American Veterinary Medical Association (AVMA) guidelines by cardiac 




intraperitoneal injections of ketamine (89-100 mg/kg, Covetrus) and xylazine (5-
10 mg/kg, Covetrus). Once deeply anesthetized, the chest cavity was exposed 
and a butterfly catheter was placed into the left ventricle of the heart, while a cut 
was made into the right auricle. The aortic arch was clamped, and PBS (~105 
mL) was slowly injected via syringe pump to remove the blood, followed by 4% 
formaldehyde (~105 mL) for fixation.  
For all rats, a segment of the spinal column was removed and fixed (48 h) 
in 10% formalin, followed by removal of the spinal cord, and storage in 70% 
ethanol until histological and immunohistochemistry (IHC) analyses. For the 
sham group (n = 3) and the GNR hydrogel group (n = 3), the blood, brain, kidney, 
liver, and spleen were collected for histological and ICP-MS analyses to 
determine gold content. Blood was collected from the heart using a syringe before 
the system was flushed with PBS and 4% formaldehyde. The blood was stored 
at –20°C until analyzed by ICP-MS analysis. The brain, kidney, liver, and spleen 
were isolated, weighed, and fixed in 10% formalin for 48 hours before a cross-
section was removed and stored in 70% ethanol for histological analysis. The 
remaining amount of each organ was frozen at –20°C until analyzed by ICP-MS. 
Functional recovery assessment 
Functional recovery for all rats was recorded using a Nikon D5500 (B&H 
Video, New York City, NY) during a 5-minute open field test using a fabricated 
acrylic box (40 x 40 x 40 cm). Measurements were taken weekly, starting from 




randomized and the affected (right) limb was scored using the Basso, Beattie, 
and Bresnahan (BBB) Open-Field Locomotion Scoring by a blinded scorer. The 
BBB scale measures hindlimb movement by accounting for use of individual 
joints, coordinated limb movement, and weight-bearing movement on a scale of 
0 to 21, where 0 indicates no movements and 21 is normal movements.(288) Any 
rats with bilateral injuries were excluded from the analyses. 
Histology & immunohistochemistry 
Spinal cords and organs stored in 70% ethanol were paraffin embedded, 
sectioned, and stained using conventional methods. Spinal cords were sectioned 
in the coronal plane and organs were sectioned transversely (4 µm thickness). 
For histological analysis on spinal cords and organs, the Leica ST5020 
multistainer (Leica Biosystems, Wetzlar, Germany) was used with the SelecTech 
hematoxylin and eosin (H&E) staining system (Leica Biosystems), following the 
manufacturer's protocol. All staining was evaluated by a hospital pathologist. 
For IHC, the spinal cord sections were stained for neurons and axons 
using a neurofilament medium/heavy antibody (NF-M/H, dilution: 1:400, mouse 
monoclonal IgG1, cat # sc-32273, Santa Cruz Biotechnology, Dallas, TX), 
astrocytes using a glial fibrillary acidic protein (GFAP) antibody (dilution: 1:1500, 
cat # ab33922, rabbit monoclonal IgG, Abcam), oligodendrocytes using an 
ionized calcium-binding adaptor molecule 1 antibody (Iba1, dilution: 1:6000, cat 
# ab178846, rabbit monoclonal IgG, Abcam), new neurons using a nestin 




CSPGs using a chondroitin sulfate-56 (CS-56) antibody (dilution: 1:400, cat # 
C8035-.2ML, mouse monoclonal IgM, Sigma Aldrich). The IHC was performed 
on a Leica Bond RX platform (Leica Biosystems) using Polymer Refine Detection 
system (DS9800). In brief, formalin-fixed, paraffin-embedded (FFPE) tissues 
were sectioned at 4-8 μm and mounted on positively charged slides. The slides 
were dried overnight at room temperature and incubated at 60°C for 45 minutes. 
Slides were transferred to the Leica Bond RX for dewax and then treated for 
target retrieval at 100°C for 20 minutes in a retrieval solution, either at pH 6.0 (for 
NF-M/H, GFAP, and CSPG antibodies) or pH 9.0 (for Iba1 and Nestin antibodies). 
The sections were incubated with 5% goat serum (cat # 01-6201, Thermo Fisher 
Scientific) for 30 minutes. Endogenous peroxidase was blocked using 
peroxidase-blocking reagent, followed by the selected incubation for 60 minutes. 
For the secondary antibody, post-primary IgG-linker and/or Poly-HRP IgG 
reagents was used. Detection was done using 3, 3-diaminobenzidine 
tetrahydrochloride (DAB) as chromogen (10 minutes) and counter stained with 
hematoxylin. Completed slides were dehydrated (Leica ST5020), and mounted 
(Leica MM24). Antibody specific positive control and negative control (omission 
of primary antibody) were stained in parallel. 
ICP-MS on organs 
For ICP-MS analysis of the gold content in the blood and organs, the 
samples were thawed, and a small section of the organs (~200-700 mg) was 




blood, ~100 mL was pipetted directly into the scintillation vial. Nitric acid (800 µL) 
was added to each sample and samples were digested in a 60°C water bath for 
3 hours, followed by addition of hydrochloric acid (200 µL) for another 3 hours in 
a 60°C water bath. Samples (1 mL) were diluted in nanopure water (40-fold for a 
2.5% acid concentration) and 5 mL of each sample was passed through a 
Millex®-GP syringe filter (0.22 µm, PES membrane, MilliporeSigma). Batch ICP-
MS was run using the same parameters as mentioned in the GNR 
Characterization methods. The total mass of gold per organ was calculated by 
multiplying the measured gold concentration by the total volume (40 mL) and 
dividing by the mass of tissue that was digested to get the gold per gram of tissue. 
The gold per milliliter of blood was calculated by multiplying the measured gold 
concentration by the 40-fold dilution and the initial 11-fold dilution. For each 
organ, the background (i.e., average amount of gold in the sham rat organs) was 
subtracted from the amount of gold in the corresponding organ of the rats of the 
GNR group. Given that 50 to 100 µL of GNR hydrogel was injected into the SCI 
at a concentration of 0.8 mg/mL of GNRs, the expected total gold that was 
delivered was 40 to 80 µg, or 60 µg on average. The gold per organ as a 
percentage of the total estimated gold delivered (i.e., 60 µg) was estimated for 
each organ by multiplying the gold per gram of organ by the total mass of the 





All statistical analyses were performed in GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA). An unpaired t-test was used to compare the CTAB- 
and citrate-GNR’s aspect ratio, length, and width, and the yield stress, and 
storage modulus recovery. A one-way analysis of variance (ANOVA) was used 
to analyze results from hydrogel conductivity, mechanical, swelling, and 
absorption testing, metabolic activity, and metabolic activity normalized to DNA 
content, followed by Tukey’s post-hoc test. A two-way ANOVA was used to 
analyze the viscosity curves and DNA content. A mixed-effects analysis with 
repeated measures was used to analyze the BBB scoring and was followed by 
Tukey’s post-hoc test. Differences with p < 0.05 were considered significant. 
Results were reported as the mean ± standard deviation. 
Results 
CTAB- and citrate-GNRs characterization 
UV-Vis-NIR spectra in Fig. 5.3A of the seed solution (dashed gray line) 
and CTAB-GNRs (solid black line) confirmed the formation of gold nanorods with 
longitudinal (LSPR) and transverse surface plasmon resonance (TSPR) peaks at 
1125 nm and 507 nm, respectively. The TEM images of CTAB-GNRs in Fig. 5.3B 
(upper left image) further confirmed the formation of nanorods with minimal 
contamination by spheres. After replacing the CTAB with citrate on GNRs, the 
UV-Vis-NIR spectrum of citrate-GNRs (Fig. 5.3A, solid lighter blue line) 




CTAB-GNRs. Fig. 5.3B (upper right) shows a representative TEM image of the 
citrate-GNRs, with higher magnification images in the lower half, which confirmed 
that GNRs had not changed shape and appeared better dispersed than CTAB-
GNRs. The replacement of CTAB with citrate was verified by a change in surface 
charge from 37 ± 7 mV of CTAB-GNRs to -25 ± 8 mV of citrate-GNRs (Fig. 5.3C, 
left side), given that CTAB is positively charged and citrate is negatively charged. 
Gel electrophoresis showed that the citrate-GNRs migrated toward the cathode 
(Fig. 5.3C, right side) and further verified the negatively charged citrate-GNRs, 
as compared to the CTAB-GNRs, which stayed in the well. 
The aspect ratio, length, and width of the CTAB- and citrate GNRs were 
determined from ImageJ analyses (Fig. 5.4A-C, respectively), and the mass 
distributions were determined from SP-ICP-MS (Fig. 5.4D). Citrate-GNRs had 
~6% higher aspect ratios (7.7 ± 1.2 vs. 7.1 ± 1.6, p < 0.0001) and were ~8% 
longer (70 ± 10 nm vs. 65 ± 13 nm, p < 0.0001) than CTAB-GNRs, but did not 
have significantly different widths (9.2 ± 0.7 vs. 9.3 ± 0.8 nm). Single-particle ICP-
MS showed that CTAB- and citrate-GNRs had similar mass distributions with 
overlapping mass histograms. 
Batch ICP-MS was used to measure the total gold content of the CTAB-
GNRs and citrate-GNRs. The synthesis had an ~80% yield, based on the 
theoretical gold content in a 200-mL batch of GNRs (19.7 mg) and total measured 
gold content of the CTAB-GNRs (15.8 mg). After replacing the CTAB-coating with 




the starting mass of CTAB-GNRs used for the indirect-ligand exchange (11.4 mg) 
to the total measured gold content of the citrate-GNRs (3.3 mg). The yield was 
further confirmed by the 3-fold decrease in absorbance of the UV-Vis-NIR 
spectrum for citrate-GNRs compared to the CTAB-GNRs (λLSPR = 1.00 vs 0.33). 
Conductivity, swelling, and mechanical performance of GNR hydrogels 
and bioprintability of the precursor 
The conductivity of the PHA/PGel/GNR hydrogels (or GNR hydrogels) 
were determined with varied amounts of GNRs (i.e., 0, 0.4, 0.6, 0.8, 1.0, and 1.2 
mg/mL), where the conductivity increased along with increasing GNR content up 
to 0.8 mg/mL GNRs (Fig. 5.5A). The conductivity of the 0.8 mg/mL GNR hydrogel 
group (1.15x10-5 ± 0.19x10-5 S/cm) had 71% and 58% higher conductivity than 
the 0 mg/mL and 0.4 mg/mL groups (p < 0.01), respectively. The conductivity of 
the 0.6 mg/mL GNR hydrogel group (1.07x10-5 ± 0.09x10-5 S/cm) was 57% and 
44% higher than the 0 and 0.4 mg/mL groups (p < 0.05), respectively. The 
conductivity of the 1.0 mg/mL and 1.2 mg/mL GNR hydrogels were not 
significantly different from any other group, therefore, the 0 to 0.8 mg/mL 
concentrations were tested in vitro. 
The compressive elastic moduli, absorption, and swelling ratio of the most 
conductive GNR hydrogel (i.e., 0.8 mg/mL GNRs) were compared to PHA/PGel, 
PHA, and PGel hydrogels (Fig. 5.5B-D, respectively). As shown in Fig. 5.5B, the 
compressive elastic moduli of the GNR hydrogels were not significantly different 




respectively). Compared to PHA or PGel hydrogels alone, the GNR hydrogels 
were 2.9 times stiffer than PHA hydrogels (29 ± 2 kPa, p < 0.0001) and 21 times 
stiffer than PGel hydrogels (4 ± 2 kPa, p < 0.0001). Similarly, PHA/PGel 
hydrogels were 2.7 and 20 times stiffer than PHA hydrogels (p < 0.001) and PGel 
hydrogels (p < 0.0001), respectively. The PHA/PGel hydrogels had greater 
compressive moduli than PHA or PGel hydrogels alone, but the addition of the 
GNRs to the PHA/PGel did not improve the compressive elastic modulus. 
As shown in Fig. 5.5C, the water absorption of the GNR hydrogels was 
2.7, 3.2, and 5.6 times greater (p < 0.0001) than PHA, PHA/PGel, and PGel 
hydrogels, respectively. PHA and PHA/PGel hydrogel absorptions were 2.1 and 
1.8 times greater (p < 0.0001) than those of PGel hydrogels, respectively. Similar 
trends were observed for swelling in Fig. 5.5D, where the swelling ratios of GNR 
hydrogels were 1.7, 3.1, and 3.4 times greater (p < 0.0001) than for PHA, PGel, 
and PHA/PGel, respectively. PHA hydrogels had a swelling ratio that was 1.8 and 
2.0 times greater (p < 0.0001) than those of PGel and PHA/PGel, respectively. 
PGel hydrogels had a swelling ratio 10% greater than those of PHA/PGel (p < 
0.05). Overall, the addition of GNRs to PHA/PGel increased the absorption of 
water from fabrication to the swollen state, and increased the swelling ratios of 
the swollen state to the dry state. 
The viscosity, yield stress, and storage modulus recovery (Fig. 5.6) of the 
GNR hydrogel precursor (labeled as PHA/PGel/GNRs in Fig. 5.6) are shown 




of GNR hydrogel precursors versus the PHA/PGel precursors were not 
significantly different over the tested shear rates. However, the yield stress (Fig. 
5.6B) of the GNR hydrogels precursors (511 ± 20 Pa) was 2.4 times higher than 
the PHA/PGel hydrogel precursors. The storage modulus recovery (Fig. 5.6C) of 
GNR hydrogel precursors (86 ± 8 Pa) was not significantly different than the 
PHA/PGel hydrogel precursors. The bioprinted GNR hydrogels precursors (Fig. 
5.6D) qualitatively showed cleaner printed struts than the PHA/PGel without 
GNRs. The strut size was 34% greater in the PHA/PGel (p < 0.01), which resulted 
in the GNR hydrogel precursors having 2.3 times larger pore areas (p < 0.01). 
In vitro toxicity of GNR hydrogels with citrate-GNRs to rat neural stem 
cells 
The cytotoxicity of varied GNR concentrations (0, 0.4, 0.6, 0.8 mg/mL) in 
PHA/PGel hydrogels was evaluated with seeded rNSCs for 7 days. The adhesion 
and proliferation of rNSCs were analyzed by the total metabolic activity (Fig. 
5.7A), DNA content (Fig. 5.7B), and the normalized metabolic activity per ng of 
DNA (Fig. 5.7C). The total metabolic activity and DNA content of rNSCs on day 
1 were not significantly different between the hydrogel groups. On day 7, the 
metabolic activity of rNSCs on hydrogels with no GNRs was ~92%, ~89%, and 
~67% greater than the 0.4 (p < 0.01), 0.6 (p < 0.01), and 0.8 (p < 0.05) mg/mL 
GNR hydrogel groups, respectively. Similarly, the total DNA content on day 7 of 
hydrogels with no GNRs was ~2, ~2.9, and ~2.9 greater than 0.4 (p < 0.00f1), 0.6 




hydrogels without GNRs on day 7 had 2.3 times greater DNA content than on 
day 1 (p < 0.0001). On day 1, the metabolic activity normalized to the DNA 
content did not show any significant differences between groups; however, on 
day 7, the 0.8 mg/mL GNR hydrogel had 68% and 45% greater metabolic activity 
per ng of DNA than 0 and 0.4 mg/mL hydrogel groups, respectively (p < 0.01). 
While the 0.6 mg/mL GNR hydrogel group had a higher metabolic activity per ng 
of DNA than 0 and 0.4 mg/mL groups, the increase was not statistically 
significant. 
The media changes from the GNR hydrogels (0.8 mg/mL of GNRs) with 
cells were analyzed for released gold by batch ICP-MS (Fig. 5.7D). The amount 
of gold in the 0 mg/mL GNR hydrogels with cells were not higher than the 
background (data not shown). The amount of gold released on the first and third 
day were not higher than the background, but there was 0.026 ± 0.043 µg in the 
day 5 media samples, and 0.11 ± 0.16 µg in the day 7 samples. One of the three 
samples did not have an amount of gold higher than the background and caused 
the large standard deviations. Compared to the theoretical maximum gold content 
per GNR hydrogel, the day 3 and day 5 media samples had released ~0.12% 
and ~0.49% of the total gold in the hydrogel, respectively. 
Behavioral and cellular response to hydrogel treatments in a rat hemi-
section SCI 
A T8 lateral hemi-section was made in all rats, and PHA, PGel, PHA/PGel, 




crosslinked (see graphic in Fig. 5.8A). The weekly rat videos were scored, and 
the histology was assessed after 8 weeks post-injury. All rats had full mobility and 
a BBB score of 21 prior to the surgery. Injuries were made at week 0, and the 
weekly post-injury videos of the rat gait and the affected right leg were scored 
(Fig. 5.8B). There were no significant differences across the sham and all 
implanted materials and there were large standard deviations within each group, 
even after the animals with bilateral injuries had been removed. 
H&E and IHC staining was performed on the spinal cords after 8 weeks 
(Fig. 5.9-5.14), and there were wide variations in the degree of injury for each 
animal (injuries that were visible were outlined in black dashed lines). In the 
stained horizontal sections of spinal cords in the coronal plane, there was 
variability seen in the injury size across all rats, regardless of group. Some cords 
did not show any injury (despite showing a functional deficit), some injuries 
spanned less than half the cord, some injuries spanned more than half the cord, 
and some had physical gaps or bi-lateral injuries across the entire cord (while not 
showing functional bilateral injuries). It was possible that there was variability in 
the amount of tissue surgically removed because of the gelatinous nature of the 
rat spinal cord and/or the cord’s orientation had deviated before the sectioning 
process. The resulting sections may not be representative of the injuries, and 
comparisons across rats and different groups were not able to be made. From 
the considerable variability without knowing more information about the 




inconclusive, but general observations and broad speculations were drawn from 
the sections with visible injuries. 
In the H&E (Fig 5.9), several cords showed collagen and a more fibrotic 
response within the injury. By 8 weeks, the hydrogel materials appeared to have 
mostly degraded as there were not large amounts of material leftover in any of 
the hydrogel groups. Although in the GNR hydrogel group, there was a foreign 
body response around a few small areas that were not tissue and may have been 
a small amount of leftover material. In a few of the rats, there was some 
calcification located more laterally in the injury. 
IHC was performed on spinal cords after 8 weeks to stain for 
neurons/axons (NF-M/H), macrophages/microglia (Iba1), activated astrocytes 
(GFAP), CSPGs (CS-56), and neural stem cells (nestin), which are shown in Fig. 
5.10-5.14, respectively. The NF-M/H (or NF) (Fig. 5.10) stained neuron cell 
bodies and axons. Medium and heavy neurofilaments are present throughout the 
cytoplasm of neurons and are more concentrated in axons compared to 
dendrites. The gray matter with the neuron cell bodies stained darker than the 
axonal tracts in the white matter, but the axons were visibly stained. In the 
animals where the injury could be distinguished, the disruption of the axonal 
pathways within the injury were observed as a lack of stain in the injury that is 
outlined by dashed lines in Fig. 5.10. While no conclusions can be drawn, there 





The GFAP (Fig. 5.11) stained for activated astrocytes, and the borders of 
the injury were distinguished by the lack of staining of the fibrotic tissue response 
within the injury. In the GFAP stained spinal cords, there were low levels of 
staining throughout the section of cord around the injury, but there was not 
substantial evidence of a reduction of activated astrocytes in any of the groups. 
From the Iba1 staining of activated microglia and macrophages (Fig. 5.12), there 
were activated microglia throughout the entire visible spinal cord sections and a 
concentration of macrophages near and within the injury (outlined by a dashed 
black line in Fig. 5.12). However, there was not any significant reduction of 
macrophages in the proximity of the injury in any of the groups. The spinal cords 
were stained for CS-56 to show CSPGs, which are one of the inhibitory 
components in the glial scar that prevent axon regeneration (Fig. 5.13). There 
was light staining of CSPGs within some of the injuries, but there was not a 
significant discernable reduction of CSPGs in any of the groups. Finally, spinal 
cords were stained for nestin to show NSCs (Fig. 5.14), but the lack of stain in 
any of the spinal cords showed no NSCs were present in any of the groups.  
Gold distribution in rat organs 
The blood, brains, kidneys, livers, and spleens of the rats in the sham 
group and GNR hydrogel group were evaluated by ICP-MS for the total gold 
content and by histology after 8 weeks (Fig. 5.15). The amount of gold detected 
by ICP-MS is shown in Fig. 5.15A. The total gold in the brains and the blood were 




received the GNR hydrogels had 0.029 ± 0.29 µg of gold, 0.018 ± 0.017 µg, and 
0.007 ± 0.012 µg of gold per gram of organ, respectively. After 8 weeks, the 
amount of gold in the kidneys, livers, and spleens of GNR treated rats as 
percentages of the estimated total implanted gold was ~0.05 ± 0.05%, ~0.34 ± 
0.34%, and ~0.007 ± 0.012% of the total theoretical gold delivered (Fig 5.15B). 
The histology of the brain, kidney, liver, and spleen (Fig. 5.15C) of the rats 
in the sham group and those that received the GNR hydrogel was evaluated for 
pathological changes due to accumulation of gold. The histology of the organs of 
the rat treated with the GNR hydrogel was selected from a rat that had higher 
amounts of dissolved gold in the kidney, liver, and spleen via ICP-MS. Individual 
GNRs would not be visible at this magnification; however, if GNRs aggregated or 
accumulated in cells (e.g., macrophages) over time, the accumulated GNRs may 
be visible at high magnifications. None of the organs showed visible 
accumulations of GNRs in the cells or aggregates of GNRs in the tissues. All the 
normal tissue architectures were observed in each organ of the rats that received 
the GNR hydrogels. 
Discussion 
In the current study, we developed a new conductive GNR hydrogel with 
an injectable and paste-like precursor, and applied the material in a rat SCI 
model. The developed PHA/PGel/GNR bioink was injectable and had a paste-
like rheology, which enabled less invasive surgical delivery and retention of the 




hydrogel was demonstrated in a lateral T8 hemi-section SCI in rats. With the 
biocompatible gelation conditions of the GNR hydrogel, the hydrogel was 
crosslinked directly in the injury and formed a conductive hydrogel. The GNR 
hydrogel provides a translational conductive biomaterial platform and starting 
point for further refinement and eventually combination with ES to promote axon 
regeneration, neural plasticity/reorganization, and functional recovery.  
High aspect ratio gold particles, such as GNRs, have potential in 
fabricating conductive composites because they are inert, biocompatible, and 
highly conductive. Gold nanoparticle-based materials have been applied to SCI, 
but the purpose of the gold was for drug delivery or to utilize other properties of 
gold,[24] but not to make a conductive composite. Outside of SCI, conductive 
GNR hydrogels have been developed and used for cardiac tissue 
engineering,(203, 206, 207, 210) but have not yet been applied to SCI. There are 
several limitations of GNRs that may hinder the development of conductive 
biomaterials for biomedical applications: challenges in the synthesis, low aspect 
ratios, low synthesis yields, cytotoxicity of the CTAB surfactant, and high 
concentrations needed for conductivity. The most popular seed-mediated 
synthesis of GNRs make fairly low aspect ratio GNRs (3 to 4) with low yields 
(~15% of Au3+ ions were reduced to Au in nanorods) and any minor deviations in 
the reagent concentration results in significant contamination of spherical or other 
shapes of particles.(289, 290) While one study synthesized a gold nanowire 




GNRs. Use of a bisurfactant growth solution has enable higher aspect ratio GNRs 
to be formed; however, the yields were still low.(289) In the current study, we 
employed a robust and repeatable synthesis by Vigderman and Zubarev(281) 
that used hydroquinone, a different reducing agent in the growth solution 
compared to the typically used ascorbic acid reducing agent. The synthesis 
required more time (12 hours versus 3 hours) but had higher yields (~80% in the 
current study, but Vigderman and Zubarev were able to achieve 100% 
conversion), higher aspect ratios (7 to 8), and minimal contamination of other 
shapes (e.g., spheres, dog-bone shapes).  
With a robust, high-yield synthesis of high aspect ratio GNRs, one major 
limitation of GNRs that we needed to overcome was the cytotoxicity of the CTAB 
surfactant that is required for shape control and rod formation. While Navaei et 
al.(207) found that CTAB-GNRs in methacrylated gelatin hydrogels were not 
cytotoxic for cardiomyocytes, preliminary studies with PHA/PGel/CTAB-GNRs at 
various concentrations were cytotoxic within 1 day for seeded rNSCs (data not 
shown), presumably from the CTAB. Direct ligand exchange for GNRs is 
challenging because CTAB binds more strongly to gold than many commonly 
used ligands (e.g., citrate, polyethylene glycol (PEG)). Instead of replacing the 
CTAB, other studies have coated CTAB-GNRs with non-toxic components (e.g., 
GelMA(203)); however, given that the hydrogels would eventually release the 
GNRs, any remaining CTAB may potentially cause toxic in vivo side effects. 




adapted from Zhou et al.(209) to first displace the CTAB with a thin silver coating 
on GNRs and then etch away the silver in the presence of sodium citrate to 
completely replace the toxic CTAB. The silver to gold ratio and initial starting GNR 
concentration was adjusted for successful exchange of CTAB for citrate on the 
longer GNRs. For example, not enough silver resulted in aggregation, possibly 
from incomplete exchange with negatively charged citrate-GNRs aggregating 
with positively charged CTAB-GNRs. In contrast, too much silver caused silver 
nanoparticles to form and a thicker silver layer around the GNR, which may result 
in incomplete etching away of the silver. Silver nanoparticles in the central 
nervous system have been shown to cause neuroinflammation and disrupt neural 
cytoskeletons,(193) so silver-coated GNRs were undesirable and complete 
replacement of CTAB with citrate was necessary. All of the PHA/PGel hydrogels 
with citrate-GNRs supported rNSC adhesion and viability, further confirming our 
speculation that the cytotoxicity of the CTAB-GNRs hydrogels was from the 
CTAB.  
Another benefit of the citrate-GNRs was that the citrate coating was a 
better stabilizer than the CTAB, and citrate-GNRs did not aggregate over time as 
quickly, compared to CTAB-GNRs, which started aggregating within 1 to 2 days. 
The wash step after synthesis with PVP was able to extend the shelf-life of CTAB-
GNRs to 1-2 weeks because the PVP is a steric stabilizer. Furthermore, 
sterilization of CTAB-GNRs was challenging, as they could not be sterile-filtered 




method to sterilize CTAB-GNRs for cytotoxicity studies was to fabricate them 
under sterile conditions, which had logistical challenges. On the other hand, 
citrate-GNRs were better dispersed and were able to be sterile filtered while 
retaining ~66% of the GNRs.  
Given that the conductivity of a composite hydrogel is dependent on the 
conductive filler concentration, the accurate determination of GNR concentration 
is necessary for comparison across studies internally and across research 
groups. Batch ICP-MS is the gold standard for directly measuring total dissolved 
gold in gold nanoparticle solutions but can be costly and not as fast as other 
alternate indirect methods. An alternative indirect method for measuring molar 
gold nanoparticle concentrations is to use the Beer-Lambert law with 
experimentally determined molar extinction coefficients and the UV-Vis 
absorption of the LSPR peak.(291) The molar extinction coefficients have been 
characterized for shorter GNRs (i.e., aspect ratios 2 - 5);(292) however, the 
coefficients have not been characterized for longer GNRs such as the GNRs 
used in the current study (aspect ratio 7 - 8). Additionally, we found that in our 
syntheses, the LSPR peak varied from batch to batch and any experimentally 
determined molar extinction coefficient would vary accordingly and could not be 
applied to determine the concentrations of batches with different LSPR peaks. 
Therefore, batch ICP-MS was the superior method compared to using the Beer-
Lambert law for determining the concentration of GNRs in our application. Batch 




enabled comparison to other developed GNR hydrogels in other fields. Given that 
higher aspect ratio conductive fillers may enable lower concentrations to be 
sufficient to achieve conductivity, the use of higher aspect ratio GNRs to fabricate 
a conductive hydrogel may have advantages of requiring fewer GNRs. The 0.6 
and 0.8 mg/mL citrate-GNR concentrations were found to be conductive and 
were in the range of, and slightly lower than, GNR concentrations in other GNR 
hydrogels (e.g., 1.0 and 1.5 mg/mL GNRs(207)) that used lower aspect ratio 
GNRs.  
With the biocompatible and conductive PHA/PGel/GNR hydrogel, the 
formulation with 0.8 mg/mL was implanted in the hemi-section SCI model in rats, 
along with material controls of PHA/PGel, PHA, PGel, and a sham. While the 
GNR hydrogels did not show discernable improved axon regeneration, reduced 
CSPGs/inflammation, or better functional recovery than the sham group, the 
current study did establish the safety and feasibility of implanting the GNR 
hydrogel. While all the formulations were injectable and easy to deliver, there 
were differences across the materials in the placement and retainment within the 
injury. The formulation that the surgeons noted had poor retention in the injury 
turned out to be the PGel hydrogel precursor. The PGel precursor did not have a 
paste-like rheology, as evidenced by the lack of a yield stress and a lower 
viscosity compared to the other formulations. After injection, it was difficult to 
discern if the PGel precursor was retained in the injury during crosslinking. 




higher viscosities) were able to stay within the injury during crosslinking and had 
better retainment than the PGel precursor. The feasibility of delivering an 
injectable and paste-like bioink to a SCI was therefore demonstrated in the 
current study. 
In addition to the feasibility of the bioink, the current study demonstrated 
the safety of the GNR hydrogel. The use of the GNR hydrogel did not inhibit 
spontaneous recovery of locomotion or cause negative clinical side effects (e.g., 
weight loss). After 8 weeks, there was minimal evidence of material leftover in 
the injury from the histological analyses of the spinal cords, indicating all the 
hydrogel groups had been mostly resorbed by 8 weeks post-injury. The GNRs 
would have been released as the hydrogel degraded and after 8 weeks, the 
kidney, liver, and spleen each had less than 0.5% of the total implanted gold, and 
the blood and brain did not have detectable levels of gold. The histological 
evaluation of the organs from the rats that received GNR hydrogels showed 
similar healthy tissue as the organs of the rats in the sham group and minimal 
subchronic toxicity. Other in vivo studies have delivered similar amounts of gold 
as the current study, or more typically, higher amounts because of repeated 
dosing regimens. For example, one study in rats with a repeated dosing regimen 
had mild histological changes (e.g., inflammation, necrosis) and no serious side 
effects after 2 weeks, 3 months, and 6 months.(293) Another single-dose study 
in mice had higher GNR accumulation in the organs after 1 day to 15 months, but 




study.(294) Given the low levels of gold in the organs compared to other studies, 
we speculate the gold may have been excreted in the urine or feces over the 
course of the 8-week study, taken up by macrophages that traveled to the lymph 
nodes, or accumulated in other organs such as the lungs or in the spinal cords, 
which was not available due to histological processing. The feces, urine, lungs, 
and lymph nodes were not collected and tested in the current study, but testing 
in future studies may benefit from confirming the accumulation and/or excretion 
of the GNRs at different timepoints post-injury. Overall, the lack of negative side 
effects and lack of pathological effect from the low levels of gold in the tested 
organs demonstrated the safety of the GNR hydrogels and the released GNRs. 
There may have been several reasons for the lack of regeneration and 
functional recovery, including possible premature hydrogel degradation, 
displacement of the hydrogel post-crosslinking, increased intraspinal pressures, 
and/or lack of regenerative cues. Ideally, the rate of tissue regeneration would 
match that of the hydrogel degradation because too slow of hydrogel degradation 
may prevent new tissue formation and axon growth, and degradation too fast may 
cause lack of a scaffold for supporting regeneration and/or additional 
inflammation or scarring.(75) In addition, hydrogel displacement after 
crosslinking may cause similar effects as too fast of degradation, or additional 
off-site effects. One study found that high molecular weight HA hydrogels did not 
degrade after 9 weeks in a rat hemi-section SCI model;(271) however, the 




increased the rate of degradation comparatively. As the histology and IHC in the 
current study showed, some of the injuries were large gaps or had fibrous scar 
tissue, and there was minimal evidence of remaining hydrogel material in the 
injuries. It is possible the lack of regeneration may, at least in part, have been 
from too fast of hydrogel degradation or hydrogel displacement; however, future 
studies to evaluate the in vivo degradation rate and hydrogel retainment post-
surgery would be needed to confirm the speculation.  
The mechanical performance and swelling properties of hydrogels 
implanted into a SCI are important to characterize because swelling may result 
in increased intraspinal pressures, which in turn may result in negative clinical 
outcomes.(295) The GNR hydrogels had increased swelling and absorption of 
water, and we speculate the cause was the high GNR concentrations. Despite 
the higher aspect ratio GNRs, the GNR concentrations in the mg/mL range are 
high for nanoparticles and resulted in limited crosslinking because of the dark 
color/opacity of the hydrogels and/or less available crosslinker. The pentenoate 
functionalization uses thiol-ene click chemistry, where the -enes of the 
pentenoate group crosslink with a dithiol crosslinker. Thiols bond to gold quickly 
and with high affinity, which may have trapped some of the dithiol crosslinker and 
instead aggregated GNRs together or tethered GNRs to PHA or PGel. No visible 
aggregates were seen in the precursor, but GNR hydrogels had increased 
swelling and absorption, which was consistent with a less crosslinked network. 




however, the GNR hydrogels did not have significantly different compressive 
moduli from the PHA/PGel hydrogels. Gold nanoparticles have been used in 
tissue engineering to generate hydrogels with improved stiffness,(280) therefore, 
we speculated that the GNRs may have increased the moduli of PHA/PGel, but 
the inhibited crosslinking may have diminished or counterbalanced that effect. 
While the GNR hydrogels had high absorption of water that may have increased 
intraspinal pressure after gelation in the injury, the high absorption may not have 
necessarily caused high intraspinal pressures. In a comprehensive review on 
swelling and intraspinal pressures from injectable hydrogels for SCI by Khaing et 
al.,(295) 2% HA hydrogels had higher absorption (denoted as “mass swelling 
percent” in the review) than 4% poly(ethylene glycol) (PEG) hydrogels, but lower 
swelling pressure. Swelling pressure experiments or direct measurements of 
local spinal tissue pressure after hydrogel implantation would be needed to 
determine how much the high absorption of GNR hydrogels increase intraspinal 
pressure, and if those intraspinal pressures negatively affect functional 
outcomes. 
The high absorption of water and low conductivity of the GNR hydrogels 
used in the current study may both be solved by addressing the inhibited 
crosslinking by using different crosslinkers, hydrogel crosslinking chemistries, 
and/or incorporation of additional conductive components. Longer UV exposure 
times were already used in the current study to crosslink the GNR hydrogels (i.e., 




be still be neutralizing the crosslinker. While an increased amount of crosslinker 
may compensate for the neutralized crosslinker and improve the hydrogel 
crosslinking, high concentrations of the crosslinker used in the current study (i.e., 
DTT) are cytotoxic for rNSCs. Different non-cytotoxic dithiol crosslinkers may 
overcome the limitations of DTT, where high concentrations of a peptide 
crosslinker with a cysteine on each end may be less toxic and better crosslink the 
GNR hydrogels. Alternative fast crosslinking chemistries (e.g., alkyne-azide click 
chemistries) that do not use thiol crosslinkers or crosslinking molecules at all may 
additionally avoid the crosslinker complications. Improved crosslinking and the 
reduction of the water absorption may reduce the risks associated with increased 
intraspinal pressure, and additionally may condense the GNR network and 
improve conductivity. Furthermore, the hydrogel conductivity may be improved 
through the addition of other conductive components into the PHA/PGel/GNR 
precursor, such as poly(3,4-ethylenedioxythiophene) polystyrene sulfonate 
(PEDOT:PSS), which is one of the few conductive polymers commercially 
available as a stable colloidal suspension in water that may be able to be easily 
blended into the PHA/PGel/GNR precursor. 
There was not substantial evidence of axonal regeneration (i.e., axons 
stained by neurofilament) within the injuries of any of the hydrogel in vivo groups 
in the current study and the conductive material by itself may not have been 
sufficient to encourage axonal regeneration. Additionally, we did not see a 




inhibitory environment (e.g., CSPGs stained by CS-56) in any of the hydrogel 
groups. In other studies, HA hydrogels alone had neuroprotective effects when 
applied to rat hemi-section SCI models,(271, 296) but no differences in functional 
recovery compared to sham groups.(296) However, another study that used HA 
hydrogels combined with growth factors and cells showed some improvements 
in functional recovery in a rat hemi-section model.(76) Similar to previously used 
HA hydrogels, the GNR hydrogel used in the current study may need additional 
bioactive cues to neutralize the inhibitory environment and/or promote axonal 
regeneration. In contrast to previously used HA hydrogels, the conductivity of the 
GNR hydrogel enabled it to be a platform that is compatible with ES. The efficacy 
will need to be evaluated for a GNR hydrogel (with additional bioactive cues) 
combined with ES to promote neural differentiation and neurite growth in vitro, 
and promote axon regeneration and neural plasticity in vivo. In addition to 
evaluating the effects of conductive materials with and without ES, it will be 
important to elucidate the effects of the conductive material alone compared to a 
non-conductive material.  
Given the efficacy of combining motor training and ES after SCI in small 
clinical studies, it may be logical to combine a conductive biomaterial with ES and 
motor training. Regenerating the tissue and promoting neural plasticity with 
regenerative rehabilitation approaches may be able to restore supraspinal input 
for voluntary control and activation of CPGs and other functions for maximal 




hydrogel developed in the current study are translational platforms that may 
synergistically link regenerative medicine and rehabilitation approaches for 
developing regenerative rehabilitation treatments for SCI.  
Conclusions 
The rheology of the developed PHA/PGel/GNR hydrogel bioink enabled 
translational injection for application to a rat hemi-section model of SCI. While no 
differences in functional recovery were seen across treated groups, the goal of 
the study was accomplished with the feasibility and safety of injectable GNR 
hydrogels being established. With no previous studies evaluating a GNR-based 
conductive hydrogel for application to SCI, this study filled that gap and in the 
future, may provide a translational platform that can combine regenerative 
medicine approaches and rehabilitation approaches to maximize functional 





Chapter 6 : Conclusion 
Full functional recovery after spinal cord injury (SCI) is uncommon in 
patients with severe SCI. Rehabilitation strategies, specifically motor training 
combined with electrical stimulation (ES), are leading to better functional recovery 
in patients with incomplete injuries, possibly from leveraging spared tissue. 
Recovery of locomotion may be possible in patients with more severe injuries, 
who have little to no spared tissue, by targeted activation of intrinsic spinal 
circuits, or central pattern generators (CPGs), that are related to locomotion and 
are still intact below the injury. However, determining the necessary ES 
parameters to enable activation CPGs and identification of other CPGs and/or 
spinal networks in humans is a challenge. For full functional recovery beyond 
locomotion, the axons may need to be regenerated and retrained. Regenerative 
medicine approaches aim to regenerate the axons, but given that regenerative 
medicine approaches by themselves have not yet resulted in full functional 
recovery, there is growing evidence in the SCI literature indicating the need for 
combining rehabilitation and regenerative medicine to maximize functional 
recovery. Regenerative medicine approaches may be needed for SCI to restore 
the damaged axons and support rehabilitation approaches in promoting neural 
plasticity of any newly regenerated axons. Unfortunately, there are limited 
methods to synergistically combine rehabilitation and regenerative medicine, but 
conductive biomaterials could be the missing link that enables synergistic 




biomaterials to treat SCI. The problem is that many conductive biomaterials are 
preformed scaffolds, which may hinder clinical translation to a contusion-type SCI 
that does not have defined borders. However, an injectable biomaterial that 
conforms to the shape of the injury may be more translational for contusion SCIs. 
The field of bioprinting has been developing injectable materials for biomedical 
applications and the relevant rheology of bioinks enables translation for 
developing injectable biomaterials for SCI. In the current work, a conductive and 
bioprintable hydrogel was developed, refined for neural tissue engineering, and 
applied to a rat spinal cord injury (SCI) model, for potential future application to 
spinal cord regeneration after severe, contusion SCIs.  
In Aim 1, an existing biomaterial, pentenoate-functionalized hyaluronic 
acid (PHA) was developed into a bioink. While several biomaterials exist, not all 
biomaterials are printable by extrusion-based bioprinting. Fabrication of most 
biomaterials generates a solid scaffold and preformed scaffolds are not typically 
injectable and not suitable for bioprinting. Several hydrogels are uniquely suited 
for bioprinting with precursors that are able to be extruded through a needle or 
nozzle, and subsequently crosslinked after printing. To further universalize the 
bioprinting field, three standard rheological tests were used to characterize the 
rheology and predict the printability of materials for easier bioink development. 
Materials with low viscosity are easier to extrude through needles or nozzles, but 
materials with higher viscosities can be extruded if they demonstrate shear 




bioprinting layer-by-layer structures and is related to the possession of a yield 
stress. Finally, the retention of the shape after experiencing high shear stresses 
(i.e., extrusion through a nozzle) is related to the storage modulus recovery and 
is important for retaining the bioprinted shape after printing.  
The molecular weight and the concentration of PHA was varied to 
determine printable formulations. High molecular weight PHA was previously 
used to develop paste-like biomaterials for applications in cartilage and bone 
defects and was found to be more suitable than lower molecular weights for 
bioprinting. The 4, 5, and 6 wt% PHA formulations were printable and retained 
their shape after extrusion. However, the 5 and 6 wt% required high pressures to 
overcome the higher yield stresses, which led to overly fast extrusion and thin, 
non-uniform printed struts. We determined that the viscosity, yield stress, and 
storage modulus recovery were vital rheological parameters to characterize and 
determine printability.  
With a bioprintable ink, PHA was further developed in Aim 2 to support 
rNSC adhesion. The problem with PHA was the rNSCs did not adhere to PHA. 
Other HA-based hydrogels had incorporated gelatin to improve cell adhesion for 
oligodendrocytes and fibroblasts, therefore, gelatin was functionalized with the 
same pentenoate chemistry to form crosslinkable hydrogels. PGel 
functionalization was fully characterized by 2D NMR experiments and the PGel 
was less functionalized than PHA, despite using the same amount of pentenoic 




only ~34% of the amino acids (by weight) in gelatin have amines and hydroxyls 
that can be functionalized. In comparison, every single repeat unit of the 
repeating disaccharide has hydroxyls that can be functionalized. After polymer 
characterization, various concentrations and crosslinker concentrations were 
tested for rNSC adhesion and the 5 and 10% PGel formulations showed the best 
adhesion. The problem with PGel was the quick in vitro degradation (less than 
14 days). To solve the problems of PHA not enabling cell adhesion, and PGel 
degrading too quickly, various concentrations of PHA and PGel in PHA/PGel 
hydrogels were tested for rNSC adhesion. A few formulations were found that 
supported rNSC adhesion and the hydrogels did not visibly degrade in 14 days 
from the stability of the PHA. The rheological properties of composites may 
change upon addition or subtraction of a material, therefore the bioprintability of 
the adhesive formulations was tested. The 3/10% PHA/PGel formulation used 
large volumes of material, and was not bioprintable despite having a yield stress. 
The poor shape recovery ultimately led to relaxation following extrusion and 
merging of the printed struts. The 4%/5% PHA/PGel formulation had similar 
rheological parameters to 4% PHA and printed with good shape fidelity. Through 
the addition of PGel to PHA, each material solved the problem of the other, and 
a PHA/PGel hydrogel bioink that supported rNSC adhesion and viability over 7 
days was developed.  
In Aim 3, the PHA/PGel hydrogels were further developed into a 




cells are metals, which would damage the soft spinal cord if implanted. 
Conductive composites with biomaterials are gaining attention in biomedical 
engineering fields because biocompatible conductive materials can provide ES 
to tissues and stimulate desirable cell responses in cardiac tissue engineering 
and other fields. There are three main categories of conductive composites: 
conductive polymers, carbon-based materials, and metal particle-based 
materials. Most conductive polymers are insoluble in water and mixing with 
PHA/PGel may not be feasible because PHA/PGel hydrogels form under 
aqueous conditions. Furthermore, conductive polymer composites are typically 
less conductive than the carbon-based and metal particle-based composites. 
Carbon-based materials, such as carbon nanotubes have extremely high aspect 
ratios and have been utilized to fabricate conductive composites with high 
conductivities; however, carbon-based materials are highly hydrophobic and 
require functionalization to ensure a stable dispersion and limit cytotoxicity. Thus, 
of the metal particles, silver has been found to disrupt neuron cytoskeletons, but 
gold itself is inert, biocompatible, and highly conductive. With the aid and 
expertise of collaborators in the gold nanoparticle field, creation of a gold 
nanoparticle composite in PHA/PGel hydrogels was a viable solution for 
developing a conductive hydrogel.  
While spherical particles require high concentrations to attain conductivity 
in a composite, higher aspect ratio particles have greater interparticle distances 




conductivity. High aspect ratio gold nanorods were synthesized according to the 
gold nanorod literature, but shape-controlled synthesis of GNRs requires the use 
of a toxic surfactant, hexadecyltrimethylammonium bromide (CTAB). PHA/PGel 
hydrogels with CTAB-GNRs were highly cytotoxic for rNSCs, so the CTAB 
coating was replaced with citrate. Direct ligand exchange is insufficient for 
replacing the tightly associated CTAB coating on GNRs, so an indirect ligand 
exchange was used to remove the CTAB and replace with non-toxic sodium 
citrate. Additionally, the citrate-capping better stabilized the GNR suspension and 
better prevented aggregation than the CTAB-capping, which enabled sterile-
filtering to sterilize the GNRs and made incorporation into the PHA/PGel hydrogel 
easier.  
After successful synthesis of citrate-GNRs, the concentration of GNRs 
was varied and the 0.8 mg/mL concentration was determined to be conductive. 
The same concentrations supported the adhesion and viability of seeded rNSCs 
over 7 days. The 0.8 mg/mL GNR concentration had slightly higher metabolic 
activity per nanogram of DNA and was selected for the in vivo study. The GNR 
hydrogel was implanted in a lateral hemi-section SCI rat model, which is the least 
debilitating in vivo model of SCI that still enables analysis of functional recovery. 
The GNR hydrogel, along with a PHA/PGel hydrogel, PHA hydrogel, and PGel 
hydrogel were tested and compared to rats who received an injury and no 
treatment (sham). There was a wide variability in the functional recovery (i.e., 




another. Additionally, in the histological and immunohistochemistry analyses, 
there was variability in the visible injury size across rats. It was possible that there 
was variability in the size of surgical defect made, because the gelatinous nature 
of the rat spinal cord did not easily enable precise removal of half the cord. Rats 
with less of an injury may have recovered locomotion much faster. Additionally, 
it is possible that during the preparation process of the spinal cords, the 
orientation of the injury on the spinal cord may have deviated before the 
sectioning and the injury may not have been visible in the stained section. Without 
knowing more information about the surrounding spinal cord sections, the 
histology and IHC were inconclusive, but general observations and broad 
speculations were drawn from the sections with visible injuries. The size of the 
injury was not able to be compared without knowing if the selected section was 
at the epicenter of each injury. However, the tissue within the injury did not show 
substantial amounts of axonal staining, decreased macrophages/activated 
microglia, decreased activated astrocytes, or decreased chondroitin sulfate 
proteoglycans. Altogether, we speculated there was not robust evidence that any 
of the materials were promoting axonal regeneration or decreasing the inhibitory 
injury environment. There may have been several reasons for the lack of 
regeneration and functional recovery including premature hydrogel degradation, 
increased intraspinal pressures, and or a lack of regenerative cues. The ideal 
rate of hydrogel degradation would be the same rate of regeneration to not 




tissue if degradation were too quick. While high molecular weight HA has been 
known to have slow degradation in vivo, the inclusion of gelatin in the current 
thesis may have increased the rate of degradation. It is possible the GNR 
hydrogels degraded too quickly and influenced the functional recovery.  
While the results of the in vivo study did not show improved regeneration 
of the neural tissue or better functional recovery than the sham group, the study 
did establish the feasibility of implanting the GNR hydrogel and the long-term 
safety of the GNRs. Surgeons had noted that the precursors of the GNR hydrogel, 
PHA/PGel hydrogel, and PHA hydrogels were easy to work with in terms of 
injectability and material retention in the injury. The PGel did not have a yield 
stress or the paste-like rheology that the other formulations had, and after 
injection, it was difficult to discern if the material was retained in the injury. 
Furthermore, the use of the GNR hydrogel did not decrease or inhibit the normal 
spontaneous recovery of the rats, or cause negative side effects (e.g., weight 
loss). All of the GNR hydrogels showed a visible injury after 8 weeks, and there 
was minimal evidence of material within any of the injuries, indicating all the 
hydrogel groups had mostly degraded by 8 weeks post-injury, which would have 
released the GNRs. The organs of the rats treated with the GNR hydrogels each 
had less than 0.5% of the total implanted gold, but there was no visible 
histological evidence of GNR accumulation in macrophages in the different 
organs and the organs appeared healthy. Given the low levels of gold in the 




been excreted in the urine or feces, and/or accumulated in the lymph nodes. 
Together, the safety of GNR hydrogels was established and the rheology of the 
GNR hydrogel bioink enabled translation for application to rat SCI models.  
In the future, the conductive biomaterial that was developed may provide 
a translational platform for combination and synergy with ES to leverage the 
principles of regenerative rehabilitation for SCI. Further refinement of the material 
would overcome several limitations of the conductive hydrogel formulation 
presented in this dissertation, such as high GNR concentrations, high absorption, 
and low conductivity. While the GNRs synthesized and used in the current studies 
had high aspect ratios (7-8) compared to typically synthesized GNRs (3-4), high 
concentrations (e.g., in range of mg/mL) of GNRs were still required to reach 
conductivity in the hydrogel.  
The high GNR concentration may have disrupted the hydrogel crosslinking 
from light attenuation or decreasing the amount of available crosslinker. The high 
concentration increased the opacity/dark color of the hydrogel precursor, which 
may have resulted in limited crosslinking. Additionally, the pentenoate 
functionalization relies on thiol-ene click chemistry, where the -enes of the 
pentenoate group react with a dithiol molecule to crosslink the PHA or PGel 
polymers in an interconnected network. The high affinity and quick reaction of the 
gold-thiol bond may trap the dithiol crosslinker and instead aggregate GNRs 
together or tether GNRs to PHA or PGel. With less available crosslinker, 




evaluated mechanical performance, the GNR hydrogels did not have significantly 
different compressive moduli than the PHA/PGel hydrogels. Gold nanoparticles 
have been used in tissue engineering to generate hydrogels with improved 
stiffness, and we initially expected the GNR hydrogels to have higher moduli than 
PHA/PGel hydrogels. We speculate the GNRs may have increased the moduli of 
PHA/PGel but the inhibited crosslinking may have eliminated the effect.  
The inhibited crosslinking from high GNR concentrations may additionally 
cause greater absorption, which was observed. Hydrogel absorption of water 
after fabrication may have a negative outcome on the spinal cord if the hydrogel 
swells and increases intraspinal pressure after forming within the injury. Higher 
intraspinal pressures have been correlated with negative functional recoveries, 
so reduction of the absorption to values around 1, where no swelling occurs, may 
be more suitable for application to SCI. However, higher absorption is not always 
correlated to higher swelling pressures, and swelling pressure experiments or 
direct measurements of local spinal tissue pressures after hydrogel implantation 
will be needed to ensure the material does not increase intraspinal pressures and 
increase the risk of negative functional outcomes. Finally, the high absorption of 
the hydrogel may increase interparticle distances between GNRs, leading to a 
reduction in conductivity. While increasing the concentration typically does not 
result in substantial increases in conductivity once the interconnected network 
has been achieved, it is possible we have not reached the maximum connectivity 




Overall, the high absorption of water and low conductivity of the GNR 
hydrogels used in the current thesis may be solved by improving the crosslinking 
with additional crosslinker, changing hydrogel chemistries, and/or incorporating 
additional conductive fillers. Longer UV exposure times (i.e., 5 min versus 2 min) 
were used in the current thesis to crosslink the GNR hydrogels but increasing the 
concentration of crosslinker may counteract the amount of dithiol crosslinker 
trapped by the gold and improve hydrogel crosslinking. High concentrations of 
the crosslinker used in this study (i.e., DTT) are cytotoxic for rNSCs; however, a 
different non-cytotoxic dithiol crosslinker, such as a peptide crosslinker with a 
cysteine on each end, may be beneficial in the future. Alternatively, other fast 
crosslinking chemistries (e.g., alkyne-azide click chemistries) that do not use thiol 
crosslinkers or crosslinking molecules at all may circumvent the dithiol 
crosslinker/gold problem entirely. Finally, the conductivity may be improved 
through addition of other conductive fillers, such as poly(3,4-
ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), which is one of 
the few water stable conductive polymers and is commercially available as a 
colloidal solution.  
In addition to improving the swelling and mechanical performance of the 
GNR hydrogels, the ability of the material to encourage axon regeneration or 
reduce the inhibitory environment may be improved in the future with the addition 
of other regenerative medicine strategies into the current translational system. 




effects but HA alone was not enough to promote axon regeneration. HA 
hydrogels with growth factors and cells had demonstrated better functional 
recovery in rat hemi-section model over cell-only controls. Given that there was 
not substantial evidence of axon regeneration or a decrease in inflammation/the 
inhibitory environment in the current thesis, additional bioactive cues or 
neutralizing factors can be incorporated into the GNR hydrogel platform with 
relative ease. Methods for guiding axon growth that can be controlled non-
invasively may be beneficial (e.g., magnetic iron oxide nanofibers, self-
assembling peptides, shape-memory polymers). In contrast to the HA hydrogels 
used to treat SCI so far, the GNR hydrogel used in the current dissertation was 
conductive, which enables it to be a platform compatible with ES in future work. 
The efficacy of a refined GNR hydrogel with and without ES in promoting neural 
differentiation and/or neurite extension in vitro will be needed prior to in vivo 
studies. Furthermore, it is important in future studies to elucidate the effects of 
the conductive material versus a non-conductive material and determine if the 
conductive biomaterial by itself may be sufficient, or if ES with any material is 
sufficient, or if there is truly a synergistic effect of using a conductive material with 
ES. Finally, given the efficacy of combining motor training with ES after SCI that 
has been demonstrated in a few human patients, it may be logical to combine a 
conductive biomaterial with ES and motor training in future studies. Conductive 
bioinks may facilitate axon regeneration and the ES and motor training may 




input needed for voluntary control and activation of CPGs for locomotion among 
other functions for full functional recovery after SCI. Conductive bioinks may be 
a method to synergistically link regenerative medicine approaches and 
rehabilitation approaches to promote maximum functional recovery after SCI. 
While the rat lateral hemi-section model was a logical first step from being 
the least debilitating while allowing evaluation of functional recovery after SCI, 
there were several challenges and other animal models (e.g., species, types of 
injury, level) may be explored in future studies. In rodents, there are several types 
of cut injuries (e.g., dorsal hemi-section, lateral hemi-section, transection) and 
contusion injuries (e.g., bilateral contusion, crush),(297) where cut injuries allow 
for easier analysis of axon regeneration and contusion injuries better represent 
human injuries and pathologies. Cut injuries may be easier to analyze axon 
growth compared to contusion injuries that leave some spared tissue; however, 
rats have significant recovery after hemi-section injuries, most likely due to 
increased axonal sprouting from the unlesioned side, and are challenging to 
perform, as evident from the variable scores compared between different 
laboratories. Furthermore, transection injuries are challenging from cord 
retraction on both ends of a cut cord, and are the least representative of typical 
human injuries. Contusion injuries are more difficult to analyze because of spared 
tissue, but are the industry standard because they better represent human 




impactors. A rat thoracic level contusion injury would be the most useful model 
to use moving forward.  
In addition to the type of injury, different species are used including 
rodents, felines, canines, swine, and non-human primates (e.g., macaques,  
marmosets, squirrel monkeys).(298) Mice and rats are the most widely used for 
SCI, but rats better mimic the human pathologies compared to mice, which 
recover better than rats or humans after SCI. An inherent limitation and 
consideration for rodent and feline models of SCI is that rehabilitation approaches 
(e.g., ES, pharmacological stimulation) can enable recovery of locomotion in 
animals with complete transections. Proper controls are needed to elucidate the 
effects of treatments. There are limited larger animal models of SCI (e.g., swine, 
canine), but all laboratory animal SCI models do not accurately represent the 
heterogeneity across human injuries. Given the high occurrence of naturally 
occurring SCI in pet dogs, the Canine Spinal Cord Injury Consortium was 
established in 2015 to promote the value of the clinical dog model of SCI.(299) 
The population of dogs with chronic SCI may be valuable in the future for 
evaluating efficacy of SCI treatments in larger animal models and eventual 
translation to human patients. 
In the current dissertation, a conductive hydrogel was developed that 
supported rat neural stem cell viability and was an injectable bioink. The material 
was successfully applied in a hemi-section rat SCI model and was feasibly 




dissertation was, to the best of our knowledge, the first application of a conductive 
gold-based hydrogel to treat SCI. Gold nanoparticle hydrogels have been 
developed to deliver drugs for SCI, but the hydrogels were not conductive. On 
the other hand, gold-based conductive hydrogels have been fabricated for 
cardiac tissue engineering and other biomedical applications, but not applied to 
SCI. In the future, the rheology of the PHA/PGel bioink hydrogel may enable the 
material to be translated to a more clinically relevant contusion SCI rat model. 
Furthermore, the conductivity of the hydrogel may enable combination with ES 
as a regenerative rehabilitation approach to leverage the beneficial cellular 
effects of stimulation, enhance neural plasticity, and promote better functional 
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Figure 2.1: A Venn Diagram Illustrating Conductive Biomaterials in 
Regenerative Rehabilitation 
 
A Venn diagram of the concept of regenerative rehabilitation for spinal 
cord injury (SCI). Regenerative medicine approaches include cells, drugs, 
biologics, and biomaterials. Rehabilitation approaches for SCI include motor 
training, electrical stimulation, and neurochemical stimulation. Conductive 
biomaterials can link these two disparate fields together by providing a substrate 
to deliver electrical stimulation (ES) through the injury to elicit neural plasticity 





Figure 2.2: Illustration of the of Conductive Composites 
 
The range of conductivities for conductive substrates by themselves and 
conductive composites. The region of insulators is <10-6 S/cm (red area), the 
region of semiconductors is ~10-7 to ~102 (yellow area), and metallic conductors 
range from ~100 to 107 (green area). Abbreviations: CNTs, carbon nanotubes; 
PPy, polypyrrole; PANI, polyaniline; PEDOT, poly(3,4-ethylenedioxythiophene); 





Figure 3.1: Aim 1 Illustration of Bioprinting and Hydrogel Formation 
 
Graphic of the bioprinting, hydrogel formation, and cell culture. A) 
Hydrogel precursor containing pentenoate-functionalized hyaluronic acid (PHA), 
dithiothreitol (DTT), Irgacure 2959, and PBS with cells were mixed and loaded 
into UV-protected cartridges. PHA precursors were bioprinted in a 2 x 4 grid of 
rectangular prisms (8 x 6 x 0.3 mm, L x W x H) and onto a 24 x 76 mm glass 
microscope slide. B) Hydrogels were crosslinked after exposure to 312 nm UV 
light for 2 min. C) Silicon well chambers were sealed around the hydrogels and 






Figure 3.2: Aim 1 Shape Fidelity of PHA Precursor Formulations 
 
Shape fidelity of 1 and 1.5 MDa PHA at varying concentrations. The 1.5 
MDa  4 wt% and 1 MDa  8 wt% formulations printed the best (outlined in red 
boxes). A) The printed object was a 3-layer grid with alternating layers of 6 
horizontal or 6 vertical lines in a rectilinear pattern. Cellink Start had good shape 
fidelity after printing, while toothpaste only had medium shape fidelity due to quick 
material relaxation and loss of defined edges shortly after printing. B) Shape 
fidelity scores for 1 and 1.5 MDa PHA formulations. For both molecular weights, 
the shape fidelity increased, reached a peak, and decreased as the concentration 
of PHA increased. C) Macro images within 1 min after printing and before 
crosslinking from a top view to show the shape fidelity. Pore areas appeared to 
generally increase while strut sizes generally decreased with increasing PHA 





Figure 3.3. Aim 1 Rheology of PHA Precursor Formulations 
 
Rheological testing of varying PHA concentrations of 1 and 1.5 MDa PHA 
precursors. Viscosity data by itself did not indicate printability; however, the 
printable formulations had a yield stress between 0 and 1000 Pa and recovered 
85% or greater of their initial storage modulus. A) The viscosities of the 1 MDa 
PHA increased as the PHA concentration increased; however, all groups’ 
viscosities decreased to below 18 Pa-s at the highest tested shear rate and 
demonstrated shear thinning behavior. B) Similar to the 1 MDa PHA groups, the 
viscosity behavior of the 1.5 MDa PHA was shear thinning and increased as the 
PHA concentration increased. C) 1.5 MDa - 3 and 4 wt% had similar yield 
stresses to Cellink! Start and were less than 1000 Pa. The 1 MDa PHA groups 
did not have measurable yield stresses. D) Cellink Start®, 1.5 MDa - 3 wt%, and 
1.5 MDa - 4 wt% recovered greater than 85% of their initial storage moduli after 






Figure 3.4: Aim 1 Shape Fidelity and Rheology of PHA Precursors with 
Cells 
 
The printability, yield stress, and viscosity of varying cell concentrations in 
a 1.5 MDa - 4 wt% PHA precursor. The printability, yield stress, and viscosity 
were minimally affected by increasing cell concentrations, up to 9 x 106 cells/mL. 
A) The shape fidelity of the PHA precursor remained high for all cell 
concentrations tested (1 – 9 x 106 cells/mL). All cell concentrations had similar 
pore areas and strut sizes. B) The yield stress of PHA with 1 x 106 cells/mL was 
increased compared to PHA without cells; however, all higher concentrations had 
similar yield stresses to PHA without cells. C) The viscosity of the PHA groups 
with cells all showed similar shear thinning behavior to that of the PHA without 








Figure 3.5: Aim 1 Viability of Printed Cells 
 
Viability of rat bone marrow mesenchymal stem cells (rBMSCs) and rat 
neural stem cells (rNSCs) after bioprinting into rectangular scaffolds (8 x 6 x 0.3 
mm) with 100% infill after 0 days and 7 days of culture. The viability was high for 
both rBMSCs and rNSCs after bioprinting and cells survived for 7 days in culture. 
After rBMSCs or rNSCs were bioprinted in PHA hydrogels (day 0), there was high 
viability of both cell types (>87%) (green, live cells; red, dead cells). Over 7 days 
of culture, rBMSCs maintained a high viability (~85%) but the rNSC viability 





Figure 4.1: Aim 2 Fully Assigned 2D NMR of HA and Gelatin 
 
The 2D TOCSY (TOtal Correlation SpectroscopY) spectra of hyaluronic 
acid (HA) and gelatin significantly aided the assignment of the signals. A) Distinct 
correlations patterns were observed for each sugar ring allowing for the absolute 
proton resonance assignment for HA. The N-acetyl-D-glucosamine spin system, 
shown in red, displayed the correlation of protons 2, 3, 4, 5 and 6 to each other 
and to the anomeric proton signal 1 at 4.47 ppm. Correlations are also observed 
from the methyl on the acetyl group at 1.9 ppm to the protons on its attached ring. 
The of D-glucuronic acid spin system, shown in light blue, displayed the 
correlation of protons 2’, 3’, 4’, and 5’ correlated to each other and to the anomeric 
proton signal, 1’ at 4.33 ppm. B) The gelatin TOCSY displayed a distinct 
correlation pattern for each amino acid. The spin systems of arginine (green), 
lysine (dark blue), proline (orange), hydroxyproline (yellow), alanine (pink), 
glycine (red), glutamic acid (grey), aspartic acid (dark purple), and serine (light 







Figure 4.2: Aim 2 2D NMR of PHA or PGel 
 
The 2D TOCSY spectra of HA or gelatin versus PHA or PGel, respectively, 
showed the original polymer peaks and the appearance of new peaks of the 
pentenoate group. The integration of the PHA or PGel 1H spectra showed the 
degree of functionalization with the pentenoate group. A) The HA 2D TOCSY 
showed the original polymer signals of each sugar ring. B) The PHA 2D TOCSY 
displayed the appearance of the pentenoate group spin system. The correlation 
of the four new peaks (2.27, 2.46, 5.00, 5.82 ppm) is shown in red. C) The gelatin 
2D TOCSY shows the original polymer signals of each amino acid. D) The PGel 
2D TOCSY displayed the appearance of the pentenoate group spin system. The 
correlation of the four new peaks (2.33, 2.51, 5.04, 5.84 ppm) is shown in red. E) 
The PHA proton signal (10) at 5.82 ppm was integrated  and normalized to the 3 
protons of the methyl group of proton signal (7) at 1.9 ppm revealing that 38% of 
the repeating disaccharide units were functionalized with a pentenoate group, or 
there was ~0.108 millimoles of the pentenoate group per gram of PHA. F) The 
same proton signal (10) of the pentenoate group at 5.84 ppm was integrated on 
the PGel 1H signal and quantified with an internal standard (TMSP, 9 protons, 0 








Figure 4.3: Aim 2 Mechanical Performance and Swelling of PGel and 
PHA/PGel Hydrogels 
 
The mechanical performance and swelling were characterized for different 
formulations of PGel and PHA/PGel. A) The compressive modulus of PGel 
hydrogels (n = 5-6) showed increased compressive moduli with increased 
polymer content. The higher concentration of DTT crosslinker (gray bars) 
additionally increased the moduli compared to the lower DTT concentration 
(black bars) in all groups except the 5 wt% PGel hydrogels. B) The absorption of 
all tested PGel hydrogels (n = 6) were close to or less than 1, showing minimal 
swelling or slight contraction after fabrication, despite the PGel concentration and 
DTT concentration. C) The swelling ratio of PGel hydrogels (n = 6) decreased 
with increasing PGel concentration, and the effect of the different DTT 
concentrations was minimal. D) The compressive moduli of the PHA/PGel 
hydrogels (n = 5-6) showed increased moduli with increased PHA content. The 
10% PGel concentrations (gray bars) additionally increased the moduli compared 
to the 5% PGel concentrations (black bars). E) The absorption of all tested 
PHA/PGel hydrogels (n = 6) was between 1 and 1.5, showing absorption of water 
after fabrication and greater absorption with increased PHA content. Significance 
was marked with ‘A’ or ‘B’, where groups denoted by ‘B’ were significantly greater 
than those denoted by ‘A’, and those with the same letter were not significantly 
different from each other. F) The PHA/PGel hydrogels had decreased swelling 
ratios (n = 6) with increased PGel content and there was a minimal effect of the 






Figure 4.4: Aim 2 Rheology of PHA/PGel Precursors 
 
The rheology of the PHA/PGel precursor formulations that were adhesive 
for rNSCs show that the 4%/5% formulation was shear thinning, had a higher 
yield stress, and higher storage modulus recovery than the 3%/10% formulation. 
A) The viscosity (n = 3) of the 4%/5% precursor (blue line, circle points), was 
higher at the three lowest tested shear rates than the 3%/10% (black line, square 
points). Both formulations were shear thinning. B) The yield stress (n = 3-5) of 
the 4%/5% precursor (blue bar) was higher than the 3%/10% precursor (black 
bar). C) The storage modulus recovery (n = 3) of the 4%/5% precursor (blue bar) 
was higher than the 3%/10% precursor (black bar). D) Given the higher yield 
stress and better storage modulus recovery, the 4%/5% formulation was 
bioprinted in a 3-layer grid pattern, and the strut size (1.07  0.08 mm) and pore 





Figure 4.5: Aim 2 Cell Viability on PGel Hydrogels 
 
Across varied PGel and DTT crosslinker concentrations, seeded rat neural 
stem cells (rNSCs) had the highest normalized metabolic activity after 7 days on 
the 5% and 10% PGel hydrogels (n = 6-8). A) The metabolic activity of seeded 
rNSCs the PGel hydrogels were similar on day 1, and higher for the 5% and 10% 
PGel hydrogels with 0.5 xDTT on day 7 compared to all other groups. Significance 
is denoted by letters, where groups marked by ‘A’ were significantly higher than 
‘B’, ‘C’, ‘D’, and ‘E’, and groups marked by ‘B’ were significantly higher than those 
marked by ‘C’, ‘D’, and ‘E’, etc. B) On day 1, the DNA content was lower on the 
5%/0.25 xDTT hydrogel than most of the other groups. On day 7, the 5%/0.5 xDTT 
hydrogel had higher DNA content than all groups except the 10%/0.5 xDTT 
hydrogel. C) The metabolic activity normalized to the DNA content and to the 
plated cells group, showed similar activity of all hydrogels on day 1, and higher 
activity of the 5% and 10% PGel hydrogels on day 7. * p < 0.05, ** p < 0.01, *** 





Figure 4.6: Aim 2 LIVE/DEAD Staining of Cells on PGel Hydrogels 
 
The LIVE/DEAD staining of rNSCs on PGel hydrogels had similar cell 
densities after 1 day and similar spread morphologies on day 7. A) 1 day after 
seeding, the rNSCs had qualitatively adhered to all PGel hydrogels in similar 
densities of live and dead cells with minimal spread morphologies. B) After 7 
days, the rNSCs had spread morphologies on all PGel hydrogels except the 
5%/0.25 xDTT hydrogels, where PGel hydrogels had become very soft and rNSCs 
had formed neurospheres instead of adhering and spreading on the material. The 
15% PGel hydrogels appeared to have more dead cells than the 5% and 10% 





Figure 4.7: Aim 2 Cell Viability on PHA/PGel Hydrogels 
 
The PHA and PGel concentrations were varied in PHA/PGel hydrogels 
and the 3%/10%, 4%/5%, and 4%/10% hydrogels had the best adhesion and 
normalized metabolic activity (n = 5-7). A) On day 1, the metabolic activity of 
seeded rNSCs across all groups was similar and on day 7, the activity decreased 
with increasing PHA content, except for the 3%/5% hydrogel, which additionally 
had lower metabolic activity. B) On day 1, the DNA content was similar across all 
hydrogels and on day 7, the 4% and 5% PHA hydrogels had higher DNA content 
than the 3%/5% group. C) The metabolic activity normalized to the DNA content 
and further normalized to the 3%/5% hydrogel group showed that the normalized 
metabolic activity decreased with increasing PHA content with minimal 
differences between PGel concentrations. * p < 0.05, ** p < 0.01, *** p < 0.001, 





Figure 4.8: Aim 2 SEM Images of Cells on PHA/PGel Hydrogels 
 
The scanning electron microscopy (SEM) images on day 7 showed greater 
spread cell morphologies across PHA/PGel hydrogels, except for cells on the 
3%/5% hydrogel. A) On day 1, there were qualitatively similar densities and cell 
morphologies of rNSCs adhered across all PHA/PGel formulations. B) On day 7, 
rNSCs had greater spread morphologies on all the PHA/PGel hydrogels except 






Figure 5.1: Aim 3 Illustration of the GNR Synthesis and Citrate-capping 
 
A graphic depicting the synthesis of citrate-capped gold nanorods (GNRs). 
A) GNRs were synthesized using a seed-mediated growth method using 
hydroquinone as a reducing agent for longer aspect ratio, higher purity, and 
higher yields of GNRs than the ascorbic-acid based synthesis. The seed solution 
was made by quick addition of ice-cold sodium borohydride (NaBH4) to a solution 
of gold chloride and hexadecyltrimethylammonium bromide (CTAB). A small 
amount of seed solution was added to the growth solution, which contained gold 
chloride, CTAB, silver nitrate (AgNO3), and hydroquinone. The solution was left 
for 12 hours in a 30°C water bath for GNRs to grow. B) The toxic CTAB on CTAB-
GNRs were replaced with non-toxic citrate through an indirect ligand exchange 
protocol. Silver nitrate was used to coat GNRs and displace the CTAB, followed 
by the etching away of the silver with hydrogen peroxide (H2O2) in a sodium 





Figure 5.2: Aim 3 Illustration of GNR Hydrogel Formation 
 
Graphic depicting GNR hydrogel formation for in vitro studies. 1) Hydrogel 
precursor was mixed and contained pentenoate-functionalized hyaluronic acid 
(PHA), pentenoate-functionalized gelatin (PGel), crosslinker dithiothreitol (DTT), 
photoinitiator Irgacure 2959 (I2959), and citrate-GNRs. 2) The hydrogel precursor 
was placed in a rubber gasket mold between two glass slides, followed by UV 
crosslinking at 312 nm for 2 minutes on each side. 3) Hydrogels were removed 
from the molds and swollen in nanopure water overnight at 37°C. 4) Cylindrical 
hydrogels were punched using a 6-mm biopsy punch. 5) Hydrogels were placed 
in a 96-well plate. 6) Rat neural stem cells (rNSCs) were seeded on top of 






Figure 5.3: Aim 3 GNRs UV-Vis, TEM, and Zeta Potential 
 
The GNRs were characterized to confirm that rods were synthesized and 
that the CTAB was replaced with citrate on the GNRs during the indirect ligand 
exchange. A) The UV-Vis-NIR spectra of the CTAB-GNRs (solid black line), 
citrate-GNRs (solid lighter blue line), and seed solution (dashed grey line) are 
shown. The seed solution absorbance was typical of 1-2 nm seeds, and the 
CTAB- and citrate-GNRs both had typical longitudinal (LSPR) and transverse 
surface plasmon resonance (TSPR) peaks at 1125 nm and 507 nm, respectively. 
B) The transmission electron microscopy (TEM) images confirmed that GNRs 
were formed from the synthesis (CTAB-GNRs, upper left panel) with minimal 
sphere contamination and that the GNRs were retained after the indirect ligand 
exchange process (citrate-GNRs, upper right panel). Higher magnification of the 
citrate-GNRs (bottom panels) show a regular rod shape (e.g., no dog-bone 
shape, or flat caps on the ends) and the atomic lattice structure of gold. C) The 
zeta potential (left half) of the CTAB-GNRs was positively charged from the CTAB 
and the ligand exchange with citrate was confirmed by the change to a negative 
zeta potential. Additionally, the ligand exchange was confirmed via gel 
electrophoresis (right half) where the citrate-GNRs migrated toward the cathode 





Figure 5.4: Aim 3 GNRs Aspect Ratio, Length, Width, and Mass 
Distributions 
 
The citrate-GNRs (shown in blue) had high aspect ratios of ~7-8 and 
lengths of ~70 nm, which were greater than those of the CTAB-GNRs (shown in 
black). A) The histogram of the aspect ratio showed similar distributions between 
the citrate- and CTAB-GNRs, but the average aspect ratio (shown in the inset) of 
citrate-GNRs was ~6% higher than the CTAB-GNRs. B) The histogram of the 
lengths showed similar distributions between the citrate- and CTAB-GNRs, but 
the average length (shown in the inset) of citrate-GNRs was ~8% longer than the 
CTAB-GNRs. C) The histogram and the average widths (shown in the inset) 
showed similar distributions and widths between the citrate- and CTAB-GNRs. 
D) Single-particle ICP-MS showed similar and overlapping mass distributions 






Figure 5.5: Aim 3 GNR Hydrogel Conductivity, Mechanical Performance, 
and Swelling 
 
The conductivity of PHA/PGel hydrogels were increased with the addition 
of 0.6 or 0.8 mg/mL of citrate-GNRs. A) The conductivity of the GNR hydrogels 
was measured with citrate-GNR concentrations ranging from 0 to 1.2 mg/mL (n 
= 5 or 6), with the most conductive formulations containing 0.6 and 0.8 mg/mL 
GNRs. Coloration of the gels after swelling is shown the respective concentration 
on the plot. Scale bar: 6 mm. B) The compressive elastic modulus of the GNR 
hydrogels were not significantly different that of the PHA/PGel hydrogels (n = 5 
or 6), but both were greater than the PHA and PGel hydrogels alone. C) The GNR 
hydrogels absorbed more water after fabrication than the PHA/PGel, PHA, and 
PGel hydrogels (n = 6). The PHA and PHA/PGel had similar absorption to each 
other and both absorbed more than PGel, which actually lost water after 
fabrication. D) The swelling ratio of the GNR hydrogels was greater than that of 
PHA/PGel, PHA, and PGel hydrogels (n = 6). The PHA had a greater swelling 
ratio than that of the PHA/PGel and gelatin hydrogels. The PHA/PGel had a 
greater swelling ratio than that of the PGel hydrogels. * p < 0.05, *** p < 0.001, 





Figure 5.6: Aim 3 GNR Hydrogel Precursor Rheology and Printability 
 
Rheological characterization of GNR hydrogel precursors showed similar 
shear thinning, higher yield stress, similar storage modulus recovery, and better 
printability than PHA/PGel alone. A) The viscosity curves of PHA/PGel/GNR 
(GNR hydrogel) precursors were not significantly different over different shear 
rates, and both were shear thinning (n = 3). B) The yield stress of GNR hydrogel 
precursors was 2.4 times higher than that of the PHA/PGel precursors (n = 3). C) 
The storage modulus recovery was not significantly different from that of the 
PHA/PGel precursors (n = 3). D) The bioprinted PHA/PGel precursors had had 
34% greater printed strut sizes compared to GNR precursors (p < 0.01), which 
led to the GNR precursors having 2.3 times larger pore areas (p < 0.01), and 






Figure 5.7: Aim 3 Cell Viability on GNR Hydrogels 
 
In vitro assessment of seeded rNSCs on GNR hydrogels showed the 
hydrogels were not cytotoxic for rNSCs and < 1% of the total gold was released 
in the media samples during the 7 days of culture. A) The total metabolic activity 
of seeded rNSCs on day 1 was not significantly different between that of different 
PHA/PGel hydrogels, but was decreased after 7 days (n = 4 or 5). B) The total 
DNA content was not significantly different between any groups on day 1 but was 
higher in the hydrogels with no GNRs on day 7 compared to the hydrogels with 
0.4 to 0.8 mg/mL of GNRs (n = 4 or 5). C) The normalized metabolic activity per 
nanogram of DNA and to the hydrogel with no GNRs was not significantly 
different between any of the groups on day 1; however, on Day 7, the hydrogels 
with 0.8 mg/mL of GNRs had 1.7 times greater metabolic activity than that of the 
hydrogels with 0 or 0.4 mg/mL GNRs. D) The media samples from the hydrogels 
with 0.8 mg/mL of GNRs and cells had 0.026 ± 0.043 µg of gold (or ~0.12% of 
the total gold in a hydrogel) in the day 5 media samples, and 0.11 ± 0.16 µg 
(~0.49% of the total gold) in the day 7 samples (n = 3). The medium samples 
from the hydrogels with no gold did not have an amount of gold that was above 





Figure 5.8: Aim 3 SCI Surgical Procedure and Functional Recovery in Rats 
 
The injectable GNR hydrogel precursors were injected into a rat hemi-
section model of SCI with no significant difference in functional recovery over 8 
weeks. A) An illustration of the surgical procedures where a T8 lateral hemi-
section was made in rats, followed by injection of a hydrogel into the injury, and 
subsequent exposure to UV-light for 2 minutes to crosslink the hydrogel precursor 
within the injury. B) The BBB scoring showed no significant difference in 
functional recovery across the GNR hydrogels (0.8 mg/mL GNRs), the other 
control materials of PGel, PHA, and PHA/PGel hydrogels, and the shams that 





Figure 5.9: Aim 3 H&E on Spinal Cords 
 
H&E staining on the spinal cords showed a high degree of variability in the 
injury after 8 weeks. The location of the injury was outlined by dashed lines, but 
the defect was not observed in several of the sections across all groups. Several 
spinal cords showed collagen (deep pink within the injury, indicated by orange 
arrows), which showed the fibrotic response within the injury. In the GNR 
hydrogel group, there was a foreign body response around a few small objects 
(smooth light purple area indicated by blue arrows), which may have been a small 
amount of leftover hydrogel. Some calcification was visible more laterally in some 





Figure 5.10: Aim 3 Neurofilament IHC on Spinal Cords 
 
Neurons/axons were stained with a neurofilament (medium/heavy) 
antibody after 8 weeks post-injury showed darker staining of the neuron cell 
bodies (gray matter) compared to the axons (white matter), but the axonal 
pathways are visibly stained compared to the negative control. In the sections 
where an injury was visible, the location of the injury was outlined by dashed 
lines. The disruption of the axonal pathways within the injuries that could be seen 
were observed as a lack of stain in the injury. While no definitive conclusions can 
be drawn regarding differences among groups, there was not substantial 
evidence of any group showing any axon staining, and thus regeneration, in the 






Figure 5.11: Aim 3 GFAP IHC on Spinal Cords  
 
Astrocytes were stained with a GFAP antibody after 8 weeks post-injury. 
In the sections where an injury was visible, the location of the injury was outlined 
by dashed lines. The borders of the injury were distinguished by the lack of 
staining of the fibrotic tissue response within the injury. There were low levels of 
staining throughout the gray and white matter, but there was not substantial 
evidence of a reduction of activated astrocytes in the proximity of the injury in any 






Figure 5.12: Aim 3 Iba1 IHC on Spinal Cords 
 
Microglia and macrophages were stained with an Iba1 antibody after 8 
weeks. In the sections where an injury was visible, the location of the injury was 
outlined by dashed lines. In all groups, there was staining of microglia throughout 
the gray and white matter of all injured spinal cords. Additionally, there were more 
macrophages in the vicinity of the injury (darker staining near the injuries) for 
most spinal cords, regardless of the group. There was not any significant 
reduction of macrophages and inflammation in the proximity or within the injury 





Figure 5.13: Aim 3 CS-56 IHC on Spinal Cords 
 
CSPGs were stained with a CS-56 antibody after 8 weeks. In the sections 
where an injury was visible, the location of the injury was outlined by dashed 
lines. There was light staining of CSPGs within some of the injuries, where the 
location of the injury is outlined by dashed lines. There did not appear to be a 
significant reduction of CSPGs, and thus reduction of the axon-inhibiting 






Figure 5.14: Aim 3 Nestin IHC on Spinal Cords 
 
Nestin was stained with a nestin antibody after 8 weeks. In the sections 
where an injury was visible, the location of the injury was outlined by dashed 
lines. There was no visible staining of nestin in any of the spinal cords, which 





Figure 5.15: Aim 3 Gold Content in Rat Organs 
 
After 8 weeks post-injury, there was <0.4% of the total estimated implanted 
gold detected in any one of the kidneys, livers, and spleens of rats treated with 
the GNR hydrogels. A) ICP-MS was used to detect the amount of total gold per 
mass of organ, and there was less than 0.03 µg of gold in the kidneys, livers, and 
spleens of the rats treated with GNR hydrogels, and no detected gold in the brain 
or blood (n = 3). The blood and organs of the rats in the sham group did not have 
amounts of gold above the background. B) As a percentage of the estimated total 
gold delivered, there was less than 0.4% of the total gold delivered that had 
accumulated in the kidneys, livers, and spleens, respectively (shown in blue 
markers, right axis). C) The histology, after 8 weeks, of the brain, kidney, liver, 
and spleen (top to bottom) of a rat treated with a GNR hydrogel are shown. 
Magnified images are to the right of the macroscopic image and show the outer 
layer of the cerebral cortex of the brain, the renal cortex with a glomerulus in the 
kidney, hepatocytes surrounding a blood vessel in the liver, and a lymphoid 
follicle of the spleen. The histology of the organs showed no pathological changes 
in the brain, kidney, liver, and spleen of the rats treated with GNR hydrogels 
versus the sham rats. There was no visible accumulation (e.g., in macrophages) 
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Table 2.1: List of acronyms 
List of acronyms 
Acronym Description 
SCI Spinal cord injury 
ES Electrical stimulation 
ASIA American Spinal Injury Association 
AIS ASIA Impairment Scale 
MAP Mean arterial pressure 
MPSS Methylprednisolone sodium succinate 
GMP Good manufacturing practice 
ChABC Chondroitinase ABC 
ISP Intracellular sigma peptide 
CSPGs Chondroitin sulfate proteoglycans 
BDNF Brain-derived growth factor 
NGF Nerve growth factor 
NT-3 Neurotrophin-3 
GDNF glial-derived neurotrophic factor 
IL-4 Interleukin 4 
BSCB Blood-spinal cord barrier 
MAIs Myelin-associated inhibitors 
NgRs Nogo receptors 
PTPΩ Protein tyrosine phosphatase sigma 
NSCs Neural stem cells 
ESCs Embryonic stem cells 
iPSCs Induced pluripotent stem cells 
MSCs Mesenchymal stem cells 
OECs Olfactory ensheathing cells 
SCs Schwann cells 
Nogo-A Neurite outgrowth inhibitor 
RGMa Repulsive Guidance Molecule A 
CSF Cerebral spinal fluid 
PLGA Poly(lactic-co-glycolic acid) 
UC-MSCs Umbilical cord-derived mesenchymal stem cells 
CNTs Carbon nanotubes 
PEG Polyethylene glycol 
PEG-DA Polyethylene glycol-diacrylate 
EES Electrical epidural stimulation 






PCLEEP Poly(ε-caprolactone-co-ethyl ethylene phosphate) 
IPN Interpenetrating network 





PPV Poly(p-phenylene vinylene) 
PSS Poly(4-styrenesulfonate) 
GelMA Methacrylated gelatin 
SLA Stereolithography 
MEH-PPV Poly[2-methoxy-5-(2-ethyl-hexyloxy)1,4-phenylene vinylene] 
PCL Polycaprolactone 
GO Graphene oxide 
CNS Central nervous system 
rGO Reduced graphene oxide 
SWCNTs Single-walled carbon nanotubes 
MWCNTs Multi-walled carbon nanotubes 
PEG-SH Thiolated PEG 
AuNPs Gold nanoparticles 
IONPs Iron oxide nanoparticles 
AgNPs Silver nanoparticles 
FGF Fibroblast growth factor 
PNIPAM Poly(N-isopropylacrylamide) 
GNRs Gold nanorods 
CTAB Hexadecyltrimethylammonium bromide 
MRI Magnetic resonance imaging 








Table 2.2: Cell-based Clinical Trials 




















1 delivery of 6 injections into 
the cord around the lesion 
with a total of 0.6x106 or 
1.2x106 cells 





































Chronic 1 intralesional injection No 
 




2 percutaneous injections, 3 
months apart 











Chronic 1 injection intramedullary 
(16x106 cells) and intrathecal 
space (32x106 cells) 
No 
 














































4 intrathecal monthly 
transplants  
















N/A Chronic 1 injection of either UCB-

















1 intrathecal injection of 
100x106 expanded cells 
No Dec 2017 – 
Nov 2023 




1 intramedullary injection of 
20 or 40x106 cells 



























1 transplant of 6.4x106 cells 
into dorsal root zone with 6 
weeks oral lithium carbonate 
and locomotor training for 
6h/day, 6d/w, for 3-6m 
Yes July 2020 – 
Sept 2021 
SciExVR Study 






N/A Not listed 1 transplant of Bilateral 
paraspinal injection, with IV 
injection, with Intranasal 
injection 
No July 2017 – 
July 2022 
Abbreviations: BMSCs, bone marrow-derived stem cells; NSCs, neural stem cells; BM, bone marrow-derived; MSCs, 
mesenchymal stem cells; WJ-MSCs, Wharton Jelly-derived MSCs; UC-MSCs, umbilical cord-derived MSCs; UCB-MSCs, 








Table 2.3: Drugs and Biologics in Clinical Trials 















Antibody that binds Nogo-A 
Phase 
II 








ReNetX Bio, Inc. 
NCT03989440 
“AXER-204” 
Human fusion protein that 
























Monoclonal antibody that 
binds and inhibits RGMa to 
be neuroprotective, promote 














































Acute (<12 h) 2x/day doses 
for first 14 
days after 
injury 













Acute (<8h) 3 oral daily 
doses  
No Feb 2017 
– Mar 
2022 














































Inhibition of PDGFR to 
restrict BSCB leakage and 














Endothelin B receptor 
agonist that augments 
activity of neural progenitor 
cells in spinal cord to form 




Acute 3 doses via 
IV/day on 
day 1, 3, and 
6 
Yes Jan 2019 
– Oct 
2020  




Recombinant human acidic 
fibroblast growth factor 









2 lumbar puncture 
boosters 












at 3dpi for 6 
weeks 















1x/day for 7 days 
subcutaneous 
injection 















Serotonin reuptake inhibitor 




4 weeks of doses 
+ gait training 
Phase I No Feb 2012 
– July 
2020 
 Shirley Ryan 
AbilityLab 
NCT02635893 
“D-Cycloserine + training + 
stimulation” 
NMDA receptor agonist to 
improve corticospinal 
plasticity, with training and 





1 dose before 
stimulation/trainin
g 






Buspirone + transcutaneous 
ES +  
some form of locomotor 
activity  
A serotonin agonist with 
stimulation and gravity-
neutral apparatus, treadmill 
training, Ekso Bionics 





2x/day oral doses 
during treatment 
phase 
Early Phase I Yes Sept 
2019 – 
Mar 2020 
Abbreviations: Nogo-A, Neurite outgrowth inhibitor-A; MAI, myelin-associated inhibitors; OMgp, oligodendrocyte-myelin 
glycoprotein; RGMa, Repulsive Guidance Molecule A; PDGFR, platelet-derived growth factor receptors; BSCB, blood-spinal 









Table 2.4: Biomaterials in Clinical Trials 





































“OECs + Nerve Grafts” 
Autologous OECs and 
olfactory nerve 
fibroblasts from the 
olfactory bulb 
embedded in a 
collagen scaffold (Glial 
Neuropatch) with 












































Collagen scaffold to 
promote axonal growth 
along fibers, with UC-











Some patients had 
improved autonomic 
functions and 
SSEPs (301)  

















Collagen scaffold to 
promote axonal growth 
along fibers, with UC-












1 thoracic SCI 
patient voluntary 
walking with brace 
and 1 cervical SCI 
patient voluntarily 














MSCs or NSCs” 
Collagen scaffold to 
promote axonal growth 
along fibers, with UC-























Collagen scaffold to 
promote axonal growth 













device with fibroblast 
growth factor 1 and 










None of the initial 9 
patients showed 
MEPs, and the 
study was 

























Abbreviations: dpi, days post injury; PLGA poly(lactic-co-glycolic acid); PLL, poly-L-lysine; OECs, olfactory ensheathing 
cells; ONFs, olfactory nerve fibroblasts; BMMCs, Bone Marrow Mononuclear Cells; UC-MSCs, umbilical cord-derived 








Table 2.5: Conductive Polymer Composites 










• In situ 
polymerization(112-
116) 
• Coating(117, 121) 




• Hydrogel(106, 107, 
123, 124) 
• PCL(112, 121) 
• PDLLA(117) 
• PEG(113) 




• PLLA(115, 121) 
• PVA(120) 
• Collagen(107, 122) 
• Hyaluronic acid(124) 
• Sodium alginate(106) 
• Tannic acid (dopant 
and crosslinker)(123) 







blended into other 
materials could fill 
a cyst-like injury 
• Susceptible to 
• irreversible 











• In situ 
polymerization(125-
127) 
• Coating(134, 135) 




• PVA(126, 127) 
• Alginate(132) 
• Agarose(132, 133) 
• Cellulose(135) 
• Chitosan(130) 
• High conductivity 



















films(128, 129) or 
scaffolds(130) 
• Hydrogel(105) 





• Silk fibroin(128) 
• Zein(134) 
• Phytic acid (dopant 
and crosslinker)(105) 
materials could fill 





• In situ 
polymerization(140) 
• Coating(11, 147) 
• Conductive scaffold 











• Chitosan(140, 142) 
• Collagen(145) 
• Gelatin(140, 142) 
• GelMA(143) 
• PEGDA(148, 149) 
• Dopants: 
• PSS(143, 146) 
• Hyaluronic acid(142) 





• High stability when 
doped with PSS 
• Water soluble 
monomers 
• Colloidal aqueous 
suspension of 
polymer 
• Additives or post-
processing needed 










• Water soluble 
monomers 
• High stability  
• Low conductivity 
• Insoluble polymer 
in water 
Abbreviations: PCL, polycaprolactone; PDLLA, poly-d,l-lactic acid; PEG, polyethylene glycol; PEGDA, PEG-diacrylate; PLA, 
polylactic acid; PLCL, poly(L-lactide-co-ε-caprolactone); PLGA, poly(lactic-co-glycolic acid); PLLA, poly (L-lactic acid); PVA, 
poly(vinyl alcohol); GelMA, methacrylated gelatin; PSS, poly(styrenesulfonate); MEH-PPV, Poly[2-methoxy-5-(2'-








Table 2.6: Carbon-based Material Composites 
Composites with carbon-based materials and translational advantages and disadvantages 
Conductive 
component 






Blended into films(172) 
or scaffolds(173) 
Coated(170, 171)  
Freeze-dried 
















Low to moderate conductivity, 
dependent on oxidation 
Toxicity not well-known, but 
dependent on method of 
synthesis, size, and dose 
Reduced form is less 








Blended into films(15, 
120, 180-182) or 














Chondroitin sulfate(186, 187) 
Collagen I(13) 






area and easy to 
functionalize 
Functionalized 
CNTs are easy 
to blend with 
other materials 
Can cross the 
BBB 




Abbreviations: PCL, polycaprolactone; PLGA, poly(lactic-co-glycolic acid); PLLA, poly (L-lactic acid); PLA, polylactic acid; PDMS, 








Table 2.7: Metal Particle Composites 
Composites with metallic particles and translational advantages and disadvantages 
Conductive 
component 







• In situ 
formation(102, 
104) 









104, 199-201, 204, 
205) 
• Nanorods(203, 
206, 207, 210, 
212) 
• Nanowires(202) 
• Chitosan(103, 104) 
• Alginate(202) 
• ECM(201, 205) 






• Silk fibroin(212) 
• High stability 
• Low initial 
cytotoxicity 
• Easy to scale 
up 
• Ease of surface 
functionalization  


















• Collagen I(217) 
• Fibrin(221, 223) 
• HA/collagen I(220) 





• Low cytotoxicity 
• Low stability 
Abbreviations: ECM, extracellular matrix; PNIPAM, poly(N-isopropylacrylamide); PLLA, poly (L-lactic acid); PCL, 









Table 3.1: Printable Bioink Yield Stresses 
Yield stresses of different printable bioinks 









0.3 151 No other printable or non-
printable formulations. 
Muller et al. (240) 
25 wt% poloxamer 407 0.25 227 15, 20, and 30 wt% 
formulations were not printable. 
Paxton et al. (244) 
8% alginate/1% CaCl2 0.25 166 No other alginate/CaCl2 
formulations were tested. 










Table 4.1: Hyaluronic Acid 1H NMR Assignments 






(1’)-CH: 4.33     (2’)-CH: 3.25     (3’,4’,5’)-CH: 3.0 – 4.0 
N-acetyl-D-
glucosamine* 
(1)-CH: 4.50     (2)-CH: 3.70      (3,4,5)-CH, (6)-CH2: 3.0 – 4.0  
(7)-CH3: 1.90 








Table 4.2: PHA 1H NMR Assignments 
PHA 1H NMR peak assignments of the disaccharide repeat unit and the pentenoate groups as determined from the 
TOCSY spectrum 
Functional Group Resonances (ppm) 
Pentenoate group α-CH2 (8): 2.46    β-CH2 (9): 2.27     γ-CH (10): 5.82        
δ-CH2 (11): 5.00 
D-glucuronic 
acid** 
(1’)-CH: 4.36     (2’)-CH: 3.27     (3’,4’,5’)-CH: 3.0 – 4.0 
N-acetyl-D-
glucosamine** 
(1)-CH: 4.50      (2)-CH: 3.72      (3,4,5)-CH, (6)-CH2: 3.0 – 4.0  
(7)-CH3: 1.93 










Table 4.3: Gelatin 1H NMR Assignments 
Gelatin 1H NMR peak assignments of the amino acids as determined from the TOCSY spectrum 
Functional 
Group   
Resonances (ppm) 
Arginine α-CH: 4.35     β-CH2: 1.78     β-CH2: 1.91     γ-CH2: 1.67    δ-CH2: 3.21 
Lysine α-CH: 4.33     β-CH2: 1.78     β-CH2: 1.87     γ-CH2: 1.45    δ-CH2: 1.68      
ε-CH2: 3.00        
Proline α-CH: 4.43     β-CH2: 1.94      β-CH2: 2.29     γ-CH2: 2.02    δ-CH2: 3.64              
Hydroxyproline α-CH: 4.57     β-CH2: 2.08      β-CH2: 2.36     γ-CH2: 4.62    δ-CH2: 3.86              
Alanine α-CH: 1.40     β-CH2: 4.33             
Glycine α-CH: 3.97             
Glutamic Acid α-CH: 4.32     β-CH2: 1.96      β-CH2: 2.06      γ-CH2: 2.26             
Aspartic Acid α-CH: 4.60     β-CH2: 2.69      β-CH2:  not detected            










Table 4.4: PGel 1H NMR Assignments 
PGel 1H NMR peak assignments of the amino acids and pentenoate group as determined from the TOCSY spectrum 
Functional 




α-CH2: 2.27    β-CH2: 2.49      γ-CH: 5.82      δ-CH2: 5.05  
Arginine α-CH: 4.35     β-CH2: 1.78      β-CH2: 1.91     γ-CH2: 1.67    δ-CH2: 3.21 
Lysine not detected        
Modified Lysine α-CH: 4.34     β-CH2: 1.77     β-CH2: 1.83     γ-CH2: 1.50    δ-CH2: 1.40  
ε-CH2: 3.16 
Proline α-CH: 4.43     β-CH2: 1.95      β-CH2: 2.29     γ-CH2: 2.02    δ-CH2: 3.61              
Hydroxyproline α-CH: 4.61     β-CH2: 2.10      β-CH2: 2.34     γ-CH2: 4.62    δ-CH2: 3.84              
Alanine α-CH: 1.40     β-CH2: 4.30            
Glycine α-CH: 3.97             
Glutamic Acid α-CH: 4.32     β-CH2: 1.96      β-CH2: 2.06      γ-CH2: 2.26             
Aspartic Acid α-CH: 4.60     β-CH2: 2.71      β-CH2: not detected         










Table 5.1: Single Particle ICP-MS Conditions 
Conditions for Single Particle Inductively Coupled Plasma Mass Spectrometer (SP-ICP-MS) 
Parameter Setting 
RF Power [W] 1600 
Nebulizer Gas Flow [mL min-1] 0.4 
Make up Gas Flow [mL min-1] 0.7 
Sample Flow Rate [mL min-1] 0.010 
Sample Volume [μL] 150 
Dwell Time [μs] 50 
Scan time [s] 60 
Transport Efficiency [%], Mean ± StD 58.5 ± 3.9 
 
 
